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Behaving in a way that maximizes short-term gain is adaptive under many 
circumstances. In an uncertain and competitive world, valuing immediate rewards and 
acting quickly to obtain those rewards will often be the optimal strategy. It is when such 
opportunistic strategies become excessive and disadvantageous that the behavior is 
deemed impulsive (Ainslie, 1975; Logue, 1995). Therefore, impulsive behavior patterns 
do not differ in form from normal behavior, only in degree. For example, occasionally 
enjoying celebratory drinks with friends despite the delayed consequence of a hangover 
may be considered normal. Drinking excessively on a daily basis, on the other hand, 
despite a delayed consequence of losing one’s job and financial freedom may be 
considered impulsive. Simply observing a person drinking an alcoholic beverage does not 
necessarily convey whether that behavior is impulsive, it is the context of that drinking 
behavior in interaction with the consequences that result which determine if it is 
impulsive. Analogous examples of impulse control are central to a wide variety of daily 
behaviors. Failures in impulse control, depending on the specific context, have been 
implicated in psychological disorders as varied as substance abuse, conduct disorder, 
attention-deficit/hyperactivity disorder (ADHD), kleptomania, and pathological gambling 
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(Diagnostic and statistical manual of mental disorders-IV-TR, American Psychiatric 
Association, 2000).  
Subtypes of Impulsivity 
Given the broad brush that has been used to paint the construct of impulsivity, it is 
not surprising that researchers and theorists have identified multiple, distinct subtypes of 
impulsivity. Using answers given on self-report questionnaires as a basis, the Barratt 
Impulsivity Scale (BIS) and Eysenck Impulsiveness scales have both proposed multiple 
subtypes. Furthermore, these subtypes differ depending on the version of the scale used. 
The BIS-10 proposes cognitive impulsiveness, motor impulsivenss, and non-planning 
impulsiveness, while the BIS-11 includes attentional impulsiveness along with the motor 
and cognitive subtypes from version 10 (Patton, Stanford, & Barratt, 1995). Version 5 of 
the Eysenck Impulsiveness scale (I-5) proposes narrow impulsivity, risk taking, 
liveliness, and non-planning (Eysenck & Eysenck, 1977), while version 7 (I-7) proposes 
just two subtypes – impulsiveness and venturesomeness (Eysenk & Eysenck, 1978). One 
attempt to parse these and other self-report scales resulted in 15 distinct components of 
impulsivity, which were proposed to be separable into the three overarching components: 
spontaneous, not persistent, and carefree (Gerbing, Ahadi, & Patton, 1987).  
Behavioral measures of impulsivity have been grouped into classes that seem to 
show less volatility than the subtypes of impulsivity as described by designers of self-
report questionnaires. The existence of at least two subtypes of behavioral measures and 
corresponding behavioral patterns of impulsivity is widely agreed upon (for recent 
reviews, see Dalley, Mar, Economidou, & Robbins, 2008; de Wit, 2009; Evenden, 1999a; 
Perry & Carroll, 2008; Winstanley, Eagle, & Robbins, 2006). Impulsive action, 
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sometimes called motor impulsivity, behavioral inhibition, or behavioral disinhibition, 
refers to the inability to withhold or inhibit a prepotent response (i.e., a response the 
individual has prepared to emit). Impulsive choice, sometimes referred to more positively 
as self control, is defined by hypersensitivity to delays of reward. Impulsive preparation, 
also known as reflection impulsivity, is discussed less often in the animal literature, but 
has received much attention in the human literature. Impulsive preparation refers to the 
tendency to act before obtaining and processing relevant environmental stimuli (Evenden, 
1999a). Finally, lapses in attention which do not necessarily coincide with poor 
attentional performance overall have also been proposed as a component of impulsivity 
(de Wit, 2009). 
Impulsive Action 
Impaired performance on a number of procedures has been labeled impulsive 
action. For each, a response is reinforced in one context while the same response is 
punished in another context, but the specific characteristics of the response and the 
stimuli that signal appropriate behavior are different. To perform optimally, the organism 
must inhibit responses when appropriate. Impulsive action is most often measured 
experimentally with one of five procedures, most of which have both human and animal 
variants: the go/no-go task, the stop signal reaction time (SSRT) task, the 5-choice serial 
reaction time (5-CSRT) task, differential reinforcement of low rates (DRL) schedules, 
and fixed consecutive number (FCN) schedules. The go/no-go task and SSRT task are 
very similar (for review, see Band & van Boxtel, 1999). On the go/no-go task, responding 
is reinforced in the presence of a stimulus (the “go” stimulus), but the same response is 
punished if a second stimulus (the “no-go” stimulus) is presented slightly before or 
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concurrently with the “go” stimulus. As with the go/no-go task, responding on the SSRT 
task is reinforced in the presence of a stimulus, but the same response is punished if 
followed by a “stop signal.” In the go/no-go task, successful inhibition of responses in the 
presence of the “no-go” stimulus is measured, while in the SSRT task the reaction time of 
the subject on successful trials is typically the measure of interest. Since a successfully 
inhibited trial is defined by the absence of a response, reaction time is estimated using the 
shortest “stop signal” interval on incorrect trials. The 5-CSRT task was originally 
developed as an animal model of sustained attention similar to the continuous 
performance task (CPT) used to measure attentional processes in humans (Robbins, 
2002). On both the CPT and 5-CSRT task, visual stimuli are briefly presented in distinct 
response locations, and a response at the signaled location is reinforced. On the 5-CSRT 
task, “premature” responses made prior to the presentation of stimuli are punished, and 
this type of response has been used as a model of impulsive action (Dalley et al., 2008). 
Premature responses on another visual discrimination task, the uncertain visual 
discrimination (UVD) task, have also been studied as a model of impulsive action in 
animals (Evenden, 1999b). DRL and FCN schedules are also measures of impulsive 
action that are conceptually similar (for review, see Monterosso & Ainslie, 1999). 
Responding is reinforced on a DRL schedule based on the time since the previous 
response. For example, responses are reinforced on a DRL 60-s schedule if a fixed 60-s 
interval has elapsed since the previous response. On a FCN schedule, responses on a 
“reinforcement lever” are reinforced based on the number of responses made on a “chain 
lever” since the previous reinforcement-lever response. For example, a single response on 
the reinforcement lever is reinforced on a FCN 8 schedule if at least 8 responses have 
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been recorded on the chain lever prior to the reinforcement-lever response. Responses 
made prior to the time interval on a DRL schedule, or prior to the response requirement 
on a FCN schedule, are punished with a timeout and interpreted as impulsive action. 
Evenden (1998) developed a variant of this FCN schedule, dubbed a paced FCN 
schedule, for use when assessing drug effects. A paced FCN schedule controls for the 
rate-increasing or rate-decreasing effects many drugs have on schedule-maintained 
behavior. By withdrawing the levers after every response and reinserting them into the 
chamber after a specified interval, the maximum response rate can be controlled and set 
to an arbitrarily low rate.  
Impulsive Choice 
Impulsive choice is typically measured using procedures that provide choice 
opportunities between a smaller amount of a reinforcer delivered after little or no delay 
and large amount of the same reinforcer delivered after a longer delay (Ainslie, 1975). 
Due to the financial and logistical challenges of delivering delayed rewards to human 
subjects, delay discounting (DD) is typically measured in people by offering choices 
between hypothetical immediate and hypothetical delayed consequences (for review, see 
Reynolds, 2006). Choices between actual reinforcers have been compared to choices 
between hypothetical rewards, however, finding sufficient concordance to justify the use 
of hypothetical rewards (Baker, Johnson, & Bickel, 2003; Madden, Begotka, Raiff, & 
Kastern, 2003; Madden et al., 2004; but see Heyman & Gibbs, 2006). Procedures to 
measure impulsive choice in animals subjects fall into two categories: those that make 
within-session adjustments the amount of one reinforcer or the delay to one reinforcer 
based on the subject’s behavior (Mazur, 1987; Richards, Mitchell, de Wit, & Seiden, 
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1997), or those that arrange choices between a predefined set of delays and amounts 
(Evenden & Ryan, 1996).  
In both types of DD procedures, the tendency to choose the smaller, more 
immediate reinforcer over the larger, delayed reinforcer is interpreted as impulsive 
choice. Results are often presented as a series of indifference points, or the amount of an 
immediate reinforcer that is subjectively equal to a delayed reinforcer. For example, if a 
subject’s choices indicate indifference between $100 delayed one month and $90 
delivered immediately, that individual can be said to value that $100 at 90% of its 
absolute value when delayed one month. A hyperbolic function fitted to a series of these 
indifference points quantifies impulsive choice (Figure 1-1). The hyperbolic nature of this 
function is important for theoretical purposes. Prominent early economists and 
psychologists assumed that present value of a reward is discounted exponentially as a 
function of delay (e.g., Fishburn & Rubinstein, 1982; Hull, 1943; Lancaster, 1963). A 
major interpretive problem with exponential delay functions, however, is presented by 
considering the phenomenon of preference reversals. Anecdotal evidence abounds for the 
existence of preference reversals, or the tendency to make a self-controlled choice when 
the consequences are remote, but reverse preference to the impulsive choice when the 
options are near. For example, women often choose to forego anesthesia when asked their 
preference many hours before giving birth, but switch their preference as time to 
childbirth approaches (Christensen-Szalanski, 1984). Preference reversals are illustrated 
by Figure 1-2 (right panel). When the present value of a delayed reward is discounted 
hyperbolically, plots measuring the present value through time of two differently-sized 
reinforcers often cross, such that small rewards are preferred when nearly immediate, but 
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large rewards are preferred if the delay to both the small and large reward is increased. In 
the hypothetical example illustrated in Figure 1-2 (right panel), the choice for $50 is 
preferred at T1, when both $50 and $25 are delayed substantially (e.g., a choice between 
$50 in six weeks versus $25 in five weeks). As time progresses preferences reverse, such 
that by T2 the smaller reward is chosen (e.g., a choice between $50 in one week versus 
$25 now), even though the time between the delays is constant (one week). Analogous 
preference reversals have been observed many times in both human participants choosing 
between a variety of reinforcers (Christensen-Szalanski, 1984; Kirby & Herrnstein, 1995; 
Millar & Navarick, 1984; Solnick, Kannenberg, Eckerman, & Walker, 1980) and animal 
subjects choosing between food reinforcers (Bradshaw & Szabadi, 1992; Green & Estle, 
2003; Green, Fisher, Perlow, & Sherman, 1981; Navarick & Fantino, 1976; Rachlin & 
Green, 1972). Even before the currently-used hyperbolic function was confirmed 
experimentally (Mazur, 1987); a curve approximating this shape was proposed on 
theoretical grounds by both a psychologist (Ainslie, 1975) and economist (Thaler, 1981).  
Impulsive Preparation 
Impulsive preparation, often labeled reflection impulsivity or cognitive 
impulsivity by human-subjects researchers, refers to a tendency to act before obtaining 
and processing environmental stimuli relevant to optimal performance on a given task 
(for review, see Evenden, 1999a). On a number of laboratory tasks designed to measure 
some aspect of cognitive processing, there is often a trade-off between response speed 
and response accuracy (e.g., Yakir et al., 2007). A certain subset of individuals respond 
quickly, before fully considering and deciding upon optimal response patterns. Neither 
rapid responding nor poor accuracy alone defines impulsive responding on such tasks, it 
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is the combination of the both that is labeled impulsive. For example, the Tower of 
London task (Culbertson & Zillmer, 1998) presents participants with a series of objects 
arranged in a particular pattern within a series of wells or stacked into towers. A goal 
pattern that differs from the starting pattern is presented, and the participant has a 
predefined number of “moves” to rearrange the objects to match the goal pattern. Those 
subjects that perform poorly, not because they lack the cognitive abilities to perform the 
task but because they respond quickly, are labeled impulsive. An analogous pattern of 
responding is found on other tasks which have been used to measure impulsive 
preparation, such the Matching Familiar Figures Test (MFFT) (Kagan, 1966), the Porteus 
Maze Test (Porteus, 1973), the Trail Making Test (Lezak, 1995), and the Wisconsin Card 
Sorting Task (Heaton, Chelune, Talley, Kay, & Curtiss, 1993). On each, a pattern of 
responding described as impulsive preparation includes fast, inaccurate responding 
(Leshem & Glicksohn, 2007).  
A single task has been proposed to model impulsive preparation in animals 
(Evenden, 1999b). The UVD task is a visual discrimination task similar in many respects 
to the 5-CSRT task, but with the visual stimuli probabilistically correlated with the 
correct response location. Stimuli are presented every 200 msec in a series of cycles, and 
with each cycle, the probability that the stimulus predicts the correct response location 
increases. Therefore, similar to impulsive preparation tasks used with human subjects, it 
is advantageous to wait and observe the stimuli prior to responding. Impulsive 
responding on this task is defined by rapid, relatively inaccurate responding.  
Lapses of Attention 
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A fourth component of impulsivity characterized by lapses in attention has been 
proposed (de Wit, 2009). While sometimes cited as a component of impulsivity in self-
report questionnaires (e.g., Patton et al., 1995), a specific behavioral measure of lapses in 
attention has only recently been proposed as a way to model a distinct subtype of 
impulsivity (de Wit, 2009). Lapses in attention are defined as long reaction times on a 
sustained attention task, and to date have not been modeled as a component of 
impulsivity in laboratory animals.  
Behavioral and Psychiatric Correlates of Impulsivity  
With such an expansive list of impulsivity measures, validating each is a daunting 
task. A common method of determining the validity of a given measure is associating 
performance on a task with an impulse control disorder. Such efforts face potential 
confounds, however, when it is not clear whether a person with a given impulse control 
disorder “should” be associated with any one subtype of impulsivity. Despite these 
qualms, it is notable that many of these impulsivity measures correlate with 
characteristics thought to be related to impulse control. For example, self-report measures 
of impulsivity differentiate criminals from controls (Eysenck & McGurk, 1980), persons 
with “high-risk” psychiatric disorders involving impulse-control deficits from those with 
“low-risk” psychiatric disorders (Crean, de Wit, & Richards, 2000), and gamblers from 
non-gamblers (Petry, 2001). Pathological gamblers also make more errors on the go/no-
go task (Kertzman, Lowengrub, Aizer, Vainder, Kotler, & Dannon, 2008), and ADHD is 
correlated with impulsive responding on the Tower of London task (Culbertson & 
Zillmer, 1998), variants of the DD task (Schweitzer & Sulzer-Azaroff, 1995; Solanto et 
al., 2001; Sonuga-Barke, Taylor, Sembi, & Smith, 1992; Sonuga-Barke, Williams, Hall, 
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& Saxton, 1996), and the SSRT task (de Zeeuw et al., 2008; McAlonan et al., 2009; 
Tannock, Ickowicz, & Schachar, 1995; Tannock, Schachar, Carr, Chajczyk, & Logan, 
1989). 
Substance abuse is perhaps the most consistently and widely documented 
correlate with measures of impulsivity. Almost without exception, impulsivity is found to 
be more prevalent in substance abusers, regardless of substance of abuse. Eysenck and 
Eysenck’s (1977, 1978) impulsivity scales positively correlate with smoking status 
(Bickel, Odum, & Madden, 1999, but see Mitchell, 1999), alcohol use (Bobova, Finn, 
Rickert, & Lucas, 2009; Sher, Bartholow, & Wood, 2000; Vuchinich & Simpson, 1998), 
cocaine use (Coffey, Gudleski, Saladin, & Brady, 2003), and opioid dependency 
(Madden, Petry, Badger, & Bickel, 1997). Opioid-dependent needle-sharers scored higher 
than those that did not share needles (Odum, Madden, Badger, & Bickel, 2000), and 
scores predicted who would become alcohol dependent up to six years prior to 
development of dependence (Sher et al., 2000). Similarly, the BIS (Patton et al., 1995) is 
positively correlated with cocaine use (Coffey et al., 2003), smoking status (Heyman & 
Gibbs, 2006; Mitchell, 1999; Reynolds, Patak, Shroff, Penfold, Melanko, & Duhig, 
2007), and heroin use (Kirby, Petry, & Bickel, 1999). Scores on the BIS are also higher 
among early-onset alcoholics than among late-onset alcoholics (Dom, D’haene, Hulstijn, 
& Sabbe, 2006). On behavioral measures of impulsive action, cocaine dependent people 
(Lane, Moeller, Steinberg, Buzby, & Kosten, 2007; but see Li, Milivojevic, Hong, & 
Sinha, 2006) have been shown to make more errors. On the Tower of London model of 
impulsive preparation, smokers, amphetamine users, and opiate users have a more 
impulsive pattern of behavior (Ersche, Clark, London, Robbins, & Sahakian, 2006; Yakir 
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et al., 2007), as have amphetamine and opiate users on a novel model of impulsive 
preparation (Clark, Robbins, Ersche, & Sahakian, 2006). Animal models of impulsive 
action have also been shown to correlated with escalation of cocaine intake and continued 
cocaine use despite punishment (Belin, Mar, Dalley, Robbins, & Everitt, 2008; Dalley et 
al., 2007) 
Greater impulsive choice on the DD task has also been associated with drug 
abuse, nearly without exception. The first account of greater discounting of delayed 
rewards among substance abusers was with a group of opioid-dependent participants 
(Madden et al., 1997). The opioid-dependent group in that study was found to discount 
hypothetical delayed money more than controls, such that delayed money was discounted 
to 50% of its absolute value when delayed approximately 37 months in the control group, 
but only 4.5 months in the opioid-dependent group. Opioid-dependent subjects were 
subsequently confirmed by others to discount delayed rewards more than controls (Kirby 
& Petry, 2004; Kirby et al., 1999; Madden, Bickel, & Jacobs, 1999; Odum et al., Odum, 
Madden, & Bickel, 2002), as were cocaine users (Coffey et al., 2003; Kirby & Petry, 
2004), cigarette smokers (Audrain-McGovern, Rodriguez, Epstein, Cuevas, Rodgers, & 
Wileyto, in press; Baker et al., 2003; Bickel et al., 1999; Heyman & Gibbs, 2006; 
Johnson, Bickel, & Baker, 2007; Jones, Landes, Yi, & Bickel, in press; Mitchel, 1999; 
Reynolds, 2006; Reynolds et al., 2007), alcohol abusers (Bobova et al., 2009; Dom et al., 
2006; Vuchinich & Simpson, 1998), and methamphetamine users (Monterosso, Ainslie, 
Xu, Cordova, Domier, & London, 2007). Furthermore, the DD task differentiates opioid 
users who share needles from those that do not, with the needle-sharers demonstrating 
greater discounting of delayed rewards (Odum et al., 2000). Opioid users that are mildly 
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deprived of opioids at the time of assessment discount delayed rewards to a greater 
degree (Giordano, Bickel, Goewenstein, Jacobs, Marsch, & Badger, 2002), and substance 
users that also exhibit problem gambling have greater impulsive choice than substance 
abusers not meeting criteria for problem gambling (Petry, 2001; Petry & Casarella, 
1999). When discounting is measured at intake to a smoking-cessation treatment 
program, it has been shown that degree of discounting predicts which participants will 
remain abstinent at the end of treatment, with greater impulsive choice in those that 
relapse (Krishnan-Sarin et al., 2007; Yoon, Higgins, Heil, Sugarbaker, Thomas, & 
Badger, 2007). After an exhaustive search, the only report of any substance abusing 
population that did not demonstrate greater impulsive choice than matched controls was 
in a single group of alcoholics (Kirby & Petry, 2004). 
Dopaminergic Neural Mechanisms Involved in Impulsivity 
Dopaminergic pathways between the prefrontal cortex (PFC), anterior cingulate 
cortex (ACC), and basal ganglia are often implicated in ADHD and impulsive behavior 
(for recent reviews see Bickel, Miller, Yi, Kowal, Lindquist, & Pitcock, 2007; Dalley et 
al., 2008; Winstanley et al., 2006). Unmedicated adults with ADHD have less DOPA 
decarboxylase activity in the PFC, likely indicating fewer dopaminergic synapses in this 
area (Ernst, Zametkin, Matochik, Jons, & Cohen, 1998). Similarly, compared to control 
subjects, lower PFC activation was found in functional magnetic resonance imaging 
(fMRI) scans of adolescent boys with ADHD performing the SSRT task or a task 
involving delay to reinforcement (Rubia, Overmeyer, Taylor, Brammer, Williams, 
Simmons, & Bullmore, 1999). The ACC has also been implicated in ADHD, with lower 
activation in that region during attentional tasks (Bush et al., 1999; Zametkin et al., 
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1990). Combined with the finding that striatal dopamine transporter (DAT) availability is 
increased in untreated adults with ADHD (Krause, Dresel, Krause, Kung, & Tatsch, 
2000), the involvement in ADHD of the pathways connecting these areas is highly 
probable. Drug dependence also involves dysregulation of the same striatocortical 
pathways (Robinson & Berridge, 2003; Volkow, Fowler, & Wang, 2004); and like people 
with ADHD, methamphetamine users show lower PFC activity while making choices on 
the DD task (Monterosso et al., 2007). 
In addition to differentiating brains of people with impulse-control disorders from 
control subjects, the same striatocortical pathways seem to be involved in impulsive 
behavior in healthy adults. fMRI scans taken while people make choices on the DD task 
often find activation of the PFC and striatum during choices. More PFC activation is 
found when making delayed or difficult choices, while ventral striatum is associated with 
immediate choices or reward amount (Ballard & Knutson, 2009; Hoffman et al., 2008; 
McClure, Laibson, Loewenstein, & Cohen, 2004; Tanaka, Doya, Okada, Ueda, Okamoto, 
& Yamawaki, 2004; Shamosh et al., 2008; Wittman, Leland, & Paulus, 2007). This 
pathway is not only activated during the DD task. Individual differences in impulsive 
choice are associated with different levels of activation in healthy adults, with greater 
ventral striatal activity and less medial and dorsolateral PFC activation associated with 
greater impulsive choice (Ballard & Knutson, 2009; Hariri, Brown, Williamson, Flory, & 
de Wit, 2006). Response inhibition on the go/no-go task utilizes the same pathways 
between the striatum and medial or dorsolateral PFC, with thalamic modulation (Stevens, 
Kiehl, Pearlson, & Calhoun, 2007; Tapert et al., 2007). However, dorsolateral PFC 
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activation only occurs if the stimuli used as “go” and “no-go” signals are complex 
(Simmonds, Pekar, Mostofsky, 2008). 
Research in animal subjects has implicated the same striatocortical pathways. As 
in human subjects, the ventral striatum in rats appears to be related to reinforcer valuation 
and the PFC involved in sensitivity to delay. Rats making choices on the DD task after 
nucleus accumbens (NAc) core lesions choose the small reinforcer under all delay 
conditions, even when both the small and large reinforcers are delivered immediately 
(Bezzina et al., 2007; Cardinal, Pennicott, Sugathapala, Robbins, & Everitt, 2001). This 
counterintuitive finding seems to result from lesioned animals being unable to assess 
delay and amount under the rapidly-changing conditions present in the DD task used 
(Acheson et al., 2006). Increases in impulsive choice are seen with lesions of the orbital 
PFC (Kheramin et al., 2004) or disconnection of the orbital PFC from the NAc core by 
lesioning the orbital PFC on one side of the brain and the NAc core on the other side 
(Bezzina et al., 2008). Note that a contradictory report claims that orbital PFC lesions 
decrease impulsive choice (Winstanley, Theobald, Dalley, Cardinal, & Robbins, 2006), 
but the effect in this paper is primarily due to an increase in choice of the large reinforcer 
independent of delay. Increases in choice of the large reinforcer that are independent of 
delay are more accurately conceptualized as alterations in sensitivity to amount or 
disruptions in ability to discriminate or adapt to the consequences of responding, not an 
effect on impulsive choice (Acheson et al., 2006; Pitts & Febbo, 2004). 
Animal models of impulsive action show similar sensitivity to dopaminergic 
pathways. ACC lesions in rats increase the number of premature responses emitted on the 
5-CSRT task, but medial PFC, lateral PFC, and parietal cortex lesions had no effect 
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(Muir, Everitt, & Robbins, 1996). Dopamine levels are elevated in the PFC during 5-
CSRT task performance, but this elevation is not related to task performance (Dalley, 
Theobald, Eagle, Passetti, & Robbins, 2002). D2/D3 receptor level in the ventral striatum 
is positively correlated with premature responses emitted on the 5-CSRT task (Dalley et 
al., 2007), but a D2/D3 agonist administered directly into this brain region only produced 
a small increase in premature responses that was not statistically significant (Pezze, 
Dalley, & Robbins, 2007).  
Brain circuitry has not been explicitly associated with levels of impulsive 
responding in models of impulsive preparation. However, the PFC is critical for 
responding on these tasks (Crews & Boettiger, 2009), such as the Tower of London task 
(Schall et al., 2003; van den Heuvel, Groenewegen, Barkhof, Lazeron, van Dyck, & 
Veltman, 2003; Wagner, Kock, Reichenback, Sauer, & Schlösser, 2006). 
Specific Aims 
While impulsivity and impulsive behavior are studied extensively in both animals 
and people, relatively little is known about the ability of commonly employed animal 
models to accurately capture and provide insight into the human condition. When 
modeling cognitive disorders, three primary evaluative areas have been proposed for 
determining the quality of the model: face validity, construct validity, and predictive 
validity (Sagvolden, Russell, Aase, Johansen, & Fashbaf, 2005; Sarter, Hagan, & 
Dudchenko, 1992). Face validity refers to the degree to which a model resembles the 
clinical condition being modeled, with consideration for species-specific behavior and 
limitations. A model with construct validity should share underlying theoretical and 
neural mechanisms with the clinical condition being modeled. To have predictive 
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validity, pharmacological and behavioral manipulations should affect performance on a 
model in an analogous way in the clinic, including for previously-unknown 
manipulations. Evaluating models is difficult if the modeled disorder is not well 
understood, but such attempts are necessary if the goal is to discover treatments relevant 
to the clinic (Sarter et al., 1992). The experiments described within represent steps toward 
the evaluation of selected animal-subjects behavioral models of impulsivity used in 
laboratory experiments.  
Specific Aim 1: Determine if Individual Differences in Impulsive Choice Are Associated 
With Demand for Sucrose or Self-Administered Cocaine 
Human participants who misuse drugs of abuse, almost without exception, have 
been shown to be more impulsive than their non-using counterparts. This relationship is 
especially well-documented for impulsive choice, the subtype of impulsivity referring to 
the tendency to be hypersensitive to delays to rewards (e.g., Madden et al., 1997, 1999). 
While the drug-using status of human subjects can be ascertained with simple questioning 
and verified with physiological measures (e.g., breathalyzer for alcohol, carbon monoxide 
readings for tobacco-smoking, urinalysis for other drugs) modeling drug abuse in animals 
poses its own set of challenges. It is known that individual differences in impulsive 
choice predict acquisition of cocaine self-administration in female rats (Perry, Larson, 
German, Madden, & Carroll, 2005), as well as level of nicotine self-administration and 
reinstatement to extinguished nicotine self-administration in male rats (Diergaarde et al., 
2008). It is not clear, however, whether animals that discount delayed rewards steeply 
value these drug reinforcers to a greater extent, as response-rate-based measures of drug 
reinforcement have many shortcomings (for recent reviews, see Bergman & Peronis, 
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2006; Hursh & Silberberg, 2008). Two of the critical issues associated with measuring 
drug value in experimental animals lie with dose effects and direct effects that many 
drugs have on behavior. When self-administered, different doses of the same drug 
support different amounts of behavior, with moderate doses typically supporting more 
behavior than both high and low doses (e.g., Collins & Woods, 2007; for review, 
Bergman & Peronis, 2006). This feature makes dose an influential variable when 
assessing reinforcer value, with no clear method of choosing which dose of a given drug 
best represents the reinforcing value of that drug. In addition, many self-administered 
drugs function to increase or decrease general activity, confounding the independent 
variable being assessed (e.g., drug A versus drug B) and the dependent measure (e.g., 
lever presses maintained by drug A versus drug B). 
Behavioral economics, the application of economic terms, concepts, and 
analytical tools to the study of the behavior of individual organisms (Bickel, Green, & 
Vuchinich, 1995), provides a system of assessing reinforcer value that is independent of 
drug dose (Hursh & Silberberg, 2008). In such an analysis, total consumption of a 
reinforcer is the dependent measure instead of response rate, and this determined at a 
variety of prices (response requirements). As price increases, consumption decreases in a 
curvilinear fashion such that a unit increase in price will result in a small reduction in 
consumption initially, but a progressively larger reduction in consumption as price 
increases. The rate at which consumption declines is termed the elasticity of demand, and 
this measure reflects the reinforcer value. If price and consumption are both normalized 
to relatively unrestrained consumption levels, elasticity of demand can be used to rank 
order reinforcer value across different reinforcers (e.g., Hursh & Winger, 1995) or across 
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different environmental conditions with responding maintained by the same reinforcer 
(e.g., Hursh, 1991). Note that elasticity of demand only depends on the rate of decline in 
consumption, and does not depend on total level of responding, total consumption, or the 
dose of the drug being self-administered. Elasticity of demand therefore avoids many of 
the potential confounds introduced by response-rate-based measures when assessing 
value of self-administered drugs. 
To assess one aspect of the construct validity of the DD model of impulsive 
choice in animals, individual differences in choices on this task were used to predict 
demand elasticity for sucrose pellets and self-administered cocaine injections. If the DD 
task and drug demand are adequate models of impulsive choice and drug abuse, 
respectively, two predictions can be made regarding these comparisons. First, it is 
hypothesized that individual differences in impulsive choice will predict individual 
differences in drug demand. Second, individual differences in impulsive choice should 
fail to predict individual differences in sucrose demand.  
Specific Aim 2: Determine if Receptor-Selective Dopamine Agonists and Antagonists 
Improve Performance on Models of Three Subtypes of Impulsivity 
Dopaminergic pathways are known to be influential in impulsive behavior, and 
both D1-like (D1 and D5) and D2-like (D2, D3, and D4) dopamine receptors, as well as DAT, 
are known to exist in the dopaminergic pathways connecting the striatum to the PFC 
(Ciliax et al., 1995; Gaspar, Bloch, & Le Moine, 1995; Lévesque et al., 1992; Mrzljak, 
Bergson, Pappy, Huff, Levenson, & Goldman-Rakic, 1996; Muly III, Szigeti, & 
Goldman-Rakic, 1998; Revay, Vaughan, Grant, & Kuhar, 1996; Wędzony, Chocyk, 
Maćkowiak, Fijał, & Czyrak, 2000). DAT, important to the effects of clinically-used 
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ADHD drugs amphetamine and methylphenidate, is present in higher levels in the NAc 
and striatum than in the PFC (Ciliax et al., 1995; Revay et al., 1996). Despite this, 
methylphenidate has been shown to increase dopamine in the PFC to a greater extent and 
at lower doses than in the NAc (Berridge et al., 2006). D2 and D3 receptors are located in 
higher concentrations in the striatum and NAc than in the PFC (Lévesque et al., 1992; 
Bouthenet, Souil, Martres, Sokoloff, Giros, & Schwartz, 1991), while D1-like and D4 
receptors are the most prevalent dopamine receptor subtypes in the PFC (Fare, Halldin, 
Stone-Elander, & Sedvall, 1987; Lidow, Goldman-Rakic, Gallager, & Rakic, 1991; 
Mrzljak et al., 1996). Since these areas are highly connected, it is difficult to make 
predictions regarding the actions of systemically-administered, selective dopamine 
agonists and antagonists on behavior. In accordance with the research discussed above 
regarding the role of brain pathways in impulsive behavior in people, receptor subtypes 
with preferential locations in the basal ganglia (D2, D3) are expected to be involved in 
modulating impulsive action, while receptor subtypes with preferential location in the 
PFC (D1-like, D4) are expected to be more involved in modulating impulsive choice.  
With the abundance of tasks available to model impulsive behavior in animals, 
choosing specific tasks for evaluation is not trivial. Evenden (1999a) proposed a 
theoretical framework for classifying impulsivity tasks which appears to be based on 
Skinner’s (1953) three-term contingency. Skinner’s three-term contingency, consisting of 
a discriminative stimulus, a behavior, and a consequence, describes the interrelationship 
of behavior and environment. A discriminative stimulus sets the occasion for behavior, 
the organism engages in that behavior, and a consequence is delivered that either 
increases or decreases the likelihood of that behavior occurring in the future in the 
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presence of that discriminative stimulus. Evenden (1999a) envisioned impulsive behavior 
as behavior that is abnormal with respect to one of these terms, with each of three 
subtypes of impulsivity corresponding to abnormalities with one component of the three-
term contingency. He proposed that abnormal integration of discriminative stimuli 
characterizes impulsive preparation, abnormal execution of the behavior characterizes 
impulsive action, and abnormal evaluation of the consequences of behavior characterizes 
impulsive choice (Evenden, 1999a). This framework is appealing for conceptualizing the 
vast field of impulsivity research, and a behavioral task proposed to fit within each of 
these subtypes was chosen for further evaluation. The DD task (Evenden & Ryan, 1996) 
was chosen as a model of impulsive choice, a paced FCN schedule (Evenden, 1998) was 
chosen as a model of impulsive action, and the UVD task (Evenden, 1999b) was chosen 
as a model of impulsive preparation and impulsive action. 
Subaim 2.1. Determine the effects of selective dopaminergic compounds on a 
delay discounting task. Given the extensive role of dopamine in impulsive choice, the 
selective dopaminergic compounds listed in Table 1-1 were evaluated for potential 
therapeutic effects on the chosen model of impulsive choice, the DD task (Evenden & 
Ryan, 1996). As the organization of dopamine receptors within the pathways involved in 
impulsive behavior are complex, the role of specific systemically-administered 
compounds is difficult to predict a priori. However, given the critical role of the PFC in 
impulsive choice and the relatively greater concentration of D1-like and D4 receptors in this 
area (see above), it is hypothesized that compounds binding preferentially to these 
receptor subtypes will be influential in modulating impulsive choice.   
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Subaim 2.2. Determine the effects of selective dopaminergic compounds on a 
paced fixed consecutive number schedule. Dopaminergic pathways are also critically 
involved in impulsive action. To determine the potential therapeutic effects of receptor-
specific compounds on impulsive action, the selective dopaminergic compounds listed in 
Table 1-1 were evaluated for effects on the chosen model of impulsive action, a paced 
FCN schedule (Evenden, 1998). As the organization of dopamine receptors within the 
pathways involved in impulsive behavior are complex, the role of specific systemically-
administered compounds is difficult to predict a priori. However, given the critical role 
of the striatum and NAc in impulsive action and the relatively greater concentration of D2 
and D3 receptors in this area (see above), it is hypothesized that compounds binding 
preferentially to these receptor subtypes will be influential in modulating impulsive 
action. 
Subaim 2.3. Determine the effects of selective dopaminergic compounds on an 
uncertain visual discrimination task. Little is known about the neural pathways involved 
in impulsive behavior on tasks that measure impulsive preparation. While it is known that 
the PFC is important for the cognitive processes involved in these tasks (Crews & 
Boettiger, 2009), it is not known which pathways are important for impulsive behavior 
patterns on these tasks. Therefore, Subaim 2.3 is largely exploratory. Given the critical 
role of dopaminergic pathways in impulsivity, and for comparison purposes with Subaim 
2.1 and Subaim 2.2, the selective dopaminergic compounds listed in Table 1-1 were 
evaluated for effects on the chosen model of impulsive preparation, the UVD task 
(Evenden, 1999b). It is hypothesized that dopaminergic compounds will be active on this 
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task, but specific predictions with specific compounds would be highly speculative and of 
little value. 
Specific Aim 3: Assess Inter-Model Congruity of Animal Models of Impulsive Behavior 
The theoretical framework proposed by Evenden (1999a) relating subtypes of 
impulsivity to behavioral contingencies is appealing, but remains speculative until tested 
empirically. Some environmental and pharmacological manipulations have been assessed 
across models of impulsivity, allowing for comparisons of effects between tasks. For 
example, d-amphetamine has been tested on the DD task, a paced FCN schedule, and on 
the UVD task. On the DD task with intact animals, d-amphetamine has been shown to 
reduce impulsive choice (Floresco, Tse, & Chods-Sharifi, 2008; van den Bergh, 
Bloemarts, Groenink, Olivier, & Oosting, 2006; van Gaalen, van Koten, Schoffelmeer, & 
Vanderschuren, 2006; Wade, de Wit, & Richards, 2000; Winstanley, Theobald, Dalley, & 
Robbins, 2005), increase impulsive choice (Evenden & Ryan, 1996; Helms, Reeves, & 
Mitchell, 2006), or have no significant effect (Stanis, Avila, White, & Gulley, 2008; 
Uslaner & Robinson, 2006). On a paced FCN schedule, d-amphetamine increases 
impulsive action (Evenden, 1998; Evenden & Myerson, 1999), as it does on the UVD 
task (Evenden, 1999b) and 5-CSRT task (Cole & Robbins, 1987; van Gaalen, 
Brueggeman, Bronius, Schoffelmeer, & Vanderschuren, 2006). On the UVD task, d-
amphetamine has no effect on impulsive preparation, as defined by this task (Evenden, 
1999b). Analyzing group effects for differences such as these does not definitively 
determine whether different tasks are measuring the same subtype of impulsivity. Since 
there are generally only three results possible on these tasks (increase, decrease, or no 
effect), observing the same overall result with d-amphetamine, for example, on two 
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models does not determine if these models are measuring the same construct or whether 
d-amphetamine is affecting behavior on each through different mechanisms.  
The three tasks chosen for assessment of the effects of dopaminergic compounds 
in Specific Aim 2 were also chosen for comparison in Specific Aim 3 with a within-
subjects comparison technique. After completion of Specific Aim 2, the same subjects 
were retrained on a new task. A subset of the drugs listed in Table 1-1 were reassessed, 
such that baseline performance levels and drug effects could be directly compared among 
the three tasks on a within-subject basis. The rationale for this experiment depends on the 
hypothesis that individual differences in performance on these tasks and individual 
differences in reactions to drugs on these tasks will correlate across measures that rely on 
the same underlying behavioral and neural processes, while they will not necessarily 
correlate if different behavior and neural processes are at work. For example, d-
amphetamine increases premature responses (increases impulsive action) on the UVD 
task (Evenden, 1999b) and decreases chain length (increases impulsive action) on a paced 
FCN schedule (Evenden, 1998; Evenden & Myerson, 1999). As with most any behavioral 
measure, however, individual differences exist in this effect. It is hypothesized that if 
both of these tasks measure impulsive action as purported, those rats that show the largest 
response to d-amphetamine on the UVD task should also show the largest response to d-
amphetamine on a paced FCN schedule. Conversely, if these measures are mediated 
through distinct processes, the effects of d-amphetamine on these measures should not 
necessarily correlate on a within-subject basis. Specific Aim 3 tests such correlations 
with baseline performance and selected drug effects on the DD task, a paced FCN 
schedule, and the UVD task.  
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Table 1-1. Compounds assessed in Specific Aim 2, including the mechanism of action 
and selectivity profile of each. Selectivity refers to the difference in affinity between the 
first receptor or transporter listed and the second. 






Han & Gu, 2006 
Han & Gu, 2006 
Han & Gu, 2006 
GBR 12909 DAT blockade DAT/SERT: 59-fold 
DAT/NET: 281-fold 
Cao et al., 2008 






Millan et al., 2002 
Millan et al., 2002 
Millan et al., 2002 






McCall et al., 2005 
McCall et al., 2005 







Newman-Tancredi et al., 2002 
Millan et al., 2002 
Newman-Tancredi et al., 2002 
Millan et al., 2002 
ABT-724 D4 partial agonist D4/D2: >157-fold Brioni et al., 2004 





Grundt et al., 2007a 





Grundt et al., 2007b 
Grundt et al., 2007b 
L-745,870 D4 antagonist D4/D2: 2050-fold Ericksen et al., 2009 
Haloperdol D2-like antagonist D2/D1: 53-fold Tice et al., 1994 
DAT: dopamine transporter, NET: norepinephrine transporter, SERT: serotonin 
transporter 







Greater Impulsive Choice (k = 0.11)









Figure 1-1. Indifference points for two hypothetical groups making choices on a delay discounting task. 
Each point represents an indifference point from a series of choices between two amounts when delay to 
the larger amount is varied. Relatively greater impulsive choice is represented by the open symbols and 
dashed line, while relatively less impulsive choice is represented by filled symbols and a solid line. The 
hyperbolic function V = A / (1 + kD) typically fits the data well. The k value from this equation indicates 






























Figure 1-2. Hypothetical discounting curves representing the theoretical importance of hyperbolic 
discounting. Each graph shows the present subjective value of two delayed rewards, $25 and $50, with the 
$50 is delayed more than the $25. Exponential curves predict that a choice made at any time point relative 
to the delivery of the rewards with result in the same preference, and $50 will be chosen in the example. 
Hyperbolic curves are able to cross, predicting preference reversals. In the example, $50 is preferred when 
both options are delayed by a large amount (T1), but $25 is preferred if the choice is made near to the 
availability of the $25 option (T2). Note that this is true even though the delay separating the two choices 
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INDIVIDUAL DIFFERENCES IN DISCOUNT RATE ARE ASSOCIATED WITH 
DEMAND FOR SELF-ADMINISTERED COCAINE, BUT NOT SUCROSE 
Impulsivity and self control are constructs used to describe what is increasingly 
apparent to be more than one class of behaviors. Based on operant and neurobiological 
experiments in humans and animals, a growing consensus largely agrees on at least two 
types of impulsive behavior: impulsive choice and what is termed impulsive action or 
behavioral inhibition (Dalley, Mar, Economidou, & Robbins, 2008; de Wit, 2009; 
Evenden, 1999; Perry & Carroll, 2008; Winstanley, Eagle, & Robbins, 2006). Impulsive 
choice is the tendency to be hypersensitive to delays of reward, while impulsive action 
refers to the inability to withhold or inhibit a prepotent response.  
Impulsive choice is typically measured using procedures that provide choice 
opportunities between a smaller amount of a reinforcer delivered after little or no delay 
and large amount of the same reinforcer delivered after a longer delay (Ainslie, 1975). 
Impulsive choice on these procedures is defined as the tendency to tolerate only small 
delays to the larger reinforcer before switching to choose the smaller reinforcer, while 
self-control is defined as the tendency to tolerate relatively long delays to the larger 
reinforcer. Variants of this task are used in both humans and animals, and in humans 
extensive evidence links delay discounting to substance abuse. Substance abusers 
demonstrate a higher degree of impulsive choice than do matched controls, including 
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users of cocaine (Coffey, Gudleski, Saladin, & Brady, 2003; Kirby & Petry, 2004), 
cigarettes (Audrain-McGovern, in press; Baker, Johnson, & Bickel, 2003; Bickel, Odum, 
& Madden, 1999; Heyman & Gibbs, 2006; Johnson, Bickel, & Baker, 2007; Jones, 
Landes, Yi, & Bickel, in press; Mitchel, 1999; Reynolds, 2006; Reynolds, Patak, Shroff, 
Penfold, Melanko, & Duhig, 2007), alcohol (Bobova, Finn, Rickert, & Lucas, 2009; 
Dom, D’haene, Hulstijn, & Sabbe, 2006; Vuchinich & Simpson, 1998; but see Kirby & 
Petry, 2004), opioids (Kirby & Petry, 2004; Kirby, Petry, & Bickel, 1999; Madden, 
Bickel, & Jacobs, 1999; Madden, Petry, Badger, & Bickel, 1997; Odum, Madden, 
Badger, & Bickel, 2000; Odum, Madden, & Bickel, 2002), and methamphetamine 
(Monterosso, Ainslie, Xu, Cordova, Domier, & London, 2007). Discounting of delayed 
rewards is increased further in substance users who also meet criteria for problem 
gambling (Petry, 2001; Petry & Casarella, 1999), in opioid users that share needles 
relative to those that do not share needles (Odum et al., 2000), and in opioid users that are 
deprived of opioids at the time of assessment (Giordano, Bickel, Goewenstein, Jacobs, 
Marsch, & Badger, 2002). Degree of discounting is also able to predict which people 
enrolled in smoking-cessation treatment programs will remain abstinent at the end of 
treatment, with those that exhibit greater impulsive choice more likely to relapse 
(Krishnan-Sarin et al., 2007; Yoon, Higgins, Heil, Sugarbaker, Thomas, & Badger, 
2007). 
Despite the robust relationship between delay discounting and substance abuse in 
people, relatively little research has examined the analogous relationship between delay 
discounting and drug self-administration in animals. Animal-subjects research offers 
many opportunities not available in human-subjects research, including the ability to 
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determine cause-and-effect relationships through environmental manipulation. Delay 
discounting is modeled straightforwardly in animals. Procedures to measure impulsive 
choice fall into two categories: adjusting procedures that make within-session 
adjustments of the amount of one reinforcer or the delay to one reinforcer based on the 
subject’s choices (Mazur, 1987; Richards, Mitchell, de Wit, & Seiden, 1997), or those 
that arrange choices between a predefined set of delays and amounts (Evenden & Ryan, 
1996). In both types of procedures, the tendency to choose the smaller, more immediate 
reinforcer over the larger, delayed reinforcer is interpreted as impulsive choice. 
Noncontingent exposure to cocaine has been shown to produce lasting (Simon, Mendez, 
& Setlow, 2007) or transient (Logue, Tobin, Chelonis, Wang, Geary, & Schachter, 1992; 
Paine, Dringenberg, Olmstead, 2003) increases in impulsive choice. Individual 
differences in impulsive choice also predicted acquisition of cocaine self-administration 
in female rats (Perry, Larson, German, Madden, & Carroll, 2005), as well as level of 
nicotine self-administration at high response requirements and reinstatement to 
extinguished nicotine self-administration in male rats (Diergaarde et al., 2008). It is not 
clear, however, whether animals that discount delayed rewards steeply value these drug 
reinforcers to a greater extent, as response-rate-based measures of drug reinforcement 
have many shortcomings (for recent reviews, see Bergman & Peronis, 2006; Hursh & 
Silberberg, 2008). Two of the critical issues associated with measuring drug 
reinforcement or value in experimental animals lie with dose effects and direct effects 
that many drugs have on behavior. When self-administered, different doses of the same 
drug support different amounts of behavior, with moderate doses typically supporting 
more behavior than both high and low doses (Bergman & Peronis, 2006). This feature 
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makes dose an influential variable when assessing reinforcer value, with no clear method 
of choosing which dose of a given drug best represents the reinforcing value of that drug. 
In addition, many self-administered drugs function to increase or decrease general 
activity, confounding the independent variable being assessed (e.g., drug A versus drug 
B) and the dependent measure (e.g., lever presses maintained by drug A versus drug B).  
Behavioral economics, the application of economic terms, concepts, and 
analytical tools to the study of the behavior of individual organisms (Bickel, Green, & 
Vuchinich, 1995), provides a system of assessing reinforcer value that is independent of 
drug dose (Hursh & Silberberg, 2008). In such an analysis, total consumption of a 
reinforcer is the dependent measure instead of response rate, and this determined at a 
variety of prices (response requirements). As price increases, consumption decreases in a 
curvilinear fashion such that a unit increase in price will result in a small reduction in 
consumption initially, but a progressively larger reduction in consumption as price 
increases. The rate at which consumption declines is termed the elasticity of demand, and 
this measure reflects the reinforcer value. If price and consumption are both normalized 
to relatively unrestrained consumption levels, elasticity of demand can be used to rank 
order reinforcer value across different reinforcers (e.g., Hursh & Winger, 1995) or across 
different environmental conditions with responding maintained by the same reinforcer 
(e.g., Hursh, 1991). Note that elasticity of demand only depends on rate of decline in 
consumption, and does not depend on total level of responding, total consumption, or on 
the dose of the self-administered drug. Elasticity of demand therefore avoids many of the 




In the current experiment, individual differences in impulsive choice were related 
to individual differences in valuation of sucrose pellets and cocaine injections. Individual 
differences in impulsive choice were measured by a slight modification of the delay 
discounting task described by Evenden & Ryan (1996), and were associated with 
elasticity of demand for sucrose pellets and elasticity of demand for self-administered 
cocaine injections. Based on the strong relationship between drug abuse and impulsive 
choice in humans, a similar relationship was hypothesized between delay discounting and 
demand for cocaine in rats. Delay discounting measures were also assessed for stability 
over the course of the experimental procedure with a delay discounting reassessment after 
demand determination.  
Method 
Subjects 
Twenty-four male Sprague Dawley rats served as subjects (Harlan, Indianapolis, 
IN). Rats were approximately 10 weeks old at the start of the experiment. A food 
restriction protocol was in place to maintain the rats at approximately 325 g throughout 
the experiment. This weight was chosen as it is approximately 85% of the mean adult 
weight supplied by the manufacturer for this strain, and this weight was not changed once 
established. When not in session, rats were housed in accordance with institutional 
animal care and use guidelines in polycarbonate cages with fresh water continuously 
available. The lights in the housing colony were on from 7:00 AM to 7:00 PM, and 
sessions were conducted between 9:00 AM and 5:00 PM. These protocols were approved 
by the University of Michigan Committee on the Use and Care of Animals and 
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conformed to the guidelines established by the NIH Guide for the Use of Laboratory 
Animals. 
Apparatus 
Sessions were conducted in rodent operant conditioning chambers with an area of 
30.5 cm x 24.1 cm x 21.0 cm and stainless steel grid floors (ENV-008; Med-Associates 
Inc., St. Albans, VT). Both sides of the front panel of the chamber held a retractable lever 
(ENV-112CM). Between the levers was a food tray connected to a 45 mg pellet dispenser 
(ENV-200R1AM and ENV-203M-45). Above both of the levers and the food tray were 
triple stimulus lights containing a red, green, and yellow LED (ENV-222M). Centered on 
the opposite wall was a nose-poke response device containing a yellow LED (ENV-
114BM) and a houselight near the top of the wall to provide illumination to the chamber 
(ENV-215M). The houselight was unused in the current procedure. A syringe pump was 
located outside the chamber for drug deliveries (PHM-107). Chambers were connected to 
a computer running Med-PC IV software (Med-Associates, Inc.) to control experimental 
events and record data. 
Procedure 
Response and magazine training. Rats were trained to respond on a mixed fixed-
time 60 s FR 1 schedule of reinforcement, with the active lever alternating each session 
between the left and right levers. This schedule arranged one sucrose pellet to be 
delivered every 60 s independent of behavior, with every lever press also producing a 
pellet. This was continued for four sessions, at which point the schedule was switched to 
a FR 1 with no response-independent pellet deliveries. Rats were allowed to respond on 
47 
 
this schedule until 80 responses or more were recorded on two consecutive 20-min 
sessions.  
Delay discounting. The sessions were then extended to 75 min and split into five 
components of ten discrete-choice trials each. Total trial duration was 90 s and began 
with one or both levers extending into the chamber. If a single response was made within 
20 s, the levers retracted and the consequence programmed for that lever was delivered. If 
no response was made within 20 s, that trial was recorded as an omission and the levers 
retracted for the remaining 70 s of that trial. The first two trials of each component were 
always forced-choice trials where only one lever was extended into the chamber, forcing 
the subject to sample the contingencies for that component. The remaining eight trials 
were free-choice trials where both levers were extended into the chamber, allowing the 
rat to respond on either. The red stimulus light above each lever was lit whenever that 
lever was inserted in the chamber, with the left light constant and the right light flashing. 
The green and yellow stimulus lights above the pellet tray were lit during sucrose-pellet 
deliveries. Initially, the consequences for the left and right levers were immediate 
deliveries of either one or three 45-mg sucrose pellets, respectively. This condition was 
continued until rats chose the three-pellet option on at least 85% of free-choice trials. At 
this point, delays were introduced between responses made on the 3-pellet lever and the 
delivery of the 3 pellets. The delays to the three-pellet option were 0, 10, 20, 40, or 60 s 
and were always presented in ascending order with one delay in effect in each of the five 
10-trial components. Rats were exposed to this procedure for 48 sessions.   
Sucrose pellet demand. Demand for 45-mg sucrose pellets was then determined. 
Levers remained retracted throughout this procedure and the nose-poke on the back wall 
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of the chamber was the active response device. At the start of the 30-min sessions, the 
nose-poke device was lit and reinforcers were delivered on an FR schedule. The same FR 
schedule remained in effect for the entire session, but the FR schedule value changed 
between sessions. The consequence of each completed FR was a brief flash of the yellow 
and green stimulus lights above the pellet tray, the nose-poke light extinguishing, and a 
single 45-mg sucrose pellet delivered to the tray. After a 5-s timeout period, the nose-
poke was illuminated and the FR schedule was again active. FR values of 1, 3, 10, 32, 
and 100 were examined in an ascending order. This sequence was repeated three times 
with an extra FR-1 session before the first sequence only, for a total of 16 sessions.  
Catheter surgery. Each rat was then implanted with an indwelling femoral 
catheter for intravenous infusion of cocaine. Rats were surgically prepared with chronic 
indwelling femoral catheters in either the right or left femoral vein under ketamine (100 
mg/kg, i.m.) and xylazine (5 mg/kg, i.m.) anesthesia. The surgical field was shaved and 
cleaned with betadine, and lacrilube was applied to the eyes prior to the beginning of the 
surgery. A small incision was made just above the femoral vein, and the overlying tissue 
was dissected to allow for implantation of catheters into the femoral vein. The wound 
was closed using 5-0 Ethilon suture, and the catheters were tunneled under the skin and 
attached to stainless steel tubing, exiting the back through a Dacron mesh tether button 
which was sutured to the muscle between the scapula. Rats were allowed five to seven 
days to recover from surgery prior to the resumption of the experiment. Catheters were 
flushed with 0.25 ml of heperanized saline (100U/ml) daily to promote catheter patency. 
 Cocaine demand. Rats were initially allowed to respond for contingent infusions 
of 0.56 mg/kg/infusion cocaine (National Institute on Drug Abuse, Bethesda, MD) on the 
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nose-poke device on an FR 1 schedule. This continued until rats self-administered at least 
20 infusions of cocaine in a 60-min session. The dose of cocaine was then lowered to 0.1 
mg/kg/infusion and rats were allowed to self-administer this dose for two sessions on an 
FR 1 schedule. The session length was then shortened to 30 min and cocaine demand 
determination began. Rats responded for cocaine in a similar manner as for sucrose 
pellets, with the FR increasing between sessions. The FR sequence for cocaine demand 
was 1, 3, 10, 18, 32 and this sequence was repeated three times for most rats. Fewer 
repetitions were conducted for some rats that experienced catheter patency problems 
before three repetitions were complete. The mean number of total self-administration 
sessions was 28.15 (SD = 3.59). 
Delay discounting redetermination. Rats were then allowed to respond on the 
delay discounting procedure as described above for 43 sessions.  
Data Analysis  
Choice data from each rat, expressed as percent choice of three pellets at each 
delay to three pellets, was analyzed in GraphPad Prism 5 (La Jolla, CA). To be included 
in the data for group analysis, delay had to significantly affect choices. This criterion 
included a significant main effect of delay to three pellets on choices, determined by a 
one-way repeated measures analysis of variance (ANOVA) over the last five delay 
discounting sessions. In addition, three-pellet choice in the 60-s delay condition had to be 
significantly lower than in the 0-s delay condition, as measured by a planned post hoc 
comparison test. For purposes of group formation, choice data were then fit to the 
hyperbolic equation 





where V is the percent choice of three pellets at D delay, and A and k are fit parameters. A 
is the derived percent choice of three pellets when delayed 0 s, and k is a measure of the 
effect of delay on choices.  
Demand functions for sucrose pellets and cocaine infusions were plotted as 
reinforcers earned as a function of response requirement and analyzed using procedures 
described previously (Hursh & Silverberg, 2008; Hursh & Winger, 1995). Number of 
reinforcers was reported as total responses divided by FR value. This value was used 
instead of reinforcer deliveries so the responses that occurred at the end of sessions that 
did not completely fulfill the response requirement were included in the analyses. Plotted 
in this manner, data were then fit with non-linear regression techniques in Prism 5 to the 
exponential equation  
 𝑌𝑌 = log⁡(𝐿𝐿−𝑎𝑎𝑎𝑎 ) (2-2) 
where Y is reinforcer consumption at X price and L and a are fit parameters. L represents 
the derived level of unconstrained consumption under the experimental conditions, and is 
typically nearly equal to consumption at an FR 1. The a parameter indicates the elasticity 
of the curve, or the rate that consumption declines with increases in price.  
To better isolate the elasticity parameter, normalized demand curves were also 
compared. Consumption data were normalized to consumption at an FR 1 with the 
equation 
 𝑄𝑄 = 100 ∗ 𝑌𝑌𝑛𝑛
𝑌𝑌1
 (2-3) 
where normalized consumption (Q) was equal to consumption at FR n  (Yn) divided by 
consumption at FR 1 (Y1), expressed as a percent. Price was normalized with the equation 
51 
 
 𝑃𝑃 = FR∗𝑌𝑌1
100
 (2-4) 
where P is normalized price, FR is the fixed ratio value, and Y1 is consumption at an FR 
1. These normalized data were then fit to Equation 2-2, with L set to 100 since all data 
were transformed to be expressed as a percent. This left a single free parameter (a) that 
quantified elasticity of demand, the proposed measure of reinforcer value. The price that 
supported the most overall responding was also computed. This value, Pmax, is directly 






To compare correlations between two parameters that were both subject to 
experimental variability, Pearson product-moment correlations and Deming regressions 
were conducted in Prism 5. The distribution of k values was not normal in the current 
experiment, so k values were log transformed when used as the basis of statistical 
comparisons, an often-required step (e.g., Yoon et al., 2007). The best-fit parameters of 
demand functions were compared between groups using non-linear regression analyses in 
Prism 5 which are mathematically equivalent to an Analysis of Covariance (Motulsky & 
Christopoulos, 2003). 
Results 
At the end of the initial discounting assessment, 20 of the 24 rats met the 
statistical criteria for inclusion in a discounting group. These 20 rats were split into three 
groups based on the k parameter from Equation 2-1 fitted to their choice data: High (n = 
7), Medium (n = 6), and Low (n = 7). The percent choice of three pellets at each delay to 
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three pellets is shown for the last five sessions of the initial discounting assessment in 
Figure 2-1 (top panel). A two-way ANOVA revealed an overall main effect of delay on 
choice (F4,72 = 61.42, p < .001) and a main effect of discounting group (F2,72 = 5.72, p = 
.012). The choices of the three groups were similar when the delay to three pellets was 0 
s, with a difference among the groups emerging at higher delays. This pattern resulted in 
a significant delay by discounting group interaction (F8,72 = 7.35, p < .001). Individual 
discounting functions were generally well described by Equation 2-1, with median r2 = 
0.828 (interquartile range = 0.151) for subjects meeting criteria (Figure 2-1, bottom 
panel).  
Demand for sucrose pellets was then assessed in all 24 rats, with the 20 rats that 
made up the three discounting groups analyzed in detail. Demand for sucrose pellets did 
not differ among the three groups when either the L parameter (F2,94 = 0.59, p = .557) or 
a parameter (F2,94 = 0.04, p = .964) was compared with curve-fitting procedures (Figure 
2-2, top panel). The corresponding Pmax values for each of the three groups (Figure 2-2, 
top panel) were nearly identical. Note that individual differences in demand curves for 
sucrose pellets were relatively small, and curves for subjects from each of the discounting 
groups overlapped a great deal (Figure 2-2, bottom panel). Normalized demand curves 
were also similar among the discounting groups (Figure 2-3, top panel), with no 
significant difference in the best-fit a parameter (F2,97 = 0.53, p = .588). Individual 
variability in these normalized curves was also minimal (Figure 2-3, bottom panel).  
Unlike demand for sucrose pellets, demand for intravenous infusions of 0.1 
mg/kg/infusion cocaine did differ as a function of group (Figure 2-4, top panel). The 
High discounting group had less elastic demand than the Low or Medium group, which 
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was reflected by a significant difference in the a parameter of Equation 2-2 fit to these 
data (F2,73 = 3.53, p = .034). The L parameter was not different between groups, however, 
indicating this group difference was restricted to higher FR values (F2,73 = 0.21, p = 
.808). The corresponding Pmax value for the High group (6.37) was considerably higher 
than the Low (3.26) and Medium (3.43) groups. Note that there were more individual 
differences in the demand for cocaine than in demand for sucrose pellets (Figure 2-4, 
bottom panel). Although there was a significant group effect, there was still substantial 
overlap in the individual-subject data. When cocaine demand curves were normalized, 
demand in the High group was still less elastic than in the Low and Medium groups (F2,76 
= 5.2, p = .007; Figure 2-5, top panel). A great deal of overlap existed in the individual 
normalized curves, although the rats in the High group tended to have less elastic demand 
than the rats in the other two groups (Figure 2-5, bottom panel).  
Discounting was then reassessed in the 21 rats that were still alive at the end of 
the cocaine demand determination. Of these rats, 18 met the statistical criteria for 
inclusion in a second set of discounting groups. Two of the rats that failed to meet criteria 
also didn’t meet criteria in the initial assessment. The other rat met criteria in the original 
assessment, but failed to meet criteria in the reassessment. The other two of the four rats 
that failed to meet criteria in the original assessment did meet criteria in the reassessment. 
The 18 rats that met criteria in the reassessment were split into three groups of six rats 
each, using k from Equation 2-1 fit to the individual choice data. Many of the rats stayed 
in the same discounting group in both assessments, although the performance of some 
switched enough to cause a change in group composition. Analyzed by group in these 18 
subjects, there was a main effect of delay (F4,60 = 24, p < .001) and discounting group 
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(F2,60 = 48, p < .001) on choices of three pellets (Figure 2-6, top panel). These differences 
also tended to be larger at the higher delays, leading to a significant group by delay 
interaction (F8,60 = 3.8, p = .001). Note that in the discounting reassessment, the groups 
were not equal with respect to sensitivity to amount, with significant differences among 
the groups in the 0-s delay component. A large amount of individual variability can be 
noted in examination of the individual discounting curves (Figure 2-6, bottom panel). 
These discounting curves, in general, also appeared to be steeper than those in the initial 
discounting assessment (see Figure 2-1, bottom panel). This was confirmed by a paired t 
test on the log k values from the individual curves in the initial assessment and 
reassessment (t15 = 2.8, p = .013). The A values from Equation 2-1 did not differ between 
discounting assessments (t15 = 1.1, p = .306). Any changes noted between the initial 
discounting assessment and reassessment did not depend on initial discounting group for 
log k values (F2,13 = 0.78, p = .480) or A values (F2,13 = 0.43, p = .662). In those rats that 
completed and met significance criteria in both discounting assessments, the respective k 
and A values from Equation 2-1 were significantly correlated across assessments (Figure 
2-7; log k correlation r = .698, n = 16, p = .003; A correlation r = .770, n = 16, p < .001). 
In addition, the discounting groups remained similar (Figure 2-8). When discounting 
choices in the reassessment were plotted as a function of the groups determined by 
choices in the initial discounting assessment, a significant difference among groups 
remained (delay main effect F4,52 = 39, p < .001, discounting group main effect F2,52 = 
2.6, p = .109, delay by group interaction F8,52 = 2.3, p = .034).  
Using performance on the discounting reassessment as a basis for group selection, 
the effect of discounting group on demand for cocaine remained (Figure 2-9). Elasticity 
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of demand (a from Equation 2-2) for injections of 0.01 mg/kg/injection cocaine differed 
among the three discounting groups as determined by the discounting reassessment (F2,69 
= 3.2, p = .047), but the demand level (L from Equation 2-2) did not differ (F2,69 = 0.01, p 
= .986; Figure 2-9, top panel). The Pmax value derived from each of these curves was 
highest in the High discounting group and lowest in the Low discounting group. When 
normalized, this relationship between discounting and demand elasticity was more clear 
(F2,72 = 5.8, p = .005; Figure 2-9, bottom panel).  
Despite the significant and consistent relationship between demand for cocaine 
and discounting, a great deal of individual variability exists in these data. This is 
exemplified by performing a Pearson correlation analysis on the log k parameters from 
Equation 2-1 with the log Pmax value derived from Equation 2-2 fit to the normalized 
individual cocaine demand curves. This correlation, using both the initial discounting 
assessment (Figure 2-10, top panel; r = .215, n = 16, p = .424) or the discounting 
reassessment as a basis (Figure 2-10, bottom panel; r = .213, n = 15, p = .447) was 
positive, but did not approach statistical significance. Examination of Figure 2-10 reveals 
a great deal of variability, and the relatively low-power statistical test of a Pearson 
product-moment correlation in this situation (relative to curve-fitting procedures 
employed by Prism 5) did not find these positive correlations statistically significant. 
Discussion 
Subjects appeared to learn the contingencies of the operative schedule of 
reinforcement during each phase of the current experiment, with data largely following 
the expected patterns. Individual differences in delay discounting did not predict level or 
elasticity of demand for sucrose, but did predict elasticity of demand for self-
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administered cocaine injections. This relationship occurred whether delay discounting 
was measured prior to or after demand assessments. 
Sizeable individual differences in sensitivity to delay produced discounting 
groups that significantly differed from one another in their choices of immediate and 
delayed rewards (Figure 2-1). These assessments were reasonably stable, with individual 
log k and A values correlating between the initial discounting assessment and 
reassessment (Figure 2-7, Figure 2-8). Overall, discounting was steeper in the second 
assessment, however. It should be noted that Equation 2-1, used here to differentiate 
subjects based on sensitivity to delay, is not typically used to analyze data obtained from 
the Evenden & Ryan (1996) procedure. For k to be a true representation of discounting 
rate as proposed by Mazur (1987), a series of indifferent points assessed with distinct 
amount and delay comparisons should first be obtained. Only one amount comparison 
was included in the current experiment (i.e., one versus three sucrose pellets), and 
therefore only one indifference point could be obtained from any subject’s choice data. 
Curve-fitting with a single datum point is of little use. Rather, this hyperbolic function 
was used because it happened to describe the choice data in the current experiment well, 
and provided a simple one-parameter assessment of sensitivity to delay (k) and amount 
(A). To determine if the findings of the current experiment were a byproduct of the 
specific equation chosen to summarize obtained data, the slope and y-intercept of linear 
regression analyses drawn through choice data were also obtained and used as 
measurements of sensitivity to delay (slope) and amount (y-intercept). While this method 
of grouping subjects did not result in the same composition of the High, Medium, and 
Low groups, statistical conclusions of data described in this manner were not appreciably 
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different, and did not lead to different logical conclusions (i.e., the Linear Regression 
High group had significantly less elastic demand for cocaine than the Linear Regression 
Low group, with no difference in sucrose demand). 
Individual differences in discounting were associated with elasticity of demand 
for cocaine (Figure 2-4, Figure 2-5), suggesting that impulsive choice differentiates 
assessments of cocaine value. An analogous relationship was not found between 
impulsive choice and demand for sucrose (Figure 2-2, Figure 2-3), indicating that 
differences in cocaine demand were not simply due to differences in propensity to 
respond for reinforcers of any type. Instead, a specific relationship seems to exist 
between cocaine demand and impulsive choice. Previous research has suggested a 
relationship between impulsive choice and acquisition of cocaine self-administration in 
female rats (Perry et al., 2005). The current research extends this finding by relating 
elasticity of cocaine demand in male rats to impulsive choice, with a sucrose demand 
control condition. It is notable that level of cocaine demand (L from Equation 2-2), which 
approximates responding on an FR 1, did not differ between delay discounting groups. 
Only elasticity of demand differed, which agrees with the finding that delay discounting 
is associated with nicotine self-administration at high FR values only (Diergaarde et al., 
2008). 
In humans, a clear relationship between substance abuse and delay discounting 
has been demonstrated, including with cocaine abusers as subjects (Coffey et al., 2003; 
Kirby & Petry, 2004). Due to the inherent limitations of human-subjects research, 
however, the causal direction, if any, of this correlation has not been conclusively 
determined. Four explanations for this observed correlation are plausible: inborn 
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variability in impulsive choice predisposes an individual to an increased likelihood of 
abusing cocaine, cocaine exposure and the life experiences associated with procuring and 
consuming cocaine increase impulsive choice, both characteristics cause the other in a 
positive-feedback loop, or both impulsive choice and cocaine abuse vulnerability are 
caused by an unknown third variable and do not otherwise interact. Limited evidence 
exists demonstrating that impulsivity, as measured by personality questionnaires and 
behavioral assessments, predicts development of drug abuse in human subjects (for 
review, see de Wit, 2009). Perhaps most relevant to impulsive choice is a single study 
finding that individual differences in delay discounting assessed at grade 10 predicts 
initiation of smoking within the following four years (Audrain-McGovern et al., in press). 
Also, ratings by nursery school teachers of nursery school children on a behavioral 
assessment item “Is unable to delay gratification,” was associated with likelihood of 
using marijuana at age 14 (Block, Block, & Keys, 1988). However, a similar study found 
that the same assessment item measured at age 7 to 11 did not predict drug use at age 18; 
although the authors conclude that an overall psychological profile of impulsivity did 
predict drug use (Shedler & Block, 1990). The results of the current experiment, to the 
extent that the models employed capture the human condition, suggest that such a 
positive relationship does occur between impulsive choice and later propensity to self-
administer cocaine. 
Whether the act of abusing a substance increases discounting has not been studied 
experimentally in humans, for obvious reasons. However, acute drug effects have been 
shown to affect impulsive choice (for review, see de Wit, 2009) and recent opioid intake 
influences level of discounting in opioid abusers (Giordano et al., 2001). However, ex-
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smokers and never-smokers discount delayed rewards similarly and less than current-
smokers, suggesting that if smoking alters impulsive choice, it does so temporarily 
(Bickel et al., 1999). Delay discounting assessments conducted before and after the 
initiation of smoking also did not find evidence that smoking altered discounting of 
delayed rewards (Audrain-McGovern et al., in press), despite discounting in smokers 
being higher (Baker et al., 2003; Bickel et al., 1999; Heyman & Gibbs, 2006; Johnson et 
al., 2007; Jones et al., in press; Mitchel, 1999; Reynolds, 2006; Reynolds et al., 2007). 
These results suggest that impulsive choice may cause smoking, but not vice versa. The 
current study was not designed optimally to determine if cocaine self-administration 
influences discounting, but an increase in impulsive choice was measured from the initial 
discounting assessment to the discounting redetermination assessed after a period of 
cocaine self-administration. Increased impulsive choice with age is not typical, as 
impulsive choice typically negatively correlated with age in people (Green, Fry, & 
Myerson, 1994) and in rats (Simon et al., in press). An appropriate control group that 
experienced all the behavioral and surgical components of the current experiment without 
cocaine self-administration was not included, however. While noncontingent injections of 
cocaine are known to increase impulsive choice (Logue et al., 1992; Paine et al., 2003; 
Simon et al., 2007), further research is needed to determine the effects of self-
administered cocaine on impulsive choice.  
In conclusion, individual differences in impulsive choice are associated with 
elasticity of cocaine demand, a measure of reinforcer value. This relationship holds if 
impulsive choice is measured before or after cocaine demand is determined, and sucrose 
demand is not differentiated by individual differences in impulsive choice. Impulsive 
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choice was increased following cocaine self-administration, but the cause of this increase 
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Figure 2-1. Choice data from the initial delay discounting assessment. Top panel: Groups 
of rats divided based on the k parameter from Equation 2-1 fit to the individual subject 
data. Data are presented as percent choice of 3 pellets as a function of the delay to 3 pellets 
for the High (), Medium (), and Low () groups. Symbols near points indicate that 
point is significantly different from the corresponding point in the High (* p < .05, ** p < 
.01, *** p < .001) or the Med group († p < .05), as measured by a Bonferroni-adjusted post 
hoc test. Bottom panel: The fit curves obtained by fitting Equation 2-1 to the individual 
subject data. Curves in solid lines represent the 20 rats for which delay significantly 
affected their choice behavior, as described in the Data Analysis section. Curves in broken 
lines represent the four rats for which delay did not significantly reduce choice behavior. 













































Figure 2-2. Demand for sucrose pellets. Top panel: Demand for sucrose pellets graphed as a 
function of discounting group. Data are plotted as consumption of sucrose pellets as a function 
of FR value. The best-fit parameters from the non-linear regression analyses are shown in the 
inset table for each group. The p value for the statistical comparison of those groups is also 
included for each parameter. Pmax, derived from a, is also included. Bottom panel: The same 
data as in the top panel with individual-subject curves shown. The style of line indicates the 

























































Figure 2-3. Normalized demand for sucrose pellets. Top panel: Normalized demand for 
sucrose pellets as a function of discounting group. Data are plotted as normalized consumption 
of sucrose pellets as a function of normalized price. The L parameter of Equation 2-2 is set to 
100, and the best-fit a parameter is shown in the inset table with associated p value of the 
group comparison. Pmax, which for these comparisons is in arbitrary normalized units, is also 
displayed. Bottom panel: The same data as in the top panel with the individual-subject curves 































































Figure 2-4. Demand for cocaine injections. Top panel: Demand for injections of 0.1 
mg/kg/injection cocaine graphed as a function of discounting group. Data are plotted as 
consumption of cocaine as a function of FR value. The best-fit parameters from the non-linear 
regression analyses are shown in the inset table for each group. The p value for the statistical 
comparison of those groups is also included for each parameter. Pmax, derived from a, is also 
included. Bottom panel: The same data as in the top panel with individual-subject curves 


























































Figure 2-5. Normalized demand for cocaine injections. Top panel: Normalized demand for 
injections of 0.1 mg/kg/injection cocaine as a function of discounting group. Data are plotted 
as normalized consumption of cocaine as a function of normalized price. The L parameter of 
Equation 2-2 is set to 100, and the best-fit a parameter is shown in the inset table with 
associated p value of the group comparison. Pmax, which for these comparisons is in arbitrary 
normalized units, is also displayed. Bottom panel: The same data as in the top panel with the 
individual-subject curves shown. The style of the line indicates the discounting group in which 
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Figure 2-6. Choice data from the delay discounting reassessment. Top panel: Groups of rats 
divided based on the k parameter from Equation 2-1 fit to the individual subject data. Data 
are presented as percent choice of three pellets as a function of the delay to three pellets for 
the High (), Medium (), and Low () groups, not necessarily comprising the same rats 
as in Figure 1. Symbols near points indicate that point is significantly different from the 
corresponding point in the High group (* p < .05, ** p < .01, *** p < .001), as measured by 
a Bonferroni-adjusted post hoc test. Bottom panel: The fit curves obtained by fitting 
Equation 2-1 to the individual subject data. Curves in solid lines represent the 18 rats for 
which delay significantly affected their choice behavior, as described in the Data Analysis 
section. Curves in broken lines represent the three rats for which delay did not significantly 
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Figure 2-7. Discounting parameters collected from the initial discounting assessment 
compared to those collected during the discounting reassessment. Subjects for which 
data was available for both assessments () were used in statistical analyses. If a data 
point was unavailable (U) due to delay failing to significantly affect choices in the 
discounting task during one or both assessments () or if a subject died before one 
assessment (), that point was placed near the right edge or top of the graph 
corresponding to the available. The two open symbols in the upper right portion of the 
graphs represent the two subjects that did not meet criteria in either assessment. Pearson 
product-moment correlation results are shown on the graph, and a Deming regression 
line has been drawn to display this correlation visually. Top panel: Comparison of the 
log k parameter from Equation 2-1 across discounting assessments. Bottom panel: 
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Figure 2-8. Choice from the delay discounting reassessment, grouped as a function of k 
values obtained from the initial delay discounting assessment. Symbols correspond to the 
original High (), Medium (), and Low () discounting groups. Two rats that did not 
meet criteria in the original assessment, but did meet criteria in the reassessment, are also 
shown (). Symbols near points indicate that point is significantly different from the 
corresponding point in the High group (* p < .05), as measured by a Bonferroni-adjusted 







































































Figure 2-9. Demand for injections of 0.1 mg/kg/injection cocaine, with discounting groups 
determined based on the discounting reassessment. The best-fit parameters from the non-linear 
regression analyses are shown in the inset table for each group. The p value for the statistical 
comparison of those groups is also included for each parameter. Pmax, derived from a, is also 
included. Top panel: Demand plotted as consumption of cocaine as a function of FR value. 
Bottom panel: Normalized demand plotted as normalized consumption of cocaine as a 
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Figure 2-10. Discounting parameters compared to log Pmax values from the 
individual normalized cocaine demand curves (Figure 2-5, bottom panel). 
Subjects for which data was available for both assessments () were used in 
statistical analyses. If a measure was unavailable (U) for one due to failure to 
meet inclusion criteria () or if a subject died before one or both assessments 
(), that point was placed near the right edge or top of the graph corresponding 
to the available value. Pearson product-moment correlations were conducted to 
determine if a significant relationship existed between the two assessments and 
a Deming regression line was drawn to display this correlation visually. Top 
panel: Comparison of discounting and cocaine demand using the log k values 
from the initial discounting assessment as a basis. Bottom panel: Comparison of 
discounting and cocaine demand using the log k values from the discounting 
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EFFECTS OF SELECTIVE DOPAMINERGIC COMPOUNDS ON A  
DELAY DISCOUNTING TASK 
Impulsivity and self control are constructs used to describe what is increasingly 
apparent to be more than one class of behaviors. Based on operant and neurobiological 
experiments in humans and animals, a growing consensus largely agrees on two types of 
impulsive behavior: impulsive choice and what is termed impulsive action or behavioral 
inhibition (Dalley, Mar, Economidou, & Robbins, 2008; de Wit, 2009; Evenden, 1999; 
Perry & Carroll, 2008; Winstanley, Eagle, & Robbins, 2006). Impulsive choice is the 
tendency to be hypersensitive to delays of reward, while impulsive action refers to the 
inability to withhold or inhibit a prepotent response. In addition to these two, a third 
component of impulsivity has been proposed by some. Impulsive preparation or 
reflection impulsivity, acting before gathering and processing all necessary information, 
has been argued to encompass impulsive-like responding on a variety of cognitive tasks 
used in humans and an uncertain visual discrimination task in rats (Evenden, 1999).  
Impulsive choice is typically measured using procedures that provide choice 
opportunities between a smaller amount of a reinforcer delivered after little or no delay 
and large amount of the same reinforcer delivered after a longer delay (Ainslie, 1975). 
Impulsive choice on these procedures is defined as the tendency to tolerate only small 
delays to the larger reinforcer before switching to choose the smaller reinforcer, while 
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self-control is defined as the tendency to tolerate relatively long delays to the larger 
reinforcer. Variants of this task are used in both humans and animals, and in humans 
extensive evidence links delay discounting to impulse-control disorders such as attention 
deficit hyperactivity disorder (ADHD) (Schweitzer & Sulzer-Azaroff, 1995; Solanto et 
al., 2001; Sonuga-Barke, Taylor, Sembi, & Smith, 1992; Sonuga-Barke, Williams, Hall, 
& Saxton, 1996) and substance abuse (Audrain-McGovern, in press; Baker, Johnson, & 
Bickel, 2003; Bickel, Odum, & Madden, 1999; Bobova, Finn, Rickert, & Lucas, 2009; 
Coffey, Gudleski, Saladin, & Brady, 2003; Dom, D’haene, Hulstijn, & Sabbe, 2006; 
Heyman & Gibbs, 2006; Johnson, Bickel, & Baker, 2007; Jones, Landes, Yi, & Bickel, in 
press; Kirby & Petry, 2004; Kirby, Petry, & Bickel, 1999; Madden, Bickel, & Jacobs, 
1999; Madden, Petry, Badger, & Bickel, 1997; Mitchel, 1999; Monterosso, Ainslie, Xu, 
Cordova, Domier, & London, 2007; Odum, Madden, Badger, & Bickel, 2000; Odum, 
Madden, & Bickel, 2002; Petry, 2001; Petry & Casarella, 1999; Reynolds, 2006; 
Reynolds, Patak, Shroff, Penfold, Melanko, & Duhig, 2007; Vuchinich & Simpson, 
1998). 
Evidence for the importance of dopaminergic systems in impulsive choice comes 
from a variety of experimental approaches. Dopaminergic pathways from the basal 
ganglia to the prefrontal cortex have been identified as abnormal in people with ADHD, 
as well as involved in choices on the delay discounting task in animals (for recent 
reviews see Bickel, Miller, Yi, Kowal, Lindquist, & Pitcock, 2007; Winstanley et al., 
2006). Functional magnetic resonance imaging (fMRI) scans of people choosing between 
delayed or immediate rewards show activation of prefrontal cortex (PFC) and the 
striatum, with delayed or difficult choices associated with more PFC activation (Ballard 
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& Knutson, 2009; Hoffman et al., 2008; McClure, Laibson, Loewenstein, & Cohen, 
2004; Shamosh et al., 2008). Lesion studies in animals support the involvement of these 
structures, with the nucleus accumbens (NAc) core involved in valuation of reward 
amount in delay discounting (Acheson et al., 2006; Bezzina et al., 2007; Cardinal, 
Pennicott, Sugathapala, Robbins, & Everitt, 2001) and PFC involved in sensitivity to 
delay (Bezzina et al., 2008; Kheramin et al., 2004; Winstanley, Theobald, Cardinal, & 
Robbins, 2004). Given that ADHD is associated with lower PFC dopamine activity 
(Ernst, Zametkin, Matochik, Jons, & Cohen, 1998) and lower PFC activation during a 
task involving delayed reward (Rubia et al., 1999), and that methamphetamine abusers 
also show lower PFC activity during the delay discounting task (Monterosso et al., 2007), 
this neural pathway is a plausible target for treatment of impulse control disorders. 
Both D1-like (D1 and D5) and D2-like (D2, D3, and D4) dopamine receptors, as well as 
dopamine transporters, are known to exist in the dopaminergic pathways connecting the 
striatum to the PFC (Ciliax et al., 1995; Gaspar, Bloch, & Le Moine, 1995; Lévesque et 
al., 1992; Mrzljak, Bergson, Pappy, Huff, Levenson, & Goldman-Rakic, 1996; Muly III, 
Szigeti, & Goldman-Rakic, 1998; Revay, Vaughan, Grant, & Kuhar, 1996). As 
amphetamine and methylphenidate are the two most common pharmaceutical treatments 
for ADHD, it is not surprising that these have been extensively studied in experiments 
with rodents behaving on delay discounting tasks. Systemic methylphenidate treatment 
typically reduces impulsive choice (i.e., animals tolerate longer delays to the larger 
reinforcer) (e.g., Perry, Stairs, & Bardo, 2008; Pitts & Febbo, 2004; Pitts & McKinney, 
2005; van Gaalen, van Koten, Schoffelmeer, & Vanderschuren, 2006), while treatment 
with d-amphetamine shows mixed results. In intact animals, d-amphetamine has been 
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shown to reduce impulsive choice (Floresco, Tse, & Chods-Sharifi, 2008; van den Bergh, 
Bloemarts, Groenink, Olivier, & Oosting, 2006; van Gaalen et al., 2006; Wade, de Wit, & 
Richards, 2000; Winstanley, Theobald, Dalley, & Robbins, 2005), increase impulsive 
choice (Evenden & Ryan, 1996; Helms, Reeves, & Mitchell, 2006), or have no 
significant effect (Stanis, Avila, White, & Gulley, 2008; Uslaner & Robinson, 2006). 
Others have explored these discrepancies further, noting that the effects of amphetamine 
may depend on whether there is a stimulus present during the delay to the larger 
reinforcer (Cardinal, Robbins, & Everitt, 2000), environmental enrichment (Perry et al., 
2008), or baseline level of delay discounting (Barbelivien, Billy, Lazarus, Kelche, & 
Majchrzak, 2008). The nonselective dopamine antagonist flupenthixol has been shown to 
increase impulsive choice (Floresco et al., 2008; Wade et al., 2000). This effect may be 
due to D1-like antagonism or D2-like antagonism, as some reports show that the D1-like 
antagonist SCH 23390 increases impulsive choice while the D2-like antagonists 
haloperidol and eticlopride have no effect (Evenden & Ryan, 1996; van Gaalen et al., 
2006), while another found an increase in impulsive choice with the D2-like antagonist 
raclopride and no effect with SCH 23390 (Wade et al., 2000). To the author’s knowledge, 
the only direct dopamine agonist examined for effects on impulsive choice is the D3-
preferring agonist 7-OH-DPAT, which increased impulsive choice (van den Bergh et al., 
2006). 
As dopaminergic systems that involve a variety of dopamine receptor subtypes 
are involved in impulsive choice, and the effects of systemic injections of selective 
dopamine receptor agonists and antagonists are largely unknown, we administered the 
most selective dopamine receptor agonists and antagonists readily available to male 
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Sprague Dawley rats responding on a slight variation of the delay discounting task 
described by Evenden and Ryan (1996). The drugs administered included d-
amphetamine, the selective dopamine transporter blocker GBR 12909, the D1-like agonist 
SKF 81297, the D1-like antagonist SCH 23390, the D2-like antagonist haloperidol, the D2-
preferring agonist sumanirole, the D2-preferring antagonist L-741,626, the D3-preferring agonist 
pramipexole, the D3-preferring antagonist PG01037, the D4 partial agonist ABT 724, the D4 
antagonist L-745,870, and the nonselective dopamine agonist apomorphine.  
Method 
Subjects 
Twenty-four male Sprague Dawley rats served as subjects (Harlan, Indianapolis, 
IN). Rats were approximately 10 weeks old at the start of the experiment. A food 
restriction protocol was in place to maintain the rats at approximately 325 g throughout 
the experiment. This weight was chosen as it is approximately 85% of the mean adult 
weight supplied by the manufacturer for this strain, and this weight was not changed once 
established. When not in session, rats were housed in accordance with institutional 
animal care and use guidelines in polycarbonate cages with fresh water continuously 
available. The lights in the housing colony were on from 7:00 AM to 7:00 PM, and 
sessions were conducted between 9:00 AM and 3:00 PM. These protocols were approved 
by the University of Michigan Committee on the Use and Care of Animals and 





Sessions were conducted in rodent operant conditioning chambers with an area of 
30.5 cm x 24.1 cm x 21.0 cm and stainless steel grid floors (ENV-008; Med-Associates 
Inc., St. Albans, VT). Both sides of the front panel of the chamber held a retractable lever 
(E23-17, Coulbourn Instruments, Whitehall, PA). Between the levers was a food tray 
connected to a 45 mg pellet dispenser (ENV-200R1AM and ENV-203M-45, Med-
Associates, Inc.). Above both of the levers and the food tray were triple stimulus lights 
containing a red, green, and yellow LED (ENV-222M, Med-Associates, Inc.). A 
houselight was located near the top of the opposite wall to provide illumination to the 
chamber (ENV-215M, Med-Associates, Inc.). Chambers were connected to a computer 
running Med-PC IV software (Med-Associates, Inc.) to control experimental events and 
record data. 
Procedure 
Rats were trained to respond on a mixed fixed-time 60 s fixed ratio (FR) 1 
schedule of reinforcement, with the active lever alternating each session between the left 
and right levers. This schedule arranged one sucrose pellet to be delivered every 60 s 
independent of behavior, with every lever press also producing a pellet. This was 
continued for four sessions, at which point the schedule was switched to a FR 1 with no 
response-independent pellet deliveries. Rats were allowed to respond on this schedule 
until 80 responses or more were recorded on two consecutive 20-min sessions.  
The sessions were then extended to 75 min and split into five components of ten 
discrete-choice trials each. Total trial duration was 90 s and began with one or both levers 
extending into the chamber and illumination of the triple-stimulus lights above the 
lever(s). If a single response was made within 20 s, the levers retracted, the lights were 
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extinguished, and the consequence programmed for that lever was delivered. If no 
response was made within 20 s, that trial was recorded as an omission and the levers 
retracted for the remaining 70 s of that trial. The first two trials of each component were 
always forced-choice trials where only one lever was extended into the chamber, forcing 
the subject to sample the contingencies for that component. The remaining eight trials 
were free-choice trials where both levers were extended into the chamber, allowing the 
rat to respond on either. The three stimulus lights above each lever were lit whenever that 
lever was inserted in the chamber, and the stimulus lights above the pellet tray were lit 
during sucrose pellet deliveries. Initially, the consequences for both levers were 
immediate deliveries of either one or three 45-mg sucrose pellets, with the side associated 
with each amount counterbalanced across subjects. This condition was continued until 
rats chose the three-pellet option on at least 85% of free-choice trials. The three-pellet 
and one-pellet levers were then switched two times, with each new lever assignments in 
place until rats responded on the three-pellet option on at least 85% of trials. When this 
training regimen was completed, delays were introduced between responses made on the 
three-pellet lever and the delivery of the three pellets. The delays to the three-pellet 
option were 0, 10, 20, 40, or 60 s and were always presented in ascending order with one 
delay in effect in each of the five 10-trial components.  
Drug testing began after there was an effect of delay on choices (i.e., choice of the 
three-pellet option decreased as a function of delay to the delivery of the three pellets), 
and no increasing or decreasing trend in choices was apparent over a period of five 
sessions. Sessions were generally conducted five days per week with vehicle injections 
administered on the first and fourth days of the week, drugs administered on the second 
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and fifth days, and no injections given on the third day. Vehicle injections always 
corresponded to the vehicle for the scheduled drug injection or injections for the 
following day in number, substance, and time relative to the experimental session. Each 
session was preceded by a vehicle or drug injection 5 min before the start of the session 
with the rat then immediately placed in the darkened experimental chamber. On some 
days, an antagonist or vehicle injection was administered 30 min prior to the session, with 
the rat placed back in his home cage for the intervening 25 min before the agonist or 
vehicle injection was given, as appropriate. All agonists and the corresponding vehicle 
injections were administered 5 min before the session. All antagonists and the 
corresponding vehicle injections were administered 30 min before the session start, 
except SCH 23390 which was administered 5 min before session start due to its relatively 
rapid onset and short duration of action (Hietala, Seppäla, Lappalainen, & Syvälahti, 
1992). All subjects did not receive all drugs. Each drug was tested in 12 subjects, with the 
allocation of drugs to subjects determined semi-randomly. 
Drugs 
Pramipexole was generously provided by Drs. Jianyong Chen and Shaomeng 
Wang (University of Michigan, Ann Arbor, MI), sumanirole by Benjamin Greedy and 
Dr. Stephen Husbands (University of Bath, Bath, UK), GBR 12909 by Novo Industri 
(Bagsvaerd, Denmark), ABT-724 by Dr. Kenner Rice (Chemical Biology Research 
Branch, National Institute on Drug Abuse, Bethesda, MD), and PG01037 by Drs. Amy H. 
Newman (Medicinal Chemistry Section – National Institute on Drug Abuse, Baltimore, 
MD) and Peter Grundt (University of Minnesota – Duluth, Duluth, MN). Haloperidol, 
SKF 81297, SCH 23390, and apomorphine were obtained from Sigma-Aldrich (St. Louis, 
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MO), L-741,626 and L-745,870 were obtained from Tocris (Ellisville, MO), and d-
amphetamine was obtained from the National Institute on Drug Abuse (Bethesda, MD). 
All drugs were dissolved in sterile saline except L-741,626, which was dissolved in 5% 
ethanol, and PG01037, which was dissolved in 20% β-cyclodextrin. All injections were 
administered subcutaneously (s.c.) in a volume of 1.0 ml/kg except 56 mg/kg PG01037 
which was administered in of volume of 1.75 ml/kg due to solubility limits. 
Data Analysis 
If a subject responded within the limited hold period on at least four of the eight 
free-choice trials of any component, those data were included in data analyses. Percent 
choice of the three-pellet lever was compared across delays to the three-pellet option and 
drug dose with a two-way repeated measures analysis of variance (ANOVA) with Systat 
SigmaStat 3.5 (San Jose, CA). When data were excluded in some components for some 
subjects due to the stated inclusion criterion, SigmaStat used a Mixed Models ANOVA to 
assess within- and between-subjects effects on the incomplete data set. Response latency 
was measured from the insertion of the response lever or levers into the chamber to a 
response on either lever within the limited hold period. Latencies were compared across 
trial type (free- or forced-choice) and drug dose with a two-way repeated measures 
ANOVA with GraphPad Prism 5 (La Jolla, CA). If a subject did not respond on either 
lever during the limited hold period, that trial was recorded as an omission. Omitted free-
choice trials were compared across drug doses with a one-way repeated measures 




A two-way ANOVA was conducted to assess the main effects of delay to three 
pellets, drug dose, and the interaction of the two for each drug tested. All ANOVAs 
revealed a highly significant main effect of delay on choices (F range = 23 to 45, all p < 
.001), indicating that choice of the 3 pellets decreased as the delay to this option 
increased. Individual F values will not be reported for brevity.  
Acute pretreatments of d-amphetamine tended to decrease choice of the three-
pellet option, but only at shorter delays to the three pellets (Figure 3-1). d-Amphetamine 
dose did not significantly affect choices (F4,176 = 2.3, p = .075), but there was a 
significant dose by delay interaction (F16,176 = 2.3, p = .005). Bonferroni-adjusted post 
hoc tests revealed a significant reduction in choices of three pellets after 1.0 mg/kg d-
amphetamine when the delay was 10 s (p = .008). Response latency was not different 
between forced- and free-choice trials (F1,88 = 0.80, p = .380) and was not affected by 
pretreatments of d-amphetamine up to doses of 1.0 mg/kg (dose main effect F4,88 = 1.9, p 
= .334; dose by trial type interaction F4,88 = 0.28, p = .892). d-Amphetamine also did not 
increase trials omitted (Table 3-1, F4,44 = 0.84, p = .508).  
Pretreatments of the dopamine transporter blocker GBR 12909 up to 10 mg/kg did 
not significantly alter choices (dose main effect F3,132 = 1.1, p = .344, dose by delay 
interaction F12,132 = 1.0, p = .420, Figure 3-2). Response latency (dose main effect F3,66 = 
2.5, p = .065, trial type main effect F1,66 = 0.38, p = .545, dose by trial type interaction 




A dose of 0.32 mg/kg the D3-preferring agonist pramipexole decreased large-
reinforcer choice across a range of delays, leading to a significant effect of pramipexole 
dose (F3,129 = 21, p < .001) and a dose by delay interaction (F12,129 = 1.9, p = .047; Figure 
3-3). A dose of 0.32 mg/kg pramipexole reduced large-reinforcer choice as a whole (p < 
.001), and specifically at delays from 0 to 40 (all p < .01). Response latency (dose main 
effect F3,66 = 4.7, p = .005, trial type main effect F1,66 = 0.67, p = .423, dose by trial type 
interaction F3,66 = 0.25, p = .860) and omissions (Table 3-1, F3,33 = 3.4, p = .028) were 
also increased at 0.32 mg/kg pramipexole, with response latency most increased during 
forced-choice trials at 0.32 mg/kg (p < .05). 
Large-reinforcer choices were not significantly altered by the D2-preferring agonist 
sumanirole up to 3.2 mg/kg (Figure 3-4, dose main effect F2,83 = 1.7, p = .203, dose by 
delay interaction F8,83 = 1.8, p = .085). Trials omitted (Table 3-1, F2,22 = 5.9, p = .009) 
and response latency (dose main effect F2,44 = 6.5, p = .003, trial type main effect F1,44 = 
0.42, p = .524, dose by trial type interaction F2,44 = 0.50, p = .611) were increased at 3.2 
mg/kg, however. Bonferroni-adjusted post hoc tests reveal an increase in free-choice trial 
response latency at 3.2 mg/kg sumanirole (p < .05). 
There was no main effect of the D4 partial agonist ABT-724 dose on large-
reinforcer choice (F2,88 = 0.70, p = .510), but there was a significant dose by delay 
interaction (F8,88 = 2.1, p = .049, Figure 3-5). This was due to a small, but significant 
decrease in large-reinforcer choice after 3.2 mg/kg ABT-724 with a delay of 40 s (p = 
.021). Response latency (dose main effect F2,44 = 0.53, p = .592, trial type main effect 
F1,44 = 1.2, p = .279, dose by trial type interaction F2,44 = 0.1.3, p = .291) and omissions 
(Table 3-1, F2,22 = 0.48, p = .626) were not altered by ABT-724 at the doses tested.  
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The D2-like antagonist haloperidol reduced large-reinforcer choice at a dose that 
also increased response latency (Figure 3-6). There was a significant main effect of dose 
on choice (F3,126 = 5.8, p = .003), but this effect did not significantly depend on delay 
(F12,126 = 1.7, p = .078). A dose of 0.1 mg/kg haloperidol reduced large-reinforcer choice 
(p = .002), with a significant effect at delays from 0 to 20 s (all p < .05). At this same 
dose of 0.1 mg/kg, haloperidol increased response latency (dose main effect F3,66 = 8.0, p 
< .001, trial type main effect F1,66 = 0.49, p = .491, dose by trial type interaction F3,66 = 
0.43, p = .733). This increase was observed during both forced- and free-choice trials 
(both p < .05). Omissions were not significantly increased at doses up to 0.1 mg/kg (F3,33 
= 1.9, p = .147).  
The D3-preferring antagonist PG01037 slightly decreased large-reinforcer choice at 
the highest dose tested (Figure 3-7). No main effect of dose was found (F3,132 = 2.3, p = 
.092), but there was a dose by delay interaction (F12,132 = 1.9, p = .035). The dose of 56 
mg/kg PG01037 significantly reduced large-reinforcer choice at a delay of 10 s (p = 
.043). Response latency (dose main effect F3,66 = 1.8, p = .157, trial type main effect F1,66 
= 0.96, p = .338, dose by trial type interaction F3,6 = 0.40, p = .752) and omissions (Table 
3-1, F3,33 = 0.65, p = .586) were not affected by PG01037 at the doses tested.  
The D2-preferring antagonist L-741,626 (Figure 3-8) dose-dependently decreased 
large-reinforcer choice (F3,130 = 6.5, p = .001) in a way that did not depend on delay (dose 
by delay interaction F12,130 = 1.1, p = .394). L-741,626 decreased large-reinforcer choice 
when administered at 1.0 or 3.2 mg/kg (both p < .05), with highly significant decreases 
observed in the 0 s delay condition with 3.2 mg/kg L-741,626 (p < .001). Response 
latency was increased after administration of 3.2 mg/kg L-741,626 in both forced- (p < 
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.001) and free-choice (p < .05) trials (dose main effect F3,66 = 12, p < .001, trial type main 
effect F1,66 = 0.61, p = .444, dose by trial type interaction F3,66 = 0.94, p = .426). 
Omissions were not increased at the doses tested (Table 3-1, F3,33 = 1.6, p = .217).  
The D4 antagonist L-745,870 had little effect on behavior at the doses tested 
(Figure 3-9). Large-reinforcer choice was not altered (dose main effect F3,132 = 1.2, p = 
.329, dose by delay interaction F12,132 = 0.70, p = .751), nor was response latency (dose 
main effect F3,66 = 1.1, p = .338, trial type main effect F1,66 = 0.63, p = .436, dose by trial 
type interaction F3,66 = 0.33, p = .802) or omissions (Table 3-1, F3,33 = 1.0, p = .405).  
The D1-like agonist SKF 81297 dose-dependently decreased large-reinforcer 
choice, but this effect was limited to the shorter delays (Figure 3-10). This tendency 
resulted in a significant main effect of SKF 81297 dose (F3,138 = 11, p < .001) and a 
significant dose by delay interaction (F12,138 = 7.6, p < .001). A dose of 0.32 mg/kg SKF 
81297 decreased large-reinforcer choice only at the 0 s delay condition (p = .002), while 
choice after 1.0 mg/kg hovered around 50% at all delays, significantly decreasing choice 
from 0 to 20 s (all p < .001). Omissions (Table 3-1, F3,36 = 4.1, p = .014) and response 
latency (dose main effect F3,72 = 6.1, p < .001, trial type main effect F1,72 = 4.5, p = .046, 
dose by trial type interaction F3,72 = 0.57, p = .636) were slightly increased at 1.0 mg/kg, 
this effect most notable during free-choice trials (p < .01).  
Administration of the D1-like antagonist SCH 23390 produced a selective increase 
in impulsive choice, with 0.01 mg/kg decreasing choice at moderate delays without 
affecting choice in the 0 s delay condition (Figure 3-11). A main effect of dose was 
observed (F4,152 = 6.7, p < .001), with both 0.01 (p < .001) and 0.032 (p < 0.05) SCH 
23390 decreasing large-reinforcer choice. A dose by delay interaction was also noted 
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(F16,152 = 3.1, p < .001). The effects of 0.01 mg/kg were selective to the 10 and 20 s 
delays (both p < .001), while 0.032 mg/kg resulted in more indifferent choice and a 
significant reduction in large-reinforcer choice at the 0 and 10 s delays (both p < .05). 
This move toward indifference at 0.032 mg/kg SCH 23390 was accompanied by a large 
increase in trials omitted (Table 3-1, F4,44 = 26, p < .001) and a large increase in both 
forced- and free choice latency (both p < .001, dose main effect F4,88 = 13, p < .001, trial 
type main effect F1,88 = 1.5, p = .230, dose by trial type interaction F4,88 = 0.06, p = .993). 
A range of doses of the D1-like agonist SKF 81297 were co-administered with 0.01 
mg/kg of the D1-like antagonist SCH 23390 to determine if the effects seen with SCH 
23390 were reversible by a D1-like agonist. Little systematic reversal was found with doses 
of SKF 81297 up to 1.0 mg/kg (Figure 3-12). There was a main effect of dose on large-
reinforcer choice (F4,156 = 23, p < .001), with 0.01 mg/kg SCH 23390 alone decreasing 
choice (p < .001). No dose of SKF 81297 significantly reversed this effect, although there 
were some effects of SKF 81297 dose that depended on delay (F16,156 = 5.1, p < .001). A 
dose of 0.01 mg/kg SCH 23390 alone decreased large-reinforcer choice relative to 
vehicle at delays ranging from 10 s to 40 s (all p < .05). When co-administered with SCH 
23390, compared to the effects of 0.01 mg/kg SCH 23390 alone 0.1 mg/kg SKF 81297 
further decreased large-reinforcer choice at a 40 s delay (p < .05) and 1.0 mg/kg SKF 
81297 increased large-reinforcer choice at a 20 s delay (p < .05), but decreased it at a 0 s 
(p < .001) and 60 s (p < .05) delay. Adding 1.0 mg/kg SKF 81297 to 0.01 mg/kg SCH 
23390 increased the response latency over that observed with 0.01 mg/kg SCH 23390 
alone in both the forced- and free-choice trials (both p < .05, dose main effect F4,88 = 7.8, 
p < .001, trial type main effect F1,88 = 5.0, p = .036, dose by trial type interaction F4,88 = 
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0.46, p = .763). No significant effect on trials omitted was observed across these dosing 
conditions (Table 3-1, F4,44 = 1.9, p = .120).  
The nonselective dopamine agonist apomorphine (Figure 3-13) had little effect on 
large-reinforcer choice until a dose of 0.32 mg/kg, at which a sizeable decrease in choice 
was observed (p < .001, dose main effect F3,128 = 43, p < .001 dose by delay interaction 
F12,128 = 6.1, p < .001). That dose of 0.32 mg/kg apomorphine decreased large-reinforcer 
choice to below 50%, such that a majority of responses were allocated to the small-
reinforcer option at all delays. This decrease was significantly different from vehicle 
choice data at delays ranging from 0 to 40 s (all p < .001). This pattern of choice was 
accompanied by an increase in response latency in both the forced- and free-choice trials 
(both p < .01, dose main effect F3,66 = 22, p < .001, trial type main effect F1,66 = 1.1, p = 
.300, dose by trial type interaction F3,66 = 2.9, p = .039) and in increase in omissions 
(Table 3-1, F3,33 = 10, p < .001).  
Discussion 
In general, doses of drugs that increased response latency or trials omitted also 
moved choice data toward indifference (50% choice). A decrease or increase in choice 
that is independent of delay is not an increase or decrease, respectively, in impulsive 
choice. Rather, changes in choice behavior that occurs when both consequences are not 
delayed are better conceptualized as an effect on sensitivity to the amount of the 
reinforcer or an inability to discriminate or adapt to the consequences of responding 
(Acheson et al., 2006; Pitts & Febbo, 2004). For the purposes of this paper, selective, 
potentially clinically-relevant effects were considered to be those effects on delay that did 
not coincide with a decrease in sensitivity to amount or a significant increase in response 
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latency. Those effects on delayed choice that coincided with decreases in sensitivity to 
amount (decrease in three-pellet choice at delay = 0 s) or increase in response latency 
were of less interest. The selectivity of effects on impulsive choice is indicated in the 
legend of each graph, with selective increases () in impulsive choice or disruptions in 
behavior in the form of decreased sensitivity to amount or increase response latency () 
indicated. Two drugs tested did affect choice of the large reinforcer as a function of delay 
without altering response latency or ability to discriminate amount. These drugs are SCH 
23390 and ABT-724, and are discussed in more detail below.  
The D1-like antagonist SCH 23390 selectively increased impulsive choice at 0.01 
mg/kg (Figure 3-11). This effect has been reported previously at a similar dose (van 
Gaalen et al., 2006), but not on an adjusting-amount procedure over the same dose range 
(Wade et al., 2000). The D4 partial agonist ABT-724, which has not been previously 
assessed on a model of impulsive choice, also selectively increased choice of the smaller 
reward when the larger reward was delayed 40 s. Both D4 and D1-like receptors are located 
in the frontal cortex. D1-like receptors are located both on GABAergic interneurons (Muly 
III et al., 1998) and on pyramidal neurons with projections back to the striatum, among 
other areas (Gaspar et al., 1995). D4 receptors are located primarily on GABAergic 
interneurons in the monkey cortex (Mrzljak et al., 1996), but have been located on both 
GABAergic interneurons and pyramidal neurons in the rat cortex (Wędzony, Chocyk, 
Maćkowiak, Fijał, & Czyrak, 2000). As GABA is an inhibitory neurotransmitter, D4 
agonism and D1-like antagonism in the prefrontal cortex may functionally have the same 
effect depending on relative influence of binding sites on GABAergic and pyramidal 
sites. This complex organization of the prefrontal cortex, and the fact that the D4 
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antagonist L-745,870 and the D1-like agonist SKF 81297 did not have the opposite result 
as ABT-724 and SCH 23390 in the present study, may result from the hypothesized 
notion that moderate stimulation of D1-like  receptors results in optimal cell firing (Muly 
III et al., 1998). D4 receptors are an intriguing target for ADHD medications. D4 
polymorphisms in humans are associated with ADHD (Faraone et al., 2005), and D4 
receptor distribution in the brain is relatively limited, but includes the prefrontal cortex 
(Van Tol et al., 1991). Methylphenidate has been shown to increase dopamine and 
norepinephrine in the prefrontal cortex to a greater extent and at lower doses than in the 
nucleus accumbens (dopamine) or medial septal area (norepinephrine) (Berridge et al., 
2006). Added to the finding that D4 receptors have high affinity for both dopamine and 
norepinephrine (Wedemeyer, Goutman, Avale, Franchini, Rubinstein, & Calvo, 2007) 
and dopaminergic and noradrenergic mechanisms are involved in the current commonly 
used ADHD treatments, the D4 receptor is an appealing target for ADHD treatment. The 
effect seen with ABT-724 in the present study was small in magnitude, but this could be 
due to the relatively low efficacy of this compound (Brioni et al., 2004). The selective 
increase in impulsive choice was also in the opposite direction than would be clinically 
relevant, however. Further research is needed to determine if a D4 ligand could produce a 
reliable, therapeutically-relevant effect. 
Both the agonists (pramipexole and sumanirole) and the antagonists (haloperidol, 
PG01037, and L-741,626) acting through D2 and/or D3 receptors had similar effects. As a 
whole, these drugs tended to decrease amount discrimination by decreasing choice of the 
large reinforcer when it was not delayed. None had a selective effect on impulsive choice. 
In the brain, D2 and D3 receptors are found in large numbers in the nucleus accumbens, 
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but are also found in prefrontal cortex (Bouthenet, Souil, Martres, Sokoloff, Giros, & 
Schwartz, 1991). The core of the nucleus accumbens has been shown to be involved in 
accurately assessing reinforcer value on delay discounting tasks (Acheson et al., 2006; 
Cardinal et al., 2001). It is unknown why stimulation and blockade of D2 or D3 receptors 
would have similar effects, however.  
Apomorphine had a unique profile of effects on choice, with the first active dose 
producing a bias toward the lever arranging the small reinforcer at all delays to the large 
reinforcer. Choice for the large reinforcer after administration of 0.32 mg/kg 
apomorphine was even below 50%, which would indicate indifference. Apomorphine has 
been shown to produce a robust anorectic effect at this dose (Willner, Towell, & Muscat, 
1985). However, if apomorphine was causing the sucrose pellets to be unpalatable, it 
would seem that one pellet would not be preferred. Apomorphine has also been shown to 
induce perseverative responding that appears disconnected from response consequences 
(Robbins, Watson, Gaskin, & Ennis, 1983) or that is punished (Chapter 4), which 
could potentially explain these data. Why the subjects tended to perseverate on the 
response option producing fewer reinforcers is unknown. 
Neither d-amphetamine nor the selective dopamine transporter blocker GBR 
12909 selectively increased or decreased impulsive choice at the doses tested. At 1.0 
mg/kg, d-amphetamine decreased sensitivity to amount. Previous research has found an 
increase, decrease, or lack of effect with d-amphetamine. The one study to previously test 
GBR 12909 found a decrease in impulsive choice, the same effect that was found with d-
amphetamine in that report (van Gaalen et al., 2006). The absence of consistent effects 
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with these drugs is curious, although environmental conditions are known to affect the 
effects of d-amphetamine on this task (Cardinal et al., 2000; Perry et al., 2008).  
In conclusion, of the five dopamine receptors D1-like and D4 receptors appear to be 
most selectively involved in mediating impulsive choice. Both the D1-like antagonist SCH 
23390 and the D4 partial agonist ABT-724 increased impulsive choice, which may be 
explained by their differing locations within the PFC, an area known to be involved in 
impulsive choice. None of the selective agonists and antagonists tested reduced impulsive 
choice; however, so further research is needed to determine if direct dopaminergic 
agonists or antagonist may be therapeutically useful in the treatment of impulse control 
disorders.  
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Table 3-1. Average number of the 40 free-choice trials omitted (± SEM) for each dose of 



































































































































0.01 SCH 23390 







+ 0.1 SKF 
6.6 (±3.2) 
+ 0.32 SKF 
3.1 (±3.0) 














Veh: Vehicle for the drug or drugs in that condition. SCH = SCH 23390. SKF = SKF 
81297. 
* p < .05, ** p < .01, *** p < .001 compared to vehicle in Bonferroni-adjusted post hoc 























































Figure 3-1. Top panel: Percent choice of the three-pellet lever (+ SEM) 
when that option was delayed from 0 to 60 s as a function of d-
amphetamine pretreatment dose. Each symbol shape represents a 
pretreatment dose, and the symbol fill color represents statistical 
significance of a Bonferroni-adjusted post hoc test comparing that point 
to the corresponding Vehicle point at the same delay (black = n.s.; gray 
= p < .05; white = p < .001). Asterisks appearing near a dose in the 
legend represent a significant difference from the Vehicle condition, 
independent of delay (* p < .05; ** p < .01; *** p < .001). Selective 
effects on behavior corresponding to an increase () or decrease () in 
impulsive choice, or a disruption in behavior (), is also indicated in 
the legend. Bottom panel: Latency to respond (+ SEM) during forced 
and free choice trials as a function of d-amphetamine pretreatment 
dose. Asterisks above a bar indicate statistical significance of a 
Bonferroni-adjusted post hoc test compared to the corresponding 






















































Figure 3-2. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of GBR 12909 





















































Figure 3-3. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of pramipexole 





















































Figure 3-4. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of sumanirole 


















































Figure 3-5. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of ABT-724 pretreatment 























































Figure 3-6. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of haloperidol 





















































Figure 3-7. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of PG01037 pretreatment 






















































Figure 3-8. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of L-741,626 




















































Figure 3-9. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of L-745,870 




















































Figure 3-10. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of SKF 81297 
























































Figure 3-11. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of SCH 23390 
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Figure 3-12. Top panel: Percent choice of the three-pellet lever (+ 
SEM) when that option was delayed from 0 to 60 s as a function of 
vehicle pretreatment, 0.01 mg/kg SCH 23390 pretreatment, or 0.01 
mg/kg SCH 23390 administered with varying doses of SKF 81297. 
Each symbol shape represents a pretreatment condition, and the symbol 
fill color represents statistical significance of a Bonferroni-adjusted 
post hoc test comparing that point to the corresponding Vehicle point at 
the same delay (SCH 23390 alone) or to the corresponding SCH 23390 
alone point at the same delay (SCH 23390 + SKF 81297 combinations) 
(black = p > .05; gray = p < .05; white = p < .001). The selective 
increase () in impulsive choice in the SCH 23390 alone condition is 
also indicated in the legend.  Bottom panel: Latency to respond (+ 
SEM) during forced and free choice trials as a function of pretreatment. 
Daggers above a bar indicate statistical significance of a Bonferroni-
adjusted post hoc test compared to the corresponding agonist alone 











































Figure 3-13. Percent choice of the three-pellet lever (top panel) and 
response latency (bottom panel) as a function of apomorphine 
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EFFECTS OF SELECTIVE DOPAMINERGIC COMPOUNDS ON A  
PACED FIXED CONSECUTIVE NUMBER SCHEDULE 
Impulsivity and self control are constructs used to describe what is increasingly 
apparent to be more than one class of behaviors. Based on operant and neurobiological 
experiments in humans and animals, a growing consensus largely agrees on two types of 
impulsive behavior: impulsive choice and what is termed impulsive action or behavioral 
inhibition (Dalley, Mar, Economidou, & Robbins, 2008; de Wit, 2009; Evenden, 1999; 
Perry & Carroll, 2008; Winstanley, Eagle, & Robbins, 2006). Impulsive choice is the 
tendency to be hypersensitive to delays to reward, while impulsive action refers to the 
inability to withhold or inhibit a prepotent response. In addition to these two, a third 
component of impulsivity has been proposed by some. Impulsive preparation or 
reflection impulsivity, acting before gathering and processing all necessary information, 
has been argued to encompass impulsive-like responding on a variety of cognitive tasks 
used in humans and the uncertain visual discrimination task in rats (Evenden, 1999).  
Behavior maintained on a fixed consecutive number (FCN) has been purported to 
measure impulsive action (Evenden, 1999). To obtain a reinforcer on an FCN 8 schedule, 
for example, a series of at least eight responses must be emitted on a “chain” lever before 
a single response on a second “reinforcement lever” results in a reinforcer delivery. If 
fewer than 8 responses are made on the chain lever (i.e., chain length < 8), responding on 
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the reinforcement lever is punished with a timeout. Impulsive action on this task is 
defined as response chains of fewer than the requisite number before responding on the 
reinforcement lever. Evenden (1998b) developed a variant of this task, dubbed a paced 
FCN schedule, that controls for the rate-increasing or rate-decreasing effects many drugs 
have on schedule-maintained behavior. By withdrawing the levers after every response 
and reinserting them into the chamber after a specified interval, the maximum response 
rate can be controlled. On this procedure, spontaneously hypertensive rats, a purported 
rodent model of ADHD, show more impulsive action than Wistar Kyoto rats, the strain 
from which spontaneously hypertensive rats were selectively bred (Evenden & Myerson, 
1999; for a review of spontaneously hypertensive rats, see Sagvolden, Russell, Aase, 
Johansen, & Fashbaf, 2005).  
Dopaminergic pathways between the prefrontal cortex, anterior cingulate cortex, 
and basal ganglia are often implicated in attention deficit hyperactivity disorder (ADHD) 
and impulsive behavior (for recent reviews see Dalley et al., 2008; Winstanley et al., 
2006). Imaging studies in people with ADHD reveal abnormalities in this system, with 
lower prefrontal activity (Ernst, Zametkin, Matochik, Jons, & Cohen, 1998; Rubia et al., 
1999) and enhanced dopamine transporter availability in the striatum (Krause, Dresel, 
Krause, Kung, & Tatsch, 2000). Similarly, animal models of impulsive action have 
implicated these same pathways. Anterior cingulate cortex lesions greatly increase 
premature responding on the 5-choice serial reaction time (5-CSRT) task (Muir, Everitt, 
& Robbins, 1996), another purported measure of impulsive action (see Dalley et al., 
2008). Number of premature responses emitted on the 5-CSRT task is also related to 
dopamine D2-like receptor levels in the ventral striatum (Dalley et al., 2007). While 
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dopamine levels in the prefrontal cortex measured during 5-CSRT task performance are 
elevated, the level of this elevation is not related to the amount of premature responses 
emitted (Dalley, Theobald, Eagle, Passetti, & Robbins, 2002), nor do prefrontal cortex 
lesions affect premature responding (Muir et al., 1996).  
Both D1-like (D1 and D5) and D2-like (D2, D3, and D4) dopamine receptors, as well as 
dopamine transporters, are known to exist in the dopaminergic pathways connecting the 
striatum to the prefrontal cortex (Ciliax et al., 1995; Gaspar, Bloch, & Le Moine, 1995; 
Lévesque et al., 1992; Mrzljak, Bergson, Pappy, Huff, Levenson, & Goldman-Rakic, 
1996; Muly III, Szigeti, & Goldman-Rakic, 1998; Revay, Vaughan, Grant, & Kuhar, 
1996). Amphetamine has been tested extensively on FCN and paced FCN schedules, and 
generally decreases chain lengths (i.e., increases impulsive action; Bardo, Cain, & Bylica, 
2006; Bronson & Moerschbaecher, 1987; Evenden, 1998a, 1998b; Evenden & Myerson, 
1999; Laties, 1972; Laties, Wood, & Rees, 1981; Rees, Wood, & Laties, 1985, 1987). 
The opposite effect has been occasionally reported with d-amphetamine, but only when a 
distinct discriminative stimulus was associated with completing the series of chain 
responses (Rivalan, Grégoire, & Dellu-Hagedorn, 2007, one subject in Laties, 1972). As 
d-amphetamine has been shown to increase responding associated with a stimulus paired 
with reinforcement (e.g., Robbins, Watson, Gaskin, & Ennis, 1983), the addition of such 
a stimulus may have contributed to this discrepancy. To the author’s knowledge, no 
selective dopamine agonists or D1-like antagonists have been administered to rats 
responding on FCN schedules. On FCN schedules, the D2-like antagonist haloperidol has 
been shown to increase (Picker, 1988), decrease (Evenden, 1998a), or have no effect on 
chain lengths (Laties, 1972; Picker, 1989), and decreases in chain lengths are seen after 
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haloperidol administration on a paced FCN schedule (Evenden, 1998b; Evenden & 
Myerson, 1999).  
As dopaminergic systems that involve a variety of dopamine receptor subtypes 
are involved in impulsivity, and the effects of systemic injections of selective dopamine 
receptor agonists and antagonists is largely unknown, we administered the most selective 
dopamine receptor agonists and antagonists readily available to Sprague Dawley rats 
responding on a paced FCN schedule as described by Evenden (1998b). The drugs 
administered included d-amphetamine, the selective dopamine transporter blocker GBR 
12909, the D1-like agonist SKF 81297, the D1-like antagonist SCH 23390, the D2-like 
antagonist haloperidol, the D2-preferring agonist sumanirole, the D2-preferring antagonist L-
741,626, the D3-preferring agonist pramipexole, the D3-preferring antagonist PG01037, the D4 
partial agonist ABT 724, the D4 antagonist L-745,870, and the nonselective dopamine 
agonist apomorphine. The antagonists listed above were sometimes administered prior to 
these agonists to further elucidate the mechanisms of action of these drugs. 
Method 
Subjects 
Eight male Sprague Dawley rats served as subjects (Harlan, Indianapolis, IN). 
Rats were approximately 10 weeks old at the start of the experiment. A food restriction 
protocol was in place to maintain the rats at approximately 325 g throughout the 
experiment. This weight was chosen as it is approximately 85% of the mean adult weight 
supplied by the manufacturer for this strain, and this weight was not changed once 
established. When not in session, rats were housed in accordance with institutional 
animal care and use guidelines in polycarbonate cages with fresh water continuously 
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available. The lights in the housing colony were on from 7:00 AM to 7:00 PM, and 
sessions were conducted between 2:30 PM and 6:30 PM. These protocols were approved 
by the University of Michigan Committee on the Use and Care of Animals and 
conformed to the guidelines established by the NIH Guide for the Use of Laboratory 
Animals. 
Apparatus 
Sessions were conducted in rodent operant conditioning chambers with an area of 
30.5 cm x 24.1 cm x 21.0 cm and stainless steel grid floors (ENV-008; Med-Associates 
Inc., St. Albans, VT). Both sides of the front panel of the chamber held a retractable lever 
(E23-17, Coulbourn Instruments, Whitehall, PA). Between the levers was a food tray 
connected to a 45-mg pellet dispenser (ENV-200R1AM and ENV-203M-45, Med-
Associates, Inc.). Above both of the levers and the food tray were triple stimulus lights 
containing a red, green, and yellow LED (ENV-222M, Med-Associates, Inc.). A 
houselight was located near the top of the opposite wall to provide illumination to the 
chamber (ENV-215M, Med-Associates, Inc.). Chambers were connected to a computer 
running Med-PC IV software (Med-Associates, Inc.) to control experimental events and 
record data. 
Procedure 
Rats were trained to respond on a mixed fixed-time 60 s FR 1 schedule of 
reinforcement, with the active lever alternating each session between the left and right 
levers. This schedule arranged one sucrose pellet to be delivered every 60 s independent 
of behavior, with every lever press also producing a pellet. This was continued for four 
sessions, at which point the schedule was switched to a FR 1 with no response-
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independent pellet deliveries. Rats were allowed to respond on this schedule until 80 
responses or more were recorded on two consecutive 20-min sessions. 
Paced FCN schedule training then began with the subjects placed in the operant 
chambers and both levers extended. Left and right levers were randomly assigned to each 
subject as either the “chain lever” or the “sucrose lever”, and these assignments did not 
change over the course of the experiment. The FCN contingency reinforced responding 
on the chain lever a number of times equal to or greater than the FCN schedule value 
followed by a single response on the sucrose lever. Training started with an FCN 1 
schedule, where one or more responses on the chain lever followed by one response on 
the sucrose lever resulted in a 45-mg sucrose pellet delivery and both levers being 
retracted for 5 s. After each response, both levers were retracted and reinserted such that 
the maximum response rate was controlled, but with no minimum response rate, as 
described in detail by Evenden (1998b). Sessions were also split into five components, 
separated by 1-min blocks with the houselight off and the levers retracted. Components 1, 
3, and 5 were 10 min in duration with a pacing interval of 2.5 s, and components 2 and 4 
were 20 min in duration with a pacing interval of 5.0 s. The total session duration during 
all paced FCN sessions with the five components and four intervening blackout periods 
was 74 min. The FCN schedule value was then gradually increased over a number of 
sessions to FCN 8, where eight or more responses on the chain lever were required before 
one response on the sucrose lever was reinforced with a food pellet. At each paced FCN 
schedule value, chain lengths greater than required were reinforced with a sucrose pellet, 




Drug testing began after there was no apparent increasing or decreasing trend in 
mean chain length in each component over a period of five sessions. Sessions were 
generally conducted five days per week with vehicle injections administered on the first 
and fourth days of the week, drugs administered on the second and fifth days, and no 
injections given on the third day. Vehicle injections always corresponded to the vehicle 
for the scheduled drug injection or injections for the following day in number, substance, 
and time relative to the experimental session. Each session was preceded by a vehicle or 
drug injection 5 min before the start of the session with the rat then immediately placed in 
the darkened experimental chamber. On some days, an antagonist or vehicle injection 
was administered 30 min prior to the session, with the rat placed back in his home cage 
for the intervening 25 min before the agonist or vehicle injection was given, as 
appropriate. All agonists and the corresponding vehicle injections were administered 5 
min before the session. All antagonists and the corresponding vehicle injections were 
administered 30 min before the session start, except SCH 23390 which was administered 
5 min before session start due to its relatively rapid onset and short duration of action 
(Hietala, Seppäla, Lappalainen, & Syvälahti, 1992). 
Drugs 
Pramipexole was generously provided by Drs. Jianyong Chen and Shaomeng 
Wang (University of Michigan, Ann Arbor, MI), sumanirole by Benjamin Greedy and 
Dr. Stephen Husbands (University of Bath, Bath, UK), GBR 12909 by Novo Industri 
(Bagsvaerd, Denmark), ABT-724 by Dr. Kenner Rice (Chemical Biology Research 
Branch, National Institute on Drug Abuse, Bethesda, MD), and PG01037 by Drs. Amy H. 
Newman (Medicinal Chemistry Section – National Institute on Drug Abuse, Baltimore, 
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MD) and Peter Grundt (University of Minnesota – Duluth, Duluth, MN). Haloperidol, 
SKF 81297, SCH 23390, and apomorphine were obtained from Sigma-Aldrich (St. Louis, 
MO), L-741,626 and L-745,870 were obtained from Tocris (Ellisville, MO), and d-
amphetamine was obtained from the National Institute on Drug Abuse (Bethesda, MD). 
All drugs were dissolved in sterile saline except L-741,626, which was dissolved in 5% 
ethanol, and PG01037, which was dissolved in 20% β-cyclodextrin. All injections were 
administered subcutaneously (s.c.) in a volume of 1.0 ml/kg except 56 mg/kg PG01037 
which was administered in of volume of 1.75 ml/kg due to solubility limits. 
Data Analysis 
Chain length was defined as the number of consecutive responses on the chain 
lever before a response was recorded on the sucrose lever, and a decrease in chain length 
was interpreted as an increase in impulsive action. Chain length data were analyzed and 
plotted as survival plots, or the percent of chains of at least X responses as a function of 
drug dose. Summarized in this manner, data were well-approximated by the sigmoidal 
equation 
  𝑌𝑌 = 100
1+10(𝐶𝐶50−𝑎𝑎 )∗𝑆𝑆
 (4-1)  
where Y is the percent chains meeting X or more responses and C50 and S are derived 
parameters, C50 indicating the chain length that 50% of chains met or exceeded, and S 
indicating the slope of the curve at point C50. Data were fit to Equation 4-1 and curves 
were compared with GraphPad Prism 5 (La Jolla, CA) to determine if drug dose 
significantly altered the C50 parameter. Specific doses were considered to be significantly 
different from each other if the 95% confidence intervals around the C50 parameter did 
not overlap for those doses. Specific chain lengths were also compared between doses 
124 
 
with Bonferroni-adjusted post hoc tests following a significant main effect of dose or a 
dose by chain length interaction of a two-way Analysis of Variance (ANOVA) in Prism 
5. Chain lengths were computed separately for the short (2.5 s) pacing-interval 
components and the long (5.0 s) pacing-interval components. Chain-length data for the 
short or long components of any session for any subject were excluded if less than five 
chains were completed for that session. Data for any dose were excluded if less than two 
rats met this chains-completed criterion.  
Perseverative responses were defined as sucrose-lever responses that were not 
preceded by at least one chain-lever response (i.e., consecutive sucrose-lever responses), 
and were expressed as a percent of total sucrose-lever responses. These were compared 
across dose with a one-way repeated measures ANOVA in Systat SigmaStat 3.5 (San 
Jose, CA), with Bonferroni-adjusted post hoc tests following significant main effects of 
dose. Perseverative-response data for any session were only included in analyses if ten or 
more trials were recorded for that subject. If data were excluded, SigmaStat uses a Mixed 
Models ANOVA to assess within- and between-subjects effects on an incomplete data 
set. Total trials were defined as the total number of sucrose-lever responses (including 
perseverative responses), each of which was followed by a timeout. Trials were recorded 
separately for short and long components, and compared with a two-way repeated 
measures ANOVA with Prism 5. Relevant Bonferroni-adjusted post hoc tests were 





The dopaminergic drugs assessed in the current paper had varied effects on 
behavior, but of most interest were “selective” increases or decreases in impulsive action 
that did not coincide with overall disruptions in responding. Significant increases or 
decreases in chain length in either component after a given dose of a drug were 
considered selective unless those effects coincided with a significant reduction in trials 
completed. Defined in this way, increases in impulsive action (), decreases in impulsive 
action (), and disruptions in behavior () are indicated on each graph in the legend.   
d-Amphetamine dose-dependently decreased chain lengths during both the short 
and long components (Figure 4-1, Table 4-1). In the short components, the derived chain 
length met 50% of the time (C50 in Equation 4-1; roughly equal to the median chain 
length) was significantly decreased at 0.32 and 1.0 mg/kg, with 1.0 mg/kg being the only 
dose with significant post hoc tests for specific points. In the long components, each dose 
of d-amphetamine tested from 0.1 to 1.0 mg/kg decreased the C50 parameter, while post 
hoc tests revealed significant reductions at specific chain lengths at 0.32 and 1.0 mg/kg. 
Total trials completed (Table 4-2) and perseverative responses (Table 4-3) were both 
dose-dependently increased by d-amphetamine. Larger increases in number of trials 
completed were seen in the long-pacing components, leading to a significant main effect 
of dose (F3,20 = 4.6, p = .014) and a dose by pacing interval interaction (F3,20 = 4.8, p = 
.012) with no main effect on pacing interval (F1,20 = 0.19, p = .666). Perseverative 
responses were also increased at 1.0 mg/kg (main effect, F3,15 = 13, p < .001). 
The dopamine transporter blocker GBR 12909 significantly affected chain lengths 
in both the short and long components, but these shifts were not dose-dependent or 
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sizeable (Figure 4-2, Table 4-1). Significant increases in chain lengths were seen with 1.0 
mg/kg in both the short and long components and at 10.0 mg/kg in the short components 
only. The 3.2 mg/kg dose had no significant effect on chain lengths in either component. 
Across this same dose range, GBR 12909 did not alter total trials completed (pacing 
interval main effect F1,28 = 195, p < .001, dose main effect F3,28 = 1.3, p = .305, dose by 
pacing interval interaction F3,28 = 1.1, p = .351; Table 4-2) or perseverative responses 
(F3,21 = 1.8, p = .187; Table 4-3). 
The D3-preferring agonist pramipexole dose-dependently decreased chain lengths in 
both the short and long pacing interval components (Figure 4-3, Table 4-1). In the short 
components, doses from 0.032 to 0.32 mg/kg decreased chain lengths, while doses from 
0.01 to 0.1 mg/kg decreased chain lengths in the long components. These decreases with 
low doses of pramipexole up to 0.032 mg/kg did not significantly decrease trials 
completed (Table 4-2), but higher doses did decrease trials completed (pacing interval 
main effect F1,30 = 102, p < .001, dose main effect F4,30 = 23, p < .001, pacing interval by 
dose interaction F4,30 = 2.5, p = .067). The percent of sucrose lever responses that were 
perseverative (F4,20 = 18, p < .001) were also dose-dependently increased, but only at 
doses that also decreased responding (Table 4-3).  
The effects of the D2-preferring agonist sumanirole on chain length depended on dose 
and pacing interval (Figure 4-4, Table 4-1). In the short components, 0.32 mg/kg 
sumanirole slightly increased chain lengths, while the same dose had no effect in the long 
components. The 0.56 mg/kg dose had no effect in either component, while 1.0 mg/kg 
decreased chain length in both components. Sumanirole dose-dependently decreased 
trials completed (pacing interval main effect F1,24 = 71, p < .001, dose main effect F3,24 = 
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5.7, p = .004, pacing interval by dose interaction F3,24 = 4.1, p = .017; Table 4-2), while 
perseverative responses increased over the same dose range (F3,18 = 5.7, p = .007, Table 
4-3).  
The D4-partial agonist ABT-724 significantly altered chain lengths in the short 
components, but these shifts were small and not dose-dependent (Figure 4-5, Table 4-1). 
The doses of 0.32 and 3.2 mg/kg both decreased chain lengths, while 1.0 mg/kg had no 
effect. This same range of doses did not alter chain lengths in the long components, and 
Bonferroni-adjusted post hoc tests did not reveal a significant increase or decrease in 
chain length distributions at any number of responses in either component. ABT-724 had 
no effect on trials completed (pacing interval main effect F1,28 = 147, p < .001, dose main 
effect F3,28 = 0.37, p = .773, pacing interval by dose interaction F3,28 = 0.46, p = .714) or 
perseverative responses (F3,21 = 2.4, p = .096) over the range of doses tested (Table 4-2, 
Table 4-3). 
The D2-like antagonist haloperidol significantly shifted chain lengths in the short 
and long components, the direction of which depended on both pacing interval and dose 
(Figure 4-6, Table 4-1). The smallest dose of haloperidol tested, 0.01 mg/kg, significantly 
shifted chain lengths to the right in the short components only, while higher doses shifted 
chain lengths to the left in both components. At the highest dose tested, 0.1 mg/kg, trials 
completed were significantly reduced in both components (Table 4-2; pacing interval 
main effect F1,24 = 69, p < .001, dose main effect F3,24 = 13, p < .001, pacing interval by 
dose interaction F3,24 = 1.9, p = .015). Perseverative responses were also dose-
dependently increased, but only significantly so at a dose that also reduced trials 
completed (Table 4-3; F3,15 = 12, p < .001).  
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The D3-preferring antagonist PG01037 increased chain lengths in both the short and 
long components (Figure 4-7, Table 4-1). In the short components chain lengths were 
increased at the two highest doses tested, while 10 mg/kg had no significant effect. In the 
long components, 10 mg/kg and 32 mg/kg significantly increased chain lengths, albeit 
only slightly, while 56 mg/kg decreased chain lengths. Across this dose range, trials 
completed were not altered (Table 4-2; pacing interval main effect F1,24 = 30, p < .001, 
dose main effect F3,24 = 0.32, p = .809, pacing interval by dose interaction F3,24 = 2.7, p = 
.070), and perseverative responses were increased at 56 mg/kg (Table 4-3; dose main 
effect F3,18 = 5.0, p = .011).  
The D2-preferring antagonist L-741,626 significantly decreased chain lengths in both 
components (Figure 4-8, Table 4-1). In the short components, L-741,626 had no effect 
except when a dose of 3.2 mg/kg was administered, a dose that drastically reduced 
responding. In the long components, 1.0 mg/kg L-741,626 reduced chain lengths slightly. 
Trials completed were substantially reduced at 3.2 mg/kg (Table 4-2; pacing interval 
main effect F1,28 = 118, p < .001, dose main effect F3,28 = 107, p < .001, pacing interval 
by dose interaction F3,28 = 6.9, p = .001), while percent perseverative responses were 
increased at this same dose (Table 4-3; F3,17 = 31, p < .001). 
The D4 antagonist L-745,870 only slightly altered behavior, although some shifts 
in chain lengths did reach statistical significance (Figure 4-9, Table 4-1). Chain lengths 
were slightly increased by 0.32 mg/kg in the short components, and decreased by 3.2 
mg/kg in the long components. Specific chain lengths were not altered in either 
component, as measured by Bonferroni-adjusted post hoc tests. Across this range of 
doses, total trials completed (pacing interval main effect F1,28 = 147, p < .001, dose main 
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effect F3,28 = 0.55, p = .652, pacing interval by dose interaction F3,28 = 0.76, p = .529) or 
perseverative responses (main effect F3,21 = 0.85, p = .485) were not altered (Table 4-2, 
Table 4-3).  
To determine which receptors mediated the effects seen with pramipexole, 
antagonists at various receptors were administered as pretreatments to pramipexole. 
Haloperidol at 0.01 mg/kg was able to partially reverse the decreases in chain lengths 
caused by 0.1 mg/kg pramipexole in both components (Figure 4-10, Table 4-1). 
Haloperidol at 0.32 mg/kg partially reversed the effects of 0.1 mg/kg pramipexole in the 
long components, but potentiated this effect in the short components. Haloperidol at 
0.032 mg/kg also significantly reversed the decrease in total trials completed cause by 0.1 
mg/kg pramipexole, while 0.01 mg/kg haloperidol had no significant effect (Table 4-2; 
pacing interval main effect F1,24 = 87, p < .001, dose main effect F3,24 = 14, p < .001, 
pacing interval by dose interaction F3,24 = 0.71, p = .557). Perseverative responses were 
significantly altered across the conditions tested (F3,18 = 4.9, p = .012), but no specific 
comparisons of interest were statistically significant (Table 4-3).  
In the short component, 10 mg/kg of the D3-preferring antagonist PG01037 
administered prior to 0.1 mg/kg pramipexole completely reversed the decrease in chain 
lengths seen with this dose (Figure 4-11; Table 4-1). In the long component, effects of 
PG01037 pretreatments were difficult to interpret. Pramipexole at 0.1 mg/kg decreased 
chain lengths alone, and chain lengths were shortened further by 32 mg/kg PG01037 but 
increased by 56 mg/kg. This lack of dose-dependency may have been due to the low 
number of total trials completed on which these chain length distributions were based. 
PG01037 did not reverse the decrease in trials completed caused by 0.1 mg/kg 
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pramipexole, and in the short component further decreased trials completed at 10 and 56 
mg/kg (Table 4-2; pacing interval main effect F1,35 = 167, p < .001, dose main effect F4,35 
= 35, p < .001, pacing interval by dose interaction F4,35 = 1.8, p = .157). PG01037 also 
did not reverse the increase in perseverative responses caused by 0.1 mg/kg pramipexole 
(Table 4-3; main effect F4,27 = 3.8, p = .014). 
The D2-preferring antagonist L-741,626 at 0.32 mg/kg significantly reversed the 
decrease in chain lengths caused by 0.1 mg/kg pramipexole in both the short and long 
components (Figure 4-12, Table 4-1). Administered as a pretreatment to 0.1 mg/kg 
pramipexole, 1.0 mg/kg L-741,626 decreased chain lengths compared with pramipexole 
alone in the short component and had no effect in the long component. L-741,626 did not 
reverse the decrease in trials completed caused by 0.1 mg/kg pramipexole, instead further 
decreasing trials completed (Table 4-2; pacing interval main effect F1,28 = 94, p < .001, 
dose main effect F3,28 = 37, p < .001, pacing interval by dose interaction F3,28 = 1.1, p = 
.348). L-741,626 also did not reverse the increase in perseverative responses caused by 
0.1 mg/kg pramipexole (Table 4-3; dose main effect F3,20 = 3.7, p = .028). 
The D1-like agonist SKF 81297 slightly, but significantly, increased chain lengths 
in the short component at 0.1 and 0.32 mg/kg, but these same doses had no effect in the 
long component (Figure 4-13, Table 4-1). SKF 81297 at 1.0 mg/kg decreased chain 
lengths in both components. At the doses tested, SKF 81297 did not alter trials completed 
(Table 4-2; pacing interval main effect F1,28 = 24, p < .001, dose main effect F3,28 = 0.19, 
p = .904, pacing interval by dose interaction F3,28 = 1.2, p = .342), but did dose-




The D1-like antagonist SCH 23390 had no significant effect on behavior at doses 
that did not also significantly alter trials completed (Figure 4-14, Table 4-1). A dose of 
0.032 mg/kg in the short component and 0.01 mg/kg in the long component both reduced 
chain lengths, and not enough responses were made to compute chain lengths in the long 
component following the administration of 0.032 mg/kg. Trials completed were dose-
dependently decreased by SCH 23390 (Table 4-2; pacing interval main effect F1,28 = 255, 
p < .001, dose main effect F3,28 = 255, p < .001, pacing interval by dose interaction F3,28 = 
15, p < .001). Perseverative responses were increased, but only at a dose that decreased 
responding overall (Table 4-3; dose main effect F2,14 = 6.6, p = .010). 
The D1-like antagonist SCH 23390 was administered along with 1.0 mg/kg of the 
D1-like agonist SKF 81297 to determine whether the behavioral effects of this dose were 
reversible. SCH 23390 from 0.001 to 0.01 mg/kg did not reverse the decrease in chain 
lengths caused by 1.0 mg/kg SKF 81297, and actually decreased chain lengths further at 
each dose (Figure 4-15; Table 4-1). SKF 81297 at 1.0 mg/kg alone did not alter trials 
completed, and the addition of SCH 23390 did not significantly affect this measure 
either, although there was a trend toward a decrease in trials completed at higher doses of 
SCH 23390 (Table 4-2; pacing interval main effect F1,35 = 6.1, p = .019, dose main effect 
F4,35 = 2.5, p = .059, pacing interval by dose interaction F4,35 = 2.2, p = .085). SCH 23390 
also did not affect the increase in perseverative responses caused by 1.0 mg/kg SKF 
81297 (dose main effect F4,27 = 8.2, p < .001; Table 4-3).  
The nonselective dopamine agonist apomorphine had effects on chain lengths that 
depended on pacing-interval and dose (Figure 4-16, Table 4-1). Significant effects that 
were small in absolute magnitude were noted with 0.032 mg/kg in both components and 
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0.1 mg/kg in the long component, but sizeable increases were caused by 0.32 mg/kg in 
the short component. This same dose decreased chain lengths in the long component, and 
decreased total trials completed (Table 4-2; pacing interval main effect F1,28 = 64, p < 
.001, dose main effect F3,28 = 16, p < .001, pacing interval by dose interaction F3,28 = 2.4, 
p = .089). Perseverative responses were also dose-dependently increased with 
apomorphine (Table 4-3; main effect F3,20 = 5.5, p = .007). 
The D1-like antagonist SCH 23390 and the D2-like antagonist haloperidol were 
administered with 0.32 apomorphine to determine if the effects of this dose could be 
reversed. A dose of 0.01 mg/kg SCH 23390 reversed the increase in chain lengths in the 
short component caused by 0.32 mg/kg apomorphine, but no dose of SCH 23390 tested 
reversed the decrease in chain lengths caused by 0.32 mg/kg apomorphine in the long 
component (Figure 4-17, Table 4-1). SCH 23390 also did not reverse the decrease in 
trials completed cause by 0.32 mg/kg apomorphine, and further decreased trials 
completed at 0.01 mg/kg (Table 4-2; pacing interval main effect F1,28 = 29, p < .001, dose 
main effect F3,28 = 14, p < .001, pacing interval by dose interaction F3,28 = 2.1, p = .126). 
SCH 23390 also appeared to further increase the increase in perseverative responses 
noted with 0.32 mg/kg apomorphine, although these effects were not significant due to a 
large amount of subject variability (Table 4-3; main effect F3,16 = 2.5, p = .094).  
The D2-like antagonist haloperidol, when given as a pretreatment to 0.32 mg/kg 
apomorphine, did not reverse the effects on chain lengths seen with this dose (Figure 
4-18, Table 4-1). A dose of 0.01 mg/kg haloperidol had no effect in either pacing-interval 
component, while 0.032 mg/kg decreased chain lengths in both components. A dose of 
0.032 mg/kg haloperidol also decreased trials completed beyond the decrease seen with 
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0.32 apomorphine alone (Table 4-2; pacing interval main effect F1,28 = 38, p < .001, dose 
main effect F3,28 = 22, p < .001, pacing interval by dose interaction F3,28 = 4.7, p = .009. 
Haloperidol at the doses tested did not significantly alter the increase in perseverative 
responses seen with 0.32 mg/kg apomorphine (Table 4-3; main effect F3,13 = 5.6, p = 
.011).  
Discussion 
Responding on a paced FCN 8 schedule was learned by all subjects and 
performance remained relatively stable over the course of the experiment. Chain lengths 
on this schedule were very sensitive to the effects of the dopaminergic drugs 
administered. Chain lengths were altered after administration of most of the compounds 
tested, but selective increases and decreases that did not coincide with significant 
decreases in trials completed were more limited. 
d-Amphetamine dose-dependently decreased chain lengths over a range of doses 
that also dose-dependently increased trials completed. Similar effects have been reported 
before on FCN schedules (Bardo et al., 2006; Bronson & Moerschbaecher, 1987; 
Evenden, 1998a, 1998b; Evenden & Myerson, 1999; Laties, 1972; Laties et al., 1981; 
Rees et al., 1985, 1987). The changes in chain length induced by the dopamine 
transporter-selective ligand GBR 12909 were small in magnitude, suggesting that the 
effects of d-amphetamine were likely mediated through serotonergic or noradrenergic 
mechanisms.  
The selective drugs with affinity for D2 and D3 receptors had effects that seemed 
to depend on receptor subtype selectivity and efficacy at that receptor. The D3-preferring 
agonist pramipexole and the D2-preferring antagonist L-741,626 both selectively reduced 
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chain lengths, while the D2-preferring agonist sumanirole and the D3-preferring antagonist 
PG01037 selectively increased chain lengths in at least one case. A model of impulsive 
action have been shown to be related to D2-like receptors in the ventral striatum (Dalley et 
al., 2007), but this apparent opposing action of D2 and D3 receptors has not previously 
been demonstrated on models of impulsivity. D2 and D3 receptors have been shown to 
have opposing effects in other behavioral systems, however. D3 receptor activation 
induces yawning and penile erections while D2 receptor activation inhibits those same 
behaviors (Collins et al., 2007), and the discriminative stimulus properties of these same 
drugs share an analogous pattern of results. In rats trained to discriminate the subjective 
effects of pramipexole from saline, L-741,626 substituted for the pramipexole stimulus; 
and in rats trained to discriminate the subjective effects of sumanirole from saline, 
PG01037 substituted for the sumanirole stimulus (Koffarnus, Greedy, Husbands, Grundt, 
Newman, & Woods, 2009). It is not known for certain what pathways of the brain are 
important for paced FCN responding, but given that D3 and D2 receptors are more often 
located on presynaptic and postsynaptic sites, respectively (Bouthenet, Souil, Martres, 
Sokoloff, Giros, & Schwartz, 1991), the opposing effects in the current study of agonist 
and antagonists that act through these receptors may be a consequence of this 
relationship.  
The decreasing effect of 0.1 mg/kg pramipexole on chain lengths was antagonized 
in at least one component by at least one dose of haloperidol, PG01037, and L-741,626.  
A dose of 0.01 mg/kg haloperidol reversed the decrease in chain lengths caused by 0.1 
mg/kg pramipexole in both the short and long components, although this dose increased 
chain lengths in the short component when administered alone. A dose of 10 mg/kg 
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PG01037, which did not alter chain lengths in the short component when administered 
alone, reversed the decrease caused by pramipexole in the short component, while the 
effects of PG01037 in the long component were not dose-dependent and difficult to 
interpret. A dose of 0.32 mg/kg L-741,626, a dose that had no effect when administered 
alone, at least partially reversed the decrease caused by 0.1 mg/kg pramipexole in both 
components. These data suggest the decrease in chain lengths caused by 0.1 mg/kg 
pramipexole may be partially mediated through agonism at both D2 and D3 receptors. L-
741,626 is only about 15-fold selective for D2 over D3 receptors, however (Grundt, 
Husbands, Luedtke, Taylor, & Newman, 2007), leaving open the possibility that all three 
antagonists are acting through D3 receptors. 
The D1-like agonist SKF 81297 significantly increased chain lengths at 0.1 and 
0.32 mg/kg in the short component, although these increases were very small in 
magnitude, while 1.0 mg/kg SKF 81297 decreased chain lengths in both components. 
SCH 23390 had no significant effect on chain lengths up to doses that drastically reduced 
trials completed. In addition, SCH 23390, when administered as a pretreatment to 1.0 
mg/kg SKF 81297, only potentiated the decrease in chain lengths caused by SKF 81297 
at every dose tested. This remained true for doses of SCH 23390 that had no significant 
effect when administered alone, and the very low dose of 0.001 mg/kg which was not 
tested in isolation.  
In the short components, 0.32 mg/kg apomorphine produced the largest increase 
in chain length in absolute size of any dose of any drug administered. Since apomorphine 
is an agonist at all five dopamine receptor subtypes, SCH 23390 and haloperidol were 
administered as pretreatments to this dose of apomorphine to assess the involvement of 
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D1-like or D2-like receptors. A dose of 0.01 mg/kg SCH 23390, which had no significant 
effect when administered alone, reversed the increase in chain lengths in the short 
component caused by 0.32 mg/kg apomorphine. A dose of 0.032 mg/kg haloperidol also 
reversed this apomorphine-induced increase. This dose of haloperidol lowered chain 
lengths when administered alone, however, so it is not clear that this effect was due to an 
antagonism of apomorphine. Apomorphine is known to produce perseverative responding 
that seems disconnected from the consequences that result (Robbins et al., 1983), which 
may have contributed to these effects. Perseverating on the chain lever would likely 
manifest as an increase in chain lengths, although a similar increase was not observed in 
the long component. Perseverative responding on the reinforcement lever was also 
significantly increased with 0.32 mg/kg apomorphine (Table 4-3). 
While no drug administered significantly decreased perseverative responding on 
the sucrose lever, increases in perseverative responses were also caused by a number of 
the drugs in the current experiment. The pattern of these increases appeared to be of two 
types. One might conceptualize perseverative responses as chain lengths of zero, as each 
is a response on the sucrose lever with no preceding responses on the chain lever. In the 
current study, all of the drugs that produced large decreases in chain lengths also 
produced significant increases in perseverative responses at similar doses. As a drug 
tended to increase the proportion of lower-length chains, the proportion of the lowest-
length chain possible (0 responses) was also increased. This tendency has been described 
quantitatively on an individual-subject basis, with a strong negative correlation between 
drug effects on chain lengths and perseverative responses on the paced FCN (Chapter 
6). This pattern was observed seemingly independent of drug mechanism, and was found 
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in the current experiment with administration of relatively high doses of d-amphetamine, 
pramipexole, sumanirole, haloperidol, PG01037, L-741,626, SKF 81297, and SCH 
23390. A pattern of effects that differed from the one described above was noted for two 
drugs, however. Doses of 56 mg/kg PG01037 and 0.32 mg/kg apomorphine both 
increased perseverative responses with a mixed effect on chain length. These drugs both 
increased chain lengths in the short component, but decreased chain lengths in the long 
component. Upon further analysis, however, most of the increase in perseverative 
responses occurred in the long component along with the decrease in chain lengths. 
Additional two-way repeated measures ANOVAs (assessing pacing interval, drug dose, 
and the interaction between these factors; analysis not shown) revealed a significant 
increase in perseverative responses only in the long component with these drugs, with 
smaller non-significant increases with both drugs in the short component. Therefore, the 
pattern of the increase in perseverative responses with all drugs assessed in the current 
study is similar, with increases uniformly coinciding with decreases in chain length. Also 
of note regarding perseverative responses was the lack of any antagonism observed with 
any of the increases observed. Antagonists administered prior to 0.1 mg/kg pramipexole 
(antagonists tested: haloperidol, PG01037, and L-741,626), 1.0 mg/kg SKF 81297 
(antagonist tested: SCH 23390), or 0.32 mg/kg apomorphine (antagonists tested: 
haloperidol and SCH 23390) did not reverse the increase in perseverative responses seen 
with the respective agonist. This is true even though some of the antagonists were 
effective at reversing the change in chain lengths observed with the respective agonist 
(e.g., 0.01 mg/kg haloperidol + 0.1 mg/kg pramipexole). The strong relationship between 
chain lengths and perseverative responses noted with agonists and antagonists 
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administered alone did not seem to hold when these same compounds were co-
administered.  
In conclusion, dopaminergic modulation of paced FCN responding is apparent, 
with most compounds tested influencing chain lengths, often at low doses that did not 
disturb total responding. An interesting opposing action was observed with D2 and D3 
receptor agonists and antagonists, suggesting differential mediation of chain lengths by 
these receptors. The D2-preferring agonist sumanirole and the D3-preferring antagonist PG01037 
had similar effects, both increasing chain lengths and therefore decreasing impulsive 
action as defined by this task. These increases were observed at relatively low doses that 
did not adversely affect total responding on this or other operant schedules (e.g., 
Koffarnus et al., 2009). Involvement of D2-like receptors and brain areas rich in D2-like 
receptors in impulsive action has been proposed previously (Dalley et al., 2007). The 
opposing mechanism of D2 and D3 receptors in the current paper has not been described 
previously, and has implications for potentially therapeutically-relevant specific 
dopaminergic compounds in the treatment of impulse control disorders.   
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Table 4-1. The derived value of C50 (± SEM) from Equation 4-1, or the number of 
responses that was met by 50% of the chains for each dose of each drug tested. C50 values 
are reported separately for the long- and short-pacing components. 
d-Amphetamine 



































































































































































Haloperidol +  
0.1 Pramipexole 










+ 0.01 Hal 
9.84(0.09) †† 
7.27(0.15) †† 






PG01037 +  
0.1 Pramipexole 










+ 10 PG 
10.13(0.15) †† 
6.67(0.05) 
+ 32 PG 
8.61(0.25) 
4.64(0.26) † 
+ 56 PG 
8.85(0.25) 
7.98(0.22) †† 
L-741,626 +  
0.1 Pramipexole 










+ 0.32 L-741 
9.79(0.13) †† 
7.23(0.41) † 








































SCH 23390 +  
1.0 SKF 81297 










+ 0.001 SCH 
7.33(0.37) † 
4.71(0.27) †† 
+ 0.0032 SCH 
5.41(0.44) †† 
3.90(0.32) †† 





















SCH 23390 +  
0.32 Apomorphine 










+ 0.0032 SCH 
10.44(0.14) 
7.22(0.40) † 




Haloperidol +  
0.32 Apomorphine 










+ 0.01 Hal 
10.49(0.16) 
8.64(0.13) 




n.d.: Not enough data to compute value. Apo = apomorphine. Hal = haloperidol. L741 = 
L-741,626. PG = PG01037. Pram = pramipexole. SCH = SCH 23390. SKF = SKF 81297.  
* p < .05, ** p < 0.01, *** p < .001 compared to vehicle in Bonferroni-adjusted post hoc 
tests. 
† p < .05, †† p < 0.01, ††† p < .001 compared to agonist alone in Bonferroni-adjusted 





Table 4-2. Total trials completed (± SEM) for each dose of each drug tested. As each trial 
ends with a sucrose-lever response, this figure is also equal to total sucrose-lever 







































































































































































+ 0.01 Hal 
28.4(4.7) 
13.0(2.8) 

















+ 10 PG 
19.3(3.4) †† 
5.8(3.1) 
+ 32 PG 
25.9(3.2) 
5.6(1.9) 
+ 56 PG 
21.4(2.4) † 
7.6(1.1) 











+ 0.32 L-741 
20.3(4.0) † 
6.4(3.2) 






































SCH 23390 +  










+ 0.001 SCH 
30.1(11.6) 
22.3(8.6) 
+ 0.0032 SCH 
27.3(10.5) 
28.5(12.7) 































+ 0.0032 SCH 
27.6(8.0) 
22.5(7.4) 















+ 0.01 Hal 
17.0(6.3) 
12.5(4.7) 




Apo = apomorphine. Hal = haloperidol. L741 = L-741,626. PG = PG01037. Pram = 
pramipexole. SCH = SCH 23390. SKF = SKF 81297.  
* p < .05, ** p < 0.01, *** p < .001 compared to vehicle in Bonferroni-adjusted post hoc 
tests. 
† p < .05, †† p < 0.01, ††† p < .001 compared to agonist alone in Bonferroni-adjusted 





Table 4-3. Perseverative responses, or sucrose-lever responses not preceded by any chain 


































































































+ 0.01 Hal 
18.94(4.12) 
+ 0.032 Hal 
32.96(8.99) 
 






+ 10 PG 
23.22(5.77) 
+ 32 PG 
30.65(9.30) 
+ 56 PG 
24.80(10.24) 






+ 0.32 L-741 
24.79(5.46) 

























SCH 23390 +  





+ 0.001 SCH 
40.02(9.09) 
+ 0.0032 SCH 
39.11(8.96) 


















+ 0.0032 SCH 
28.70(11.49) 
+ 0.01 SCH 
38.53(13.26) 
 





17.75(6.04) *  
+ 0.01 Hal 
12.85(5.57) 
+ 0.032 Hal 
22.48(6.41) 
 
n.d.: Not enough data to compute value. Apo = apomorphine. Hal = haloperidol. L741 = 
L-741,626. PG = PG01037. Pram = pramipexole. SCH = SCH 23390. SKF = SKF 81297.  
* p < .05, ** p < 0.01, *** p < .001 compared to vehicle in Bonferroni-adjusted post hoc 
tests. 
† p < .05, †† p < 0.01, ††† p < .001 compared to agonist alone in Bonferroni-adjusted 














































































Figure 4-1. Effects of d-amphetamine pretreatments on chain length distributions 
in the short (top panel) and long (bottom panel) pacing components. Chain lengths 
are displayed as a percent of chains meeting or exceeding x responses as function 
of dose. All chains meeting or exceeding eight responses (dashed vertical line) 
were reinforced with a sucrose pellet. Asterisks appearing in the legend indicate, 
following a significant F test, that the 95% (*) or 99% (**) confidence intervals 
around the C50 parameter of the function fit to the data for the indicated dose and 
the corresponding vehicle point did not overlap. Shading of individual points 
indicates a significant difference from the corresponding vehicle point (black, n.s.; 
gray, p < .05; white, p < .001). Selective effects on behavior corresponding to an 
increase () or decrease () in impulsive action, or a disruption in behavior (), 






























































Figure 4-2, Effects of GBR 12909 pretreatments on chain length distributions in 
the short (top panel) and long (bottom panel) pacing components. All other details 































































Figure 4-3. Effects of pramipexole pretreatments on chain length distributions in 
the short (top panel) and long (bottom panel) pacing components. All other details 






























































Figure 4-4. Effects of sumanirole pretreatments on chain length distributions in 
the short (top panel) and long (bottom panel) pacing components. All other 






























































Figure 4-5. Effects of ABT-724 pretreatments on chain length distributions in the 
short (top panel) and long (bottom panel) pacing components. All other details as 





























































Figure 4-6. Effects of haloperidol pretreatments on chain length distributions in 
the short (top panel) and long (bottom panel) pacing components. All other details 






























































Figure 4-7. Effects of PG01037 pretreatments on chain length distributions in the 
short (top panel) and long (bottom panel) pacing components. All other details as 





























































Figure 4-8. Effects of L-741,626 pretreatments on chain length distributions in 
the short (top panel) and long (bottom panel) pacing components. All other 






























































Figure 4-9. Effects of L-745,870 pretreatments on chain length distributions in the 
short (top panel) and long (bottom panel) pacing components. All other details as 













+ 0.01 Hal ††
0.1 Pram ** ()


























+ 0.01 Hal ††
0.1 Pram ** ()



















Figure 4-10. Effects of haloperidol pretreatments on the effects of 0.1 mg/kg 
pramipexole on chain length distributions in the short (top panel) and long 
(bottom panel) pacing components. Chain lengths are displayed as a percent of 
chains meeting or exceeding x responses as function of dose. All chains meeting 
or exceeding eight responses (dashed vertical line) were reinforced with a sucrose 
pellet. Asterisks appearing in the legend indicate, following a significant F test, 
that the 95% (*) or 99% (**) confidence intervals around the C50 parameter of the 
function fit to the data for the indicated dose and the corresponding vehicle point 
did not overlap. Daggers indicate that the 95% (†) or 99% (††) confidence 
intervals of the agonist plus antagonist and agonist alone lines do not overlap. 
Shading of individual points in the agonist alone curve indicates a significant 
difference from the corresponding vehicle point, while shading of the antagonist 
plus agonist points indicates a significant difference from the corresponding 
agonist alone point (black, n.s.; gray, p < .05; white, p < .001). Selective effects 
on behavior corresponding to an increase () or decrease () in impulsive action, 
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Figure 4-11. Effects of PG01037 pretreatments on the effects of 0.1 mg/kg 
pramipexole on chain length distributions in the short (top panel) and long 
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Figure 4-12. Effects of L-741,626 pretreatments on the effects of 0.1 mg/kg 
pramipexole on chain length distributions in the short (top panel) and long 






























































Figure 4-13. Effects of SKF 81297 pretreatments on chain length distributions in 
the short (top panel) and long (bottom panel) pacing components. All other details 





























































Figure 4-14. Effects of SCH 23390 pretreatments on chain length distributions in 
the short (top panel) and long (bottom panel) pacing components. All other details 
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Figure 4-15. Effects of SCH 23390 pretreatments on the effects of 1.0 mg/kg SKF 
81297 on chain length distributions in the short (top panel) and long (bottom 






























































Figure 4-16. Effects of apomorphine pretreatments on chain length distributions 
in the short (top panel) and long (bottom panel) pacing components. All other 
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Figure 4-17. Effects of SCH 23390 pretreatments on the effects of 0.32 mg/kg 
apomorphine on chain length distributions in the short (top panel) and long 




  Haloperidol + Apomorphine







+ 0.032 Hal ††
Vehicle



























0.32 Apo * ()
+ 0.01 Hal



















Figure 4-18. Effects of haloperidol pretreatments on the effects of 0.32 mg/kg 
apomorphine on chain length distributions in the short (top panel) and long 
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EFFECTS OF SELECTIVE DOPAMINERGIC COMPOUNDS ON AN 
UNCERTAIN VISUAL DISCRIMINATION TASK 
Impulsivity and self control are constructs used to describe what is increasingly 
apparent to be more than one class of behaviors. Based on operant and neurobiological 
experiments in humans and animals, a growing consensus largely agrees on two types of 
impulsive behavior: impulsive choice and what is termed impulsive action or behavioral 
inhibition (Dalley, Mar, Economidou, & Robbins, 2008; de Wit, 2009; Evenden, 1999a; 
Perry & Carroll, 2008; Winstanley, Eagle, & Robbins, 2006). Impulsive choice is the 
tendency to be hypersensitive to delays to reward, while impulsive action refers to the 
inability to withhold or inhibit a prepotent response. In addition to these two, a third 
component of impulsivity has been proposed by some. Impulsive preparation or 
reflection impulsivity, acting before gathering and processing all necessary information, 
has been argued to encompass impulsive-like responding on a variety of cognitive tasks 
used in humans and the uncertain visual discrimination (UVD) task in rats (Evenden, 
1999a).  
The UVD task is an interesting model of impulsivity in rats, as behavior on this 
task may include components of impulsive action and impulsive preparation (Dalley et 
al., 2008; Evenden, 1999a). In a two-lever operant chamber, responses on one lever are 
reinforced while responses on the other lever are punished with a timeout. The reinforced 
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lever is determined randomly at the beginning of each trial, and visual stimuli that 
probabilistically correlate with the correct lever are illuminated above the levers. The 
probability that the stimuli are correct increases as the trial progresses, such that 
withholding a response for a few seconds greatly increases the ability to discriminate the 
correct response location. This behavior pattern is hypothesized to model cognitive tasks 
such as the Matching Familiar Figures Test and the Tower of London, which have been 
used to study impulsivity in humans (Evenden, 1999a). Responses made prior to the 
illumination of the uncertain stimuli, or premature responses, on this task are also 
punished with a timeout. Premature responses on the 5-CSRT task, originally developed 
as a model of sustained attention (Robbins, 2002), are typically thought of as a model of 
impulsive action. Therefore, the UVD task provides two distinct measures of impulsivity 
within a single session. 
Dopaminergic pathways between the prefrontal cortex, anterior cingulate cortex, 
and basal ganglia are often implicated in attention-deficit/hyperactivity disorder (ADHD) 
and impulsive behavior (for recent reviews see Dalley et al., 2008; Winstanley et al., 
2006). Imaging studies in people with ADHD reveal abnormalities in this system, with 
lower prefrontal activity (Ernst, Zametkin, Matochik, Jons, & Cohen, 1998; Rubia et al., 
1999) and enhanced dopamine transporter availability in the striatum (Krause, Dresel, 
Krause, Kung, & Tatsch, 2000). Similarly, animal models of impulsive action have 
implicated these same pathways. Anterior cingulate cortex lesions greatly increase 
premature responding on the 5-CSRT task (Muir, Everitt, & Robbins, 1996), and number 
of premature responses emitted is related to dopamine D2-like receptor levels in the ventral 
striatum (Dalley et al., 2007). While dopamine levels in the prefrontal cortex measured 
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during 5-CSRT task performance are elevated, the level of this elevation is not related to 
the amount of premature responses emitted (Dalley, Theobald, Eagle, Passetti, & 
Robbins, 2002), nor do prefrontal cortex lesions affect premature responding (Muir et al., 
1996). Brain circuitry has not been explicitly associated with levels of impulsive 
responding in models of impulsive preparation, but prefrontal cortical areas are critical 
for responding on these tasks (Crews & Boettiger, 2009).  
Both D1-like (D1 and D5) and D2-like (D2, D3, and D4) dopamine receptors, as well as 
dopamine transporters, are known to exist in the dopaminergic pathways connecting the 
striatum to the prefrontal cortex (Ciliax et al., 1995; Gaspar, Bloch, & Le Moine, 1995; 
Lévesque et al., 1992; Mrzljak, Bergson, Pappy, Huff, Levenson, & Goldman-Rakic, 
1996; Muly III, Szigeti, & Goldman-Rakic, 1998; Revay, Vaughan, Grant, & Kuhar, 
1996). The only dopaminergic compounds to be tested on the uncertain visual 
discrimination task are haloperidol, which increased response latency (decreased 
impulsive preparation), and amphetamine which had no effect on latency, but increased 
premature responses (Evenden, 1999b). Amphetamine also increased premature 
responses on the 5-choice serial reaction time task (Cole & Robbins, 1987; van Gaalen, 
Brueggeman, Bronius, Schoffelmeer, & Vanderschuren, 2006), but not if these responses 
were not punished with a timeout (Bizzarro, Patel, Murtagh, & Stolerman, 2004; Bizarro 
& Stolerman, 2003). Cocaine and the selective dopamine transporter blocker GBR 12909 
also increasd premature responses (van Gaalen et al., 2006), but methylphenidate has this 
effect only under limited conditions or not at all (Navarra et al., 2008; Paine, 
Tomasiewicz, Zhang, & Carlezon, 2007). The dopamine D1-like antagonist SCH 23390 
and the D2-like antagonist raclopride tended to decrease premature responses, but the D2-like 
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antagonist eticlopride did not (Koskinen & Sirviö, 2006; van Gaalen, 2006). SCH 23390 
and the D2-like antagonist sulpiride administered directly into the nucleus accumbens did 
not alter premature responses, while the D1-like partial agonist SKF 38393 increased 
premature responses (Pezze, Dalley, & Robbins, 2007).  
As dopaminergic systems that include a variety of dopamine receptor subtypes are 
involved in impulsivity, and the effects of systemic injections of selective dopamine 
receptor agonists and antagonists is largely unknown, we administered the most selective 
dopamine receptor agonists and antagonists readily available to male Sprague Dawley 
rats responding on the uncertain visual discrimination task first described by Evenden 
(1999b). The drugs administered included d-amphetamine, the selective dopamine 
transporter blocker GBR 12909, the D1-like agonist SKF 81297, the D1-like antagonist SCH 
23390, the D2-like antagonist haloperidol, the D2-preferring agonist sumanirole, the D2-preferring 
antagonist L-741,626, the D3-preferring agonist pramipexole, the D3-preferring antagonist 
PG01037, the D4 partial agonist ABT 724, the D4 antagonist L-745,870, and the 
nonselective dopamine agonist apomorphine. The antagonists listed above were 
sometimes administered prior to these agonists to further elucidate the mechanism of 
effects these drugs have on this task.  
Method 
Subjects 
Twelve male Sprague Dawley rats served as subjects (Harlan, Indianapolis, IN). 
Rats were approximately 10 weeks old at the start of the experiment. A food restriction 
protocol was in place to maintain the rats at approximately 325 g throughout the 
experiment. This weight was chosen as it is approximately 85% of the mean adult weight 
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supplied by the manufacturer for this strain, and this weight was not changed once 
established. When not in session, rats were housed in accordance with institutional 
animal care and use guidelines in polycarbonate cages with fresh water continuously 
available. The lights in the housing colony were on from 7:00 AM to 7:00 PM, and 
sessions were conducted between 12:00 PM and 4:00 PM. These protocols were 
approved by the University of Michigan Committee on the Use and Care of Animals and 
conformed to the guidelines established by the NIH Guide for the Use of Laboratory 
Animals. 
Apparatus 
Sessions were conducted in rodent operant conditioning chambers with an area of 
30.5 cm x 24.1 cm x 21.0 cm and stainless steel grid floors (ENV-008; Med-Associates 
Inc., St. Albans, VT). Both sides of the front panel of the chamber held a retractable lever 
(E23-17, Coulbourn Instruments, Whitehall, PA). Between the levers was a food tray 
connected to a 45 mg pellet dispenser (ENV-200R1AM and ENV-203M-45, Med-
Associates, Inc.). Above both of the levers and the food tray were triple stimulus lights 
containing a red, green, and yellow LED (ENV-222M, Med-Associates, Inc.). The three 
colors of each of the three stimulus lights were always illuminated or extinguished in 
tandem, and each trio is referred to as a single light throughout the paper. A houselight 
was located near the top of the opposite wall to provide illumination to the chamber, and 
remained on throughout all sessions (ENV-215M, Med-Associates, Inc.). Chambers were 
connected to a computer running Med-PC IV software (Med-Associates, Inc.) to control 




Rats were trained to respond on a mixed fixed-time 60 s FR 1 schedule of 
reinforcement, with the active lever alternating each session between the left and right 
levers. This schedule arranged one sucrose pellet to be delivered every 60 s independent 
of behavior, with every lever press also producing a pellet. This was continued for four 
sessions, at which point the schedule was switched to a FR 1 with no response-
independent pellet deliveries. Rats were allowed to respond on this schedule until 80 
responses or more were recorded on two consecutive 20-min sessions. 
Rats were then trained to discriminate visual stimuli presented above the levers. 
In a series of discrete trials, the stimulus light above one of the levers was lit and both 
levers were extended into the chamber. The location of the light was determined 
randomly at the start of each trial. A response to the lever below the illuminated stimulus 
light was recorded as a correct response and led to both levers retracting, a 45-mg sucrose 
pellet delivery, and a 5-s timeout period with no stimulus lights illuminated. Responses to 
the lever with no stimulus light was recorded as an incorrect response and resulted in 
lever retraction and the timeout only. If no response occurred within a limited hold of 30 
s, an omission was recorded, the levers were retracted, and a 5-s timeout occurred. After 
four sessions, a pre-stimulus lever insertion duration was added such that the levers were 
inserted into the chamber 1 s before the randomly-determined stimulus light was 
illuminated. Responses made before the stimulus presentation, regardless of lever, led to 
the levers retracting and a 5-s timeout. Over a number of sessions, the duration that the 
levers were inserted into the chamber before a stimulus was lit was extended to 8 s. Rats 
were allowed to respond with these contingencies until at least 85% of responses made 
after stimulus illumination were on the lever under the lit stimulus light. 
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The test procedure was similar to the final training procedure, with the exception 
that the stimuli did not predict the correct lever with a probability of 1.0. Once each trial 
began, 8 s after the levers were inserted into the chamber, a series of 0.2-s cycles began 
with the stimulus location during each cycle determined on a probabilistic basis. During 
the first cycle, any of the three stimulus lights (“correct,” the light above the lever with 
the active FR 1 schedule; “incorrect,” the light above the other lever; or “irrelevant,” the 
light above the food cup that did not differentially signal food availability) had an equal 
probability of being illuminated. With each subsequent cycle (n), the probability that the 
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When 𝑛𝑛 = 1, both Equation 5-1 and Equation 5-2 equal .3� and the probability that each 
of the three stimuli being lit was the same. The probability that the lit stimulus was above 
the correct lever increased to approximately .8 after 4 s elapsed (𝑛𝑛 = 21). A response on 
the correct lever at any point after stimuli were lit was reinforced with a food pellet, 
while a response on the other lever led to the 5-s timeout period. Sessions ended after 60 
min or 144 trials, whichever occurred first.   
Drug testing began after no increasing or decreasing trend in response latency was 
apparent over a period of five sessions. Sessions were generally conducted five days per 
week with vehicle injections administered on the first and fourth days of the week, test 
compounds or conditions were assessed on the second and fifth days, and no injections 
given on the third day. Vehicle injections always corresponded to the vehicle for the 
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scheduled drug injection or injections for the following day in number, substance, and 
time relative to the experimental session. Each session was preceded by a vehicle or drug 
injection 5 min before the start of the session with the rat then immediately placed in the 
darkened experimental chamber. On some days, an antagonist or vehicle injection was 
administered 30 min prior to the session, with the rat placed back in his home cage for the 
intervening 25 min before the agonist or vehicle injection was given, as appropriate. All 
agonists and the corresponding vehicle injections were administered 5 min before the 
session. All antagonists and the corresponding vehicle injections were administered 30 
min before the session start, except SCH 23390 which was administered 5 min before 
session start due to its relatively rapid onset and short duration of action (Hietala, 
Seppäla, Lappalainen, & Syvälahti, 1992). 
To assess the influence on behavior of the 8-s pre-stimulus lever insertion 
duration and uncertain properties of the stimuli, probe trials were conducted with these 
parameters altered. Near to the end of drug testing and in the absence of any drug 
treatment, the pre-stimulus lever insertion duration was increased to either 10 or 12 s on 
separate sessions. In addition, a “certain” probe session was conducted with each subject 
wherein the stimuli presented were correlated with the correct lever with a probability of 
1.0 throughout the trial instead of the uncertain, increasing probability described by 
Equation 5-1. These “certain” trials approximated the training conditions before the 
uncertain stimuli were introduced. 
Drugs 
Pramipexole was generously provided by Drs. Jianyong Chen and Shaomeng 
Wang (University of Michigan, Ann Arbor, MI), sumanirole by Benjamin Greedy and 
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Dr. Stephen Husbands (University of Bath, Bath, UK), GBR 12909 by Novo Industri 
(Bagsvaerd, Denmark), ABT-724 by Dr. Kenner Rice (Chemical Biology Research 
Branch, National Institute on Drug Abuse, Bethesda, MD), and PG01037 by Drs. Amy H. 
Newman (Medicinal Chemistry Section – National Institute on Drug Abuse, Baltimore, 
MD) and Peter Grundt (University of Minnesota – Duluth, Duluth, MN). Haloperidol, 
SKF 81297, SCH 23390, and apomorphine were obtained from Sigma-Aldrich (St. Louis, 
MO), L-741,626 and L-745,870 were obtained from Tocris (Ellisville, MO), and d-
amphetamine was obtained from the National Institute on Drug Abuse (Bethesda, MD). 
All drugs were dissolved in sterile saline except L-741,626, which was dissolved in 5% 
ethanol, and PG01037, which was dissolved in 20% β-cyclodextrin. All injections were 
administered subcutaneously (s.c.) in a volume of 1.0 ml/kg except 56 mg/kg PG01037 
which was administered in of volume of 1.75 ml/kg due to solubility limits. 
Data Analysis 
Latency was defined as the time to a response on either lever, regardless of 
accuracy, measured from the onset of the stimulus presentations. Latencies were analyzed 
and plotted as survival plots, or the percent of latencies of at least X seconds as a function 
of drug dose or treatment condition. Summarized in this manner, data were well-
approximated by the exponential equation 
 𝑌𝑌 = 100−𝐾𝐾∗𝑎𝑎   (5-3) 
where Y is the percent of latencies of X or more s in duration and K is a derived parameter 
indicating the steepness of the exponential curve. A higher proportion of long latencies 
leads to an increased K. Latencies distributions were compared across doses with a two-
way repeated measures Analysis of Variance (ANOVA) in Systat SigmaStat 3.5 (San 
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Jose, CA) with Bonferroni-adjusted post hoc tests conducted to compare relevant 
conditions.  
Accuracy was defined as the percent of responses made to the lever on which 
sucrose reinforcement was programmed after the stimulus lights were illuminated and 
before the limited hold expired. Accuracy was analyzed as a function of response latency 
and was split into five bins: 0 ≤ x < 1 s, 1 ≤ x < 2 s, 2 ≤ x < 3 s, 3 ≤ x < 4 s, and 4 ≤ x s. 
Accuracy data for an individual bin for each session was only included for analysis if five 
or more responses were made in that bin. Accuracy was compared across doses as a 
function of response latency with a two-way repeated measures ANOVA in SigmaStat 
3.5 with Bonferroni-adjusted post hoc tests conducted to compare relevant conditions. 
When data were excluded for some latency bins for some subjects, SigmaStat used a 
Mixed Models ANOVA to assess within- and between-subjects effects on an incomplete 
data set. 
Omissions were defined as a failure to respond on either lever during the limited 
hold. Premature responses were defined as a response made to either lever before the 
illumination of stimuli above the levers. Omissions and premature responses were each 
compared across drug dose or experimental condition using a one-way repeated measures 
ANOVA or paired t-test, as appropriate, in SigmaStat 3.5 with Bonferroni-adjusted post 
hoc tests conducted to compare relevant conditions.  
Response bias was defined as the proportion of responses made on the lever on 
which the majority of responses were emitted for that session. Therefore, the possible 
range of bias values was 50% (equal responding on both levers) to 100% (exclusive 
responding on one lever). Response bias was compared across drug doses or conditions 
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using a one-way repeated measures ANOVA or paired t-test, as appropriate, in GraphPad 
Prism 5 (La Jolla, CA). In some rats, an extreme bias (defined as >90%) was noted. 
Response latency, response accuracy, omission, and premature response data were not 
included in analyses for any drug condition if that subject exhibited an extreme bias 
during the corresponding vehicle or control sessions for that condition.  
Results 
Distribution of response latencies was presented in survival plots for all 
conditions. Therefore, proportion of response latencies ≥X seconds decreased as X 
increased in all conditions, and F values for ANOVAs conducted assessing this main 
effect ranged from 37 to 316 (all p < .001). These individual values are not reported for 
brevity. Significant effects on response latency or premature responses were considered 
“selective” if they did not coincide with a significant increase in trials omitted. Selective 
effects on impulsive preparation or impulsive action, as defined, are indicated by upward 
() or downward () deflecting arrows in the legend of each graph indicating increases 
or decreases, respectively, in impulsive behavior. Disruptions in behavior are also 
indicated (). 
For all drug tests, the duration that the levers were inserted into the chamber 
before illumination of visual stimuli was 8 s. When that duration was increased during 
probe trials to 10 or 12 s, the distribution of response latencies was altered (Figure 5-1, 
top panel; insertion duration main effect F2,140 = 6.0, p = .013, insertion duration by 
response latency interaction F20,140 = 5.2, p < .001). Response latencies in the 12 s 
condition tended to be shorter in duration. Pre-stimulus lever insertion duration 
manipulations did not affect accuracy, however (Figure 5-1, middle panel). Accuracy 
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increased as a function of response latency, but this pattern did not depend on pre-
stimulus lever insertion duration (insertion duration main effect F2,72 = 1.4, p = .264, 
response latency main effect F4,72 = 21, p < .001, insertion duration by response latency 
interaction F8,72 = 0.35, p = .945). Premature responses increased as the lever insertion 
duration increased, reaching significant at a 12 s duration (Figure 5-1, bottom panel; lever 
insertion main effect F2,14 = 14, p < .001). Lever biases (Table 5-1; F2,20 = 0.58, p = .567) 
and trials omitted (Table 5-2) were not affected by increasing the lever insertion duration.  
For all the drug tests, the visual stimuli were presented in a probabilistic manner 
described by Equation 5-1 and Equation 5-2. The results of the “certain” probe sessions 
with the visual stimuli perfectly correlated with the correct response option are shown in 
Figure 5-2. Removing the probabilistic properties of the stimuli had no effect on 
distribution of response latencies (Figure 5-2, top panel; stimulus certainty main effect 
F1,70 = 0.36, p = .568, stimulus certainty by response latency interaction F10,70 = 0.08, p > 
0.999). Stimulus certainty did have a significant effect on response accuracy (Figure 5-2, 
middle panel; stimulus certainty main effect F1,44 = 11, p = .002, response latency main 
effect F4,44 = 3.7, p = .011, stimulus certainty by response latency interaction F4,44 = 1.7, 
p = .157). In the uncertain stimulus condition, response accuracy increased as a function 
of response latency, following the increase in the accuracy of the stimuli dictated by 
Equations 1 and 2 (programmed stimulus probabilities shown in Figure 5-2, middle 
panel, dashed line). When the probabilistic nature of the visual stimuli was removed, 
however, response accuracy was high at all response latencies, and was not a function of 
response latency. Stimulus certainty did not affect premature responses (Figure 5-2, 
bottom panel; t7 = 1.5, p = .167) or trials omitted (Table 5-2; t7 = 1.0, p = .351). Lever 
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bias was significantly lower in the certain stimulus condition, however (Table 5-1, t10 = 
2.7, p = .022).  
d-Amphetamine pretreatments significantly increased response latencies, with a 
significant increase at 1.0 mg/kg (Figure 5-3, top panel; dose main effect F3,210 = 4.4, p = 
.015, dose by response latency interaction F30,210 = 1.9, p = .005). Accuracy increased as 
a function of response latency, and there was a trend toward increased accuracy with d-
amphetamine pretreatments, but this effect was statistically significant (Figure 5-3, 
middle panel; dose main effect F3,96 = 2.6, p = .060, response latency main effect F4,96 = 
38, p < .001, dose by response latency interaction F12,96 = 1.2, p = .302). Premature 
responses were dose-dependently increased by d-amphetamine pretreatments, with a 
significant increase seen at 1.0 mg/kg (Figure 5-3, bottom panel; dose main effect F3,21 = 
1.7, p = .010). Lever bias (Table 5-1; dose main effect F3,27 = 0.37, p = .778) and trials 
omitted (Table 5-2; dose main effect F3,21 = 0.85, p = .183) were not altered by d-
amphetamine at the doses tested.  
At the doses tested, the dopamine transporter blocker GBR 12909 had little effect 
on response latencies, although the higher dose of 10 mg/kg tended to increase the 
proportion of response latencies exceeding 1, 2, and 3 s (Figure 5-4, top panel; dose main 
effect F3,210 = 1.4, p = .275, dose by response time interaction F30,210 = 1.7, p = .016). 
Response accuracy increased as a function of response latency, but this was not altered 
by GBR 12909 (Figure 5-4, middle panel; dose main effect F3,92 = 0.65, p = .587, 
response latency main effect F4,92 = 36, p < .001, dose by response latency interaction 
F12,92 = 0.94, p = .516). Premature responses (Figure 5-4, bottom panel; dose main effect 
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F3,21 = 0.62, p = .610), lever bias (Table 5-1; dose main effect F3,27 = 1.0, p = .397), and 
trials omitted (Table 5-2) were not affected by GBR 12909 at the doses tested.  
The D3-preferring  agonist pramipexole dose-dependently increased response latency 
(Figure 5-5, top panel; dose main effect F3,240 = 25, p < .001, dose by response time 
interaction F30,240 = 6.7, p < .001). A dose of 0.32 mg/kg increased the proportion of 
response latencies exceeding 1, 2, and 3 s, while 0.1 and 0.32 mg/kg pramipexole 
increased the proportion of response latencies across a wide range of response times. 
Response accuracy was not affected by pramipexole, however, with accuracy at each 
dose increasing as a function of response latency (Figure 5-5, middle panel; dose main 
effect F3,139 = 0.53, p = .665, response latency main effect F4,139 = 39, p < .001, dose by 
response latency interaction F12,139 = 0.55, p = .875). Premature responses (Figure 5-5, 
bottom panel; dose main effect F3,24 = 4.2, p = .083) and lever bias (Table 5-1; dose main 
effect F3,27 = 0.96, p = .425) were not significantly altered. Trials omitted were dose-
dependently increased after pramipexole administration, with a large proportion of trials 
omitted at 0.32 mg/kg pramipexole (Table 5-2; dose main effect F3,24 = 59, p < .001). The 
0.1 mg/kg pramipexole dose was administered to some rats multiple times to redetermine 
the effects of this dose prior to antagonist treatment, and the effects of 0.1 mg/kg 
pramipexole differed during some tests in some subsets of rats (see the results for L-
741,626 plus 0.1 mg/kg pramipexole, reported below). To describe more fully the effects 
of this dose, premature response data from all administrations that met bias criteria (see 
Method section) were averaged for each subject and compared with the corresponding 
mean vehicle data for these administrations. Analyzed this way, premature responses 
after administration of 0.1 mg/kg pramipexole in the 11 rats that received this dose (M = 
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17.4, SD = 10.2) were not significantly greater than after vehicle administration (M = 
15.0, SD = 16.1; paired t10 = 0.70, p = .501). 
Like pramipexole, the D2-preferring agonist sumanirole dose-dependently increased 
response latencies (Figure 5-6, top panel; dose main effect F3,210 = 13, p < .001, dose by 
response time interaction F30,210 = 3.9, p < .001) without altering the response-latency-
dependent increases in response accuracy (Figure 5-6, middle panel; dose main effect 
F3,114 = 0.44, p = .728, response latency main effect F4,114 = 25, p < .001, dose by 
response latency interaction F12,114 = 1.5, p = .143). Premature responses were not altered 
(Figure 5-6, bottom panel; F3,21 = 2.2, p = .122). A dose of 3.2 mg/kg sumanirole both 
decreased lever bias (Table 5-1; dose main effect F3,24 = 5.2, p = .007) and increased 
trials omitted (Table 5-2; dose main effect F3,21 = 15, p < .001). 
Across doses ranging from 0.1 mg/kg to 3.2 mg/kg, the D4 partial agonist ABT-
724 had no significant effect on any dependent measure. Response latency (Figure 5-7, 
top panel; dose main effect F4,280 = 2.0, p = .120, dose by response time interaction F40,280 
= 0.78, p = .822), response accuracy (Figure 5-7, middle panel; dose main effect F4,115 = 
1.8, p = .138, response latency main effect F4,115 = 20, p < .001, dose by response latency 
interaction F16,115 = 1.2, p = .293), premature response (Figure 5-7, bottom panel; dose 
main effect F4,28 = 0.91, p = .470), lever bias (Table 5-1; F4,44 = 1.7, p = .174), and trials 
omitted (Table 5-2) were all unaffected.   
The D2-like antagonist haloperidol had little effect on behavior at 0.032 mg/kg, but 
drastically reduced responding and increased response latencies at 0.1 mg/kg (Figure 5-8, 
top panel; dose main effect F2,140 = 16, p < .001, dose by response time interaction F20,140 
= 3.1, p < .001). Response accuracy was not altered by haloperidol at these doses, 
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however (Figure 5-8, middle panel; dose main effect F3,91 = 0.36, p = .779, response 
latency main effect F4,91 = 24, p < .001, dose by response latency interaction could not be 
computed due to pattern of missing data). Haloperidol did not affect premature responses 
(Figure 5-8, bottom panel; dose main effect F2,14 = 1.0, p = .383) or lever bias (Table 5-1; 
dose main effect F2,18 = 2.0, p = .165), but did increase omissions at 0.1 mg/kg (Table 
5-2; dose main effect F2,14 = 948, p < .001).   
The D3-preferring antagonist PG01037 dose-dependently increased response latency 
with 56 mg/kg significantly increasing latency compared to vehicle (Figure 5-9, top 
panel; dose main effect F3,210 = 3.0, p = .054, dose by response time interaction F30,210 = 
1.6, p = .027). Accuracy was not affected over the dose range tested (Figure 5-9, middle 
panel; dose main effect F3,106 = 0.15, p = .931, response latency main effect F4,106 = 22, p 
< .001, dose by response latency interaction F12,106 = 0.68, p = .768). PG01037 did not 
significantly alter any of the other dependent measures, including premature responses 
(Figure 5-9, bottom panel; F3,21 = 0.17, p = .914), lever bias (Table 5-1; F3,30 = 0.27, p = 
.846), and trials omitted (Table 5-2; F3,21 = 2.3, p = .107). 
The D2-preferring antagonist L-741,626 dose-dependently increased response 
latencies (Figure 5-10, top panel; dose main effect F3,286 = 45, p < .001, dose by response 
time interaction F30,286 = 0.77, p = .799; due to pattern of missing data, results are of a 
two-way ANOVA with no repeated measures). Response accuracy (Figure 5-10, middle 
panel) increased as a function of response latency F4,104 = 19, p < .001, but L-741,626 
altered response accuracy F3,104 = 6.6, p < .001 with no dose by response latency 
interaction F12,104 = 1.4, p = .188. A dose of 3.2 mg/kg L-741,626 significantly decreased 
response accuracy compared with vehicle. Premature responses were also increased at 
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this dose (Figure 5-10, bottom panel; dose main effect F3,21 = 3.1, p = .045), along with a 
large increase in trials omitted (Table 5-2; dose main effect F3,21 = 10, p < .001). Lever 
bias was not altered across the doses tested (Table 5-1; F3,30 = 0.11, p = .957).  
The D4 antagonist L-745,870 had little effect on most of the dependent measures 
assessed, but did have a small effect on latencies (Figure 5-11, top panel; dose main 
effect F3,210 = 1.2, p = .350, dose by response time interaction F30,210 = 1.7, p = .015). L-
745,870 did not affect the response-latency-dependent increase in accuracy (Figure 5-11, 
middle panel; dose main effect F3,93 = 0.25, p = .864, response latency main effect F4,93 = 
30, p < .001, dose by response latency interaction F12,93 = 0.62, p = .818), premature 
responses (Figure 5-11, bottom panel; F3,21 = 0.03, p = .994), lever bias (Table 5-1; F3,27 
= 0.23, p = .874), or trials omitted (Table 5-2).  
Haloperidol was administered as pretreatments to 0.1 mg/kg pramipexole to 
assess whether the increase in latency observed with pramipexole could be reversed. The 
dose of 0.032 mg/kg haloperidol, which had no effect when given alone (Figure 5-8), 
partially reversed the increase in latency caused by 0.1 mg/kg pramipexole (Figure 5-12, 
top panel; dose main effect F3,210 = 41, p < .001, dose by response time interaction F30,210 
= 9.1, p < .001). A dose of 0.1 mg/kg haloperidol, which increased response latencies 
when given alone, also increased latencies when given as a pretreatment to 0.1 mg/kg 
pramipexole. Pramipexole given alone or in combination with haloperidol did not alter 
the increase in accuracy that coincided with increases in response latency (Figure 5-12, 
middle panel; dose main effect F4,139 = 0.84, p = .499, response latency main effect F4,139 
= 32, p < .001, dose by response latency interaction F16,139 = 0.58, p = .894). A dose of 
0.1 mg/kg pramipexole did not increase premature responses (Figure 5-12, bottom panel) 
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or trials omitted (Table 5-2) when administered alone, but the addition of 0.1 mg/kg 
haloperidol caused significant increases in both these measures (premature responses 
main effect F3,21 = 3.1, p = .048; trials omitted main effect F3,21 = 9.8, p < .001). Lever 
bias was not altered across these dose conditions (Table 5-1; dose main effect F3,24 = 1.0, 
p = .405). 
The D2-preferring antagonist L-741,626 partially reversed the increases in response 
latency caused by 0.1 mg/kg pramipexole, although in a non-dose-dependent manner 
(Figure 5-13, top panel; dose main effect F4,280 = 7.0, p < .001, dose by response time 
interaction F40,280 = 2.2, p < .001). In the subset of animals tested under these dose 
conditions, 0.1 mg/kg pramipexole significantly decreased response accuracy, an effect 
which was not reversed by L-741,626 (Figure 5-13, middle panel; dose main effect F4,144 
= 3.7, p = .007, response latency main effect F4,144 = 19, p < .001, dose by response 
latency interaction F16,144 = 1.1, p = .346). Premature response (Figure 5-13, bottom 
panel; F4,28 = 7.7, p = .017) and trials omitted (Table 5-2; F4,28 = 5.0, p = .004) were both 
increased by 0.1 mg/kg pramipexole in the subset of animals tested under these 
conditions. A dose of 0.1 mg/kg L-741,626 significantly reversed the increase in 
premature responses and 0.32 mg/kg L-741,626 reversed the increase in trials omitted. 
This set of dosing conditions did not affect lever bias (Table 5-1; F4,36 = 1.3, p = .272).  
The D3-preferring antagonist PG01037 did not reverse the increase in latencies 
caused by administration of 0.1 mg/kg pramipexole (Figure 5-14, top panel; dose main 
effect F4,280 = 6.1, p < .001, dose by response time interaction F40,280 = 3.7, p < .001). 
This set of dosing conditions did not alter in the increase in accuracy that coincided with 
increases in response latency (Figure 5-14, middle panel; dose main effect F4,158 = 1.6, p 
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= .178, response latency main effect F4,158 = 16, p < .001, dose by response latency 
interaction F16,158 = 0.55, p = .915). Premature response (Figure 5-14, bottom panel; F4,28 
= 1.9, p = .136), lever bias (Table 5-1; F4,36 = 0.95, p = .445, and trials omitted (Table 
5-2; F4,28 = 1.9, p = .140) did not significantly differ across these dosing conditions.  
Administration of 1.0 mg/kg of the D1-like agonist SKF 81297 increased response 
latencies (Figure 5-15, top panel; dose main effect F3,210 = 5.8, p = .005, dose by response 
time interaction F30,210 = 1.6, p = .032). Accuracy was significantly affected by SKF 
81297 dose (Figure 5-15, middle panel; dose main effect F3,113 = 4.6, p = .005, response 
latency main effect F4,113 = 42, p < .001, dose by response latency interaction F12,113 = 
1.0, p = .418), but no dose significantly differed from vehicle either overall or at a 
specific response latency. Premature responses (Figure 5-15, bottom panel; F3,21 = 1.4, p 
= .262) and lever bias (Table 5-1; F3,30 = 1.8, p = .175) were not significantly altered by 
SKF 81297, but 1.0 mg/kg increased trials omitted (Table 5-2; F3,21 = 5.2, p = .008).   
The D1-like antagonist SCH 23390 increased response latencies with the largest 
effect at 0.01 mg/kg (Figure 5-16, top panel; dose main effect F3,210 = 3.2, p = .045, dose 
by response time interaction F30,210 = 1.1, p = .338). SCH 23390 did not alter the increase 
in accuracy observed as response latency increased (Figure 5-16, middle panel; dose 
main effect F3,89 = 2.2, p = .089, response latency main effect F4,89 = 21, p < .001, dose 
by response latency could not be computed due to pattern of missing data). Premature 
responses were increased slightly (Figure 5-16, bottom panel; F3,21 = 5.1, p = .008), but 
only at a dose that dramatically increased trials omitted (Table 5-2; F3,21 = 127, p < .001). 
Lever bias was also reduced at 0.032 mg/kg SCH 23390 (Table 5-1; F3,27 = 3.0, p = .047).   
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SCH 23390 was co-administered with 1.0 mg/kg SKF 81297, and at the doses 
tested, reversed the increase in response latency caused by 1.0 mg/kg SKF 81297 (Figure 
5-17, top panel; dose main effect F4,280 = 6.1, p = .001, dose by response time interaction 
F40,280 = 1.6, p = .019). No significant effect on accuracy was noted over the dose 
conditions tested (Figure 5-17, middle panel; dose main effect F4,148 = 1.6, p = .173, 
response latency main effect F4,148 = 30, p < .001, dose by response latency interaction 
F16,148 = 1.6, p = .073). There was a significant effect of dose condition on premature 
responses (Figure 5-17, bottom panel; F4,28 = 4.4, p = .007), but 1.0 mg/kg SKF 81297 
did not differ from vehicle, nor was the level of premature responses elicited by 1.0 
mg/kg SKF 81297 altered by any of the doses of SCH 23390 tested. A dose of 0.01 
mg/kg SCH 23390 did reverse the increase in trials omitted caused by 1.0 mg/kg SCH 
23390, while the addition of 0.032 mg/kg SCH 23390 increased trials omitted (Table 5-2; 
F4,28 = 42, p < .001). In the subset of animals tested under these dose conditions, 1.0 
mg/kg SKF 81297 significantly decreased lever bias, which was not reversed by SCH 
23390 at the doses tested (Table 5-1; F4,44 = 4.7, p = .003).  
The nonselective dopamine agonist apomorphine dose-dependently increased 
response latency at 0.32 mg/kg (Figure 5-18, top panel; dose main effect F3,210 = 21, p < 
.001, dose by response time interaction F30,210 = 4.9, p < .001), and decreased accuracy at 
this same dose (Figure 5-18, middle panel; dose main effect F3,103 = 3.1, p = .031, 
response latency main effect F4,103 = 35, p < .001, dose by response latency interaction 
F12,103 = 0.51, p = .906). Apomorphine tended to dose-dependently decrease premature 
responses, although the main effect of dose was not statistically significant (Figure 5-18, 
bottom panel; F3,21 = 2.5, p = .085). Apomorphine did not significantly affect lever bias 
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(Table 5-1; F3,27 = 1.4, p = .255), while 0.32 mg/kg increased trials omitted (Table 5-2; 
dose main effect F3,21 = 20, p < .001).  
Discussion 
In general, rats learned the UVD task and the uncertain visual stimuli signaled 
differential behavior patterns. As a function of response latency, response accuracy 
closely tracked the within-trial increase in the probability that the stimulus above the 
levers correctly predicted reinforcement delivery (Figure 5-2, middle panel). Further 
evidence that the rats were sensitive to the presence of the visual stimuli came from the 
probe trial with the stimuli correlated with the correct lever throughout the trial. During 
this single session, response accuracy remained high (>80%) throughout the trial, did not 
depend on response latency, and was significantly higher than in the uncertain visual 
stimuli condition (Figure 5-2, middle panel). Response bias, or percent of responses that 
occurred on the preferred lever, also decreased in this probe trial, indicating that the 
improved correlation of the stimuli with the correct response lever in this session helped 
to overcome lever biases (Table 5-1). 
Response latency, a purported measure of impulsive preparation (Evenden, 
1999a), was either unaffected or dose-dependently increased by all the dopaminergic 
drugs tested. The only decrease in latency distribution that was observed occurred when 
the lever insertion duration prior to stimuli onset was increased. As the pre-stimulus lever 
duration was increased to values greater than the training duration of 8 s latency 
decreased, reaching significance at a duration of 12 s. Both the agonist and antagonist 
tested that bind most selectively to D1-like (SKF 81297 and SCH 23390), D2 (sumanirole 
and L-741,626), and D3 (pramipexole and PG01037) receptors, as well as the dopamine 
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transporter ligands (d-amphetamine and GBR 12909), increased latency at in a dose-
dependent manner. No dose of any of these drugs decreased latency. The D4 agonist and 
antagonist tested (ABT-724 and L-745,870) had no appreciable effect on this measure. 
While L-745,870 significantly altered latency, this effect was very small in magnitude 
and did not appear dose-dependent. Increases in latency caused by 0.1 mg/kg 
pramipexole were partially antagonized by doses of haloperidol and L-741,626 but not 
PG01037, suggesting D2 receptor activation is important for this effect. The increase in 
latency caused by 1.0 mg/kg SKF 81297 was not reversed by the doses of SCH 23390 
tested. It seems as though sufficient activation or deactivation of D1-like, D2, or D3 
receptors increases response latency. As a model of impulsive preparation, this pattern of 
results is difficult to interpret. It has been found that individual differences in baseline 
and drug-altered latency on this task strongly correlates with latency to respond on the 
delay discounting task (Chapter 6). On the delay discounting task, the stimuli 
signaling reinforcer availability are presented at the beginning of a trial and signal 
availability with a constant probability of 1.0 throughout the trial. No processes 
approximating impulsive preparation seem to be associable with low response latencies 
on the delay discounting task. That response latency was strongly correlated across these 
tasks suggests that response latency on the UVD task may not be related to impulsive 
preparation. Instead, response latency on this task may more closely approximate latency 
to respond on simple reaction time experiments. This assertion is further supported by the 
stimulus certainty condition, where removing the probabilistic nature of the stimuli had 
no effect on response latency (Figure 5-2). With the uncertainty removed from the 
stimulus presentations, no information could be gained by waiting to respond. Response 
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latency remaining the same under both certain and uncertain conditions suggests 
“impulsive preparation” was not a governing force in the behavior of the subjects on 
these tasks.  
Premature responses on the 5-CSRT task are an often-studied model of impulsive 
action (Dalley et al., 2008). While the UVD task has received less attention, there is good 
reason to believe premature responses are similar on the two tasks. Increasing the 
duration of time between the onset of a trial and the presentation of visual stimuli reliably 
increases premature responses on the 5-CSRT task (e.g., Dalley et al., 2007), and the 
same effect was found by increasing the lever insertion duration prior to stimulus onset in 
the current experiment (Figure 5-1, bottom panel). In addition, d-amphetamine reliably 
increases premature responses on the 5-CSRT task (Cole & Robbins, 1987; van Gaalen et 
al., 2006), and a significant, dose-dependent increase was noted with d-amphetamine in 
the current experiment (Figure 5-3, bottom panel). Other than the lever insertion duration 
manipulation and d-amphetamine, 3.2 mg/kg L-741,626 and 0.032 mg/kg SCH 23390 
increased percent premature responses in the current experiment. These same doses also 
produced large increases in trials omitted, however, reducing the number of trials on 
which these percentage data were based. Since premature responses are expressed as a 
percent of responses in the current analysis and total responses were decreased with these 
drugs, there is discordance between these increases and the absolute number of premature 
responses recorded in the session. In absolute terms, premature responses were not 
altered by L-741,626 over the dose range tested, and decreased by 0.032 mg/kg SCH 
23390 (data not shown). The main effect of apomorphine trended toward significance, 
and a post hoc test suggested a decrease in premature responses with 0.32 mg/kg 
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apomorphine (Figure 5-18, bottom panel). Apomorphine has not been tested previously 
on premature responding in either the 5-CSRT task or the UVD task. On a paced fixed 
consecutive number schedule, another purported measure of impulsive action (Evenden, 
1999a), apomorphine decreased impulsive action as defined by this task (Chapter 4). 
In both cases, 0.32 mg/kg was the active dose, suggesting this dose range may function to 
reduce impulsive action. However, it should be noted that this same dose increased trials 
omitted (Table 5-2) and produced atypical, biased responding on a delay discounting task 
(Chapter 3), potentially limiting its usefulness as a therapeutic. 
Response accuracy was very resilient to the effects of the drugs tested, and 
followed a similar pattern throughout the experiment. Accuracy closely followed the 
probability that the uncertain stimuli signaled the correct response location (Figure 5-2, 
middle panel), and this pattern remained relatively undisturbed, even after high doses of 
drugs that caused large increases in trials omitted and response latency. For example, 0.1 
mg/kg haloperidol dramatically increased trials omitted (Table 5-2) and response latency 
(Figure 5-8, top panel), but had no significant effect on response accuracy in the latency-
based bins in which there were enough responses to compute accuracy (Figure 5-8, 
middle panel). Doses of 3.2 mg/kg L-741,626 and 0.32 mg/kg apomorphine did decrease 
response accuracy somewhat, as did 0.1 mg/kg pramipexole in the same subgroup of 
animals that showed an abnormal increase in premature responses to this same dose.  
In conclusion, further research is needed to determine if the UVD task is an 
appropriate model of impulsive preparation. The pattern of results with response latencies 
on this task suggest that the relationship of this measure to tasks measuring impulsive 
preparation in humans may be dubious, but it’s quite possible that administration of 
191 
 
dopaminergic drugs is not the best way of determining this relationship. Premature 
responses on the UVD task appear to be analogous to premature responses on the 5-
CSRT task, with increases in premature responses seen after d-amphetamine 
administration or an increase in the pre-stimulus lever insertion duration. Of the 
dopaminergic drugs tested, only apomorphine tended to decrease impulsive action as 





Table 5-1. Average percent responding on the preferred lever (±SEM) for each condition 
and drug tested. These data include rats that demonstrated extreme lever biases (<90% 
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Pramipexole 







+ 0.032 Hal 
68.6 (±4.9) 
+ 0.1 Hal 
72.3 (±3.9) 
 
L-741,626 +  
0.1 Pramipexole 







+ 0.1 L-741 
76.1 (±6.1) 
+ 0.32 L-741 
75.9 (±5.4) 
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+ 10 PG 
73.4 (±5.9) 
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SCH 23390 + 1.0 
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1.0 SKF ** 
67.3 (±4.2) 
+ 0.0032 SCH  
67.9 (±4.0) 
+ 0.01 SCH 
66.6 (±3.3) 
+ 0.032 SCH 
68.5 (±3.0) 
Apomorphine 












Cond. = Condition, Dur. = duration. Hal = haloperidol, L-741 = L-74,626, PG = 
PG01037, Pram = pramipexole, SCH = SCH 23390, SKF = SKF 81297. 





Table 5-2. Mean number of trials omitted (±SEM) for each condition and drug tested. 
These data exclude rats that demonstrated extreme lever biases (<90% responding on one 







































































































































+ 0.032 Hal 
0.9 (±0.7) 
+ 0.1 Hal †† 
40.0 (±11.7) 
 






0.1 Pram ** 
32.9 (±10.7) 
+ 0.1 L-741 
23.5 (±9.8) 
+ 0.32 L-741 † 
7.3 (±5.5) 












+ 10 PG 
8.5 (±7.0) 
+ 32 PG 
17.8 (±8.4) 
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1.0 SKF ** 
21.4 (±7.3) 
+ 0.0032 SCH  
20.0 (±5.7) 
+ 0.01 SCH † 
5.8 (±2.4) 














Cond. = Condition, Dur. = duration. Hal = haloperidol, L-741 = L-74,626, PG = 
PG01037, Pram = pramipexole, SCH = SCH 23390, SKF = SKF 81297. 
* p < .05, ** p < 0.01, *** p < .001 compared to vehicle in Bonferroni-adjusted post hoc 
tests. 
† p < .05, †† p < 0.01, ††† p < .001 compared to agonist alone in Bonferroni-adjusted 

















































































Pre-Stimulus Lever Insertion Duration Figure 5-1. Changes in performance after 
altering the duration that the levers were 
inserted into the chamber prior to 
stimulus onset. Top panel: Distribution of 
latencies to respond after onset of stimuli 
as a function of the lever insertion 
duration prior to stimulus onset. Data are 
presented as percent of total responses 
meeting or exceeding the delay indicated 
on the x axis under each lever insertion 
duration condition. Asterisks in the 
legend indicate a significant difference 
from the 8-s condition (* p < .05, ** p < 
.01, *** p < .001), while shading of 
individual points indicates a significant 
difference from the corresponding 8-s 
condition point (black, n.s.; gray, p < .05; 
white, p < .001). Selective effects on 
latency corresponding to an increase () 
or decrease () in impulsive preparation, 
or a disruption in behavior (), is also 
indicated in the legend. Middle panel: 
Accuracy of responses as a function of 
latency to respond and the pre-stimulus 
lever insertion duration. Bottom panel: 
Premature responses as a function of pre-
stimulus lever insertion duration. 
Asterisks above bars indicate statistical 
significance compared to the 8-s 
condition, as described above. Selective 
effects on premature responses 
corresponding to an increase () or 
decrease () in impulsive action, or a 
disruption in behavior (), is also 



































































Stimulus Certainty Figure 5-2. Changes in performance 
when stimuli were correlated with the 
food lever with a probability of 1.0 
throughout the trial, compared to the 
uncertain probabilities used for all other 
tests. Top panel: Distribution of response 
latencies under both stimulus certainty 
conditions. Middle panel: Accuracy of 
responses as a function of response 
latency and stimulus certainty. Asterisks 
in the legend (* p < .05, ** p < .01, *** p 
< .001) and symbol shading (black, n.s.; 
gray, p < .05; white, p < .001) indicate 
statistically significant differences from 
the uncertain stimuli condition. The bold, 
dashed line represents the programmed 
probability of the uncertain stimuli 
accurately predicting the reinforcer 
location as a function of trial duration. 
Trial duration for the purposes of this 
analysis is indicated by the upward-
deflecting tick marks on the x-axis and 
italicized axis labels, and corresponds to 
the latency bins of the response accuracy 
data. Bottom panel: Premature responses 








































































d-Amphetamine Figure 5-3. Effects of d-amphetamine 
pretreatments on performance. Top panel: 
Distribution of latencies to respond as a 
function of drug dose in mg/kg. Data are 
presented as percent of total responses 
meeting or exceeding the delay indicated 
on the x axis after each dose indicated by 
symbol shape. Asterisks in the legend 
indicate a significant difference from 
vehicle (* p < .05, ** p < .01, *** p < 
.001), while shading of individual points 
indicates a significant difference from the 
corresponding vehicle point (black, n.s.; 
gray, p < .05; white, p < .001). Selective 
effects on latency corresponding to an 
increase () or decrease () in impulsive 
preparation, or a disruption in behavior 
(), is also indicated in the legend. 
Middle panel: Accuracy of responses as a 
function of latency to respond and drug 
dose in mg/kg. Asterisks appearing in the 
legend and symbol shading indicate 
statistical significance as described 
above. Bottom panel: Premature 
responses as a function of drug dose. 
Asterisks appearing above bars indicate a 
statistically significant difference from 
vehicle (* p < .05, ** p < .01, *** p < 
.001). Selective effects on premature 
responses corresponding to an increase 
() or decrease () in impulsive action, 
or a disruption in behavior (), is also 






































































GBR 12909 Figure 5-4. Effects of GBR 12909 
pretreatments on performance. All other 







































































Pramipexole Figure 5-5. Effects of pramipexole 
pretreatments on performance. All other 







































































Sumanirole Figure 5-6. Effects of sumanirole 
pretreatments on performance. All other 








































































ABT-724 Figure 5-7. Effects of ABT-724 
pretreatments on performance. All other 





































































Haloperidol Figure 5-8. Effects of haloperidol 
pretreatments on performance. All other 






































































PG01037 Figure 5-9. Effects of PG01037 
pretreatments on performance. All other 







































































L-741,626 Figure 5-10. Effects of L-741,626 
pretreatments on performance. All other 





































































L-745,870 Figure 5-11. Effects of L-745,870 
pretreatments on performance. All other 
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Haloperidol + 0.1 Pramipexole Figure 5-12. Effects of haloperidol 
pretreatments on the effects of 0.1 mg/kg 
pramipexole. Top panel: Distribution of 
latencies to respond as a function of drug 
dose. Data are presented as percent of 
total responses meeting or exceeding the 
delay indicated on the x axis after each 
dose indicated by symbol shape. 
Asterisks in the legend indicate a 
significant difference from vehicle (* p < 
.05, ** p < .01, *** p < .001), while 
daggers indicate a significant difference 
from the effects of the agonist alone († p 
< .05, †† p < .01, ††† p < .001). Shading 
of individual points in the agonist alone 
curve indicates a significant difference 
from the corresponding vehicle point, 
while shading of the antagonist + agonist 
points indicates a significant difference 
from the corresponding agonist alone 
point (black, n.s.; gray, p < .05; white, p 
< .001). Selective effects on latency 
corresponding to an increase () or 
decrease () in impulsive preparation, or 
a disruption in behavior (), is also 
indicated in the legend near the agonist 
alone condition. Middle panel: Accuracy 
of responses as a function of latency to 
respond and drug dose. Asterisks 
appearing in the legend and symbol 
shading indicate statistical significance as 
described above. Bottom panel: 
Premature responses as a function of drug 
dose. Asterisks appearing above agonist 
alone bars indicate a statistically 
significant difference from vehicle (* p < 
.05, ** p < .01, *** p < .001), while 
daggers above antagonist plus agonist 
bars indicate a statistically significant 
difference from the agonist alone 
condition († p < .05, †† p < .01, ††† p < 
.001). Selective effects on premature 
responses corresponding to an increase 
() or decrease () in impulsive action, 
or a disruption in behavior (), is also 










































































L-741,626 + 0.1 Pramipexole Figure 5-13. Effects of L-741,626 
pretreatments on the effects of 0.1 mg/kg 









































































PG01037 + 0.1 Pramipexole Figure 5-14. Effects of PG01037 
pretreatments on the effects of 0.1 mg/kg 








































































SKF 81297 Figure 5-15. Effects of SKF 81297 
pretreatments on performance. All other 









































































SCH 23390 Figure 5-16. Effects of SCH 23390 
pretreatments on performance. All other 









































































SCH 23390 + 1.0 SKF 81297 Figure 5-17. Effects of SCH 23390 
pretreatments on the effects of 1.0 mg/kg 












































































Apomorphine Figure 5-18. Effects of apomorphine 
pretreatments on performance. All other 
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ASSESSING INTER-MODEL CONGRUITY OF ANIMAL MODELS OF 
IMPULSIVE BEHAVIOR: DELAY DISCOUNTING, UNCERTAIN VISUAL 
DISCRIMINATION, AND PACED FIXED CONSECUTIVE NUMBER 
SCHEDULES 
Impulsivity and self control are constructs used to describe what is increasingly 
apparent to be more than one class of behaviors. Although as many as 15 subtypes of 
impulsive behavior patterns have been posited (Gerbing, Ahadi, & Patton, 1987), two or 
three subtypes have been argued more frequently. Based on operant and neurobiological 
experiments in humans and animals, a growing consensus largely agrees on two types of 
impulsive behavior: impulsive choice and what is termed impulsive action or behavioral 
inhibition (Dalley, Mar, Economidou, & Robbins, 2008; de Wit, 2008; Evenden, 1999a; 
Perry & Carroll, 2008; Winstanley, Eagle, & Robbins, 2006). Impulsive choice is the 
tendency to be hypersensitive to delays to reward, while impulsive action refers to the 
inability to withhold or inhibit a prepotent response. In addition to these two, a third 
component of impulsivity has been proposed by some. Impulsive preparation or 
reflection impulsivity, acting before gathering and processing all necessary information, 
has been argued to encompass impulsive-like responding on a variety of cognitive tasks 
used in humans and an UVD task in rats (Evenden, 1999a). Lapses in attention which do 
not necessarily coincide with poor attentional performance overall have also been 
proposed as a component of impulsivity (de Wit, 2009). 
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Impulsive choice is typically measured using procedures that provide choice 
opportunities between a smaller amount of a reinforcer delivered after little or no delay 
and large amount of the same reinforcer delivered after a longer delay (Ainslie, 1975). 
Procedures to measure impulsive choice fall into two categories: those that make within-
session adjustments the amount of one reinforcer or the delay to one reinforcer based on 
the subject’s behavior (Mazur, 1987; Richards, Mitchell, de Wit, & Seiden, 1997), or 
those that arrange choices between a predefined set of delays and amounts (Evenden & 
Ryan, 1996). In both types of procedures, the tendency to choose the smaller, more 
immediate reinforcer over the larger, delayed reinforcer is interpreted as impulsive 
choice.  
Impulsive action has been modeled using a number of procedures, including but 
not limited to the go/no-go task, the stop signal reaction time (SSRT) task, the 5-choice 
serial reaction time (5-CSRT) task, differential reinforcement of low rates (DRL) 
schedules, and FCN schedules. Performance on each of these tasks required suppressing 
or withholding a response that is reinforced in another context. The go/no-go task and 
SSRT task are very similar (for review, see Band & van Boxtel, 1999). Both reinforce 
responding in the presence of a stimulus, but punish responding if a distinct, second 
stimulus is present. In the go/no-go task, the second “no-go” stimulus is presented prior 
to or simultaneously with the “go” stimulus. In the SSRT task, the second “stop signal” is 
presented briefly after the first stimulus. The 5-CSRT task, originally developed as a 
model of sustained attention, reinforces responding in the presence of brief visual stimuli 
(Robbins, 2002). Responses that occur prior to the presentation of these brief stimuli are 
punished with a timeout, and have been studied as a model of impulsive action. DRL 
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schedules and FCN are also conceptually similar (for review, see Monterosso & Ainslie, 
1999). Responding is reinforced on a DRL schedule based on the time that has elapsed 
since the previous response. For example, responses are reinforced on a DRL 60-s 
schedule if a fixed 60-s interval has elapsed since the previous response. On a FCN 
schedule, responses on a “reinforcement lever” are reinforced based on the number of 
responses made on a “chain lever” since the previous reinforcement-lever response. For 
example, a single response on the reinforcement lever is reinforced on a FCN 8 schedule 
if at least eight responses have been recorded on the chain lever prior to the 
reinforcement-lever response. Responses made prior to the time interval on a DRL 
schedule, or prior to the response requirement on a FCN schedule, are punished with a 
timeout and interpreted as impulsive action. Evenden (1998) developed a variant of this 
task, dubbed a paced FCN schedule, that controls for the rate-increasing or rate-
decreasing effects many drugs have on schedule-maintained behavior. By withdrawing 
the levers after every response and reinserting them into the chamber after a specified 
interval, the maximum response rate can be controlled. 
Subtypes of impulsivity other than impulsive choice and impulsive action have 
been proposed. Impulsive preparation, or acting before obtaining and processing all 
necessary environmental stimuli, has been proposed as a component of impulsive 
behavior (Evenden, 1999a). The UVD task mentioned above is an interesting model of 
impulsivity in rats, as behavior on this task may include components of impulsive action 
and impulsive preparation (Dalley et al., 2008; Evenden, 1999b). In a two-lever operant 
chamber, responses on one lever are reinforced while responses on the other lever are 
punished with a timeout. The reinforced lever is determined randomly at the beginning of 
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each trial, and visual stimuli that probabilistically correlate with the correct lever are 
illuminated above the levers. The probability that the stimuli are correct increases as the 
trial progresses, such that withholding a response for a few seconds greatly increases the 
likelihood of a correct response. This behavior pattern is hypothesized to model cognitive 
tasks such as the Matching Familiar Figures Test and the Tower of London, which have 
been used to study impulsivity in humans (Evenden, 1999a). Responses made prior to the 
illumination of the uncertain stimuli, or premature responses, on this task are also 
punished with a timeout similar to premature responses on the 5-CSRT task. Therefore, 
the UVD task provides two distinct measures of impulsivity within a single session. 
While tasks used to model impulsive behavior in the laboratory are typically 
grouped into categories such as these, little is known about the relationship among the 
dependent measures on these tasks. If tasks that measure impulsive choice are distinct 
from those that measure impulsive action or impulsive preparation, then one would 
expect choices on a DD task, for example, to be uncorrelated with premature responses 
on the UVD task. One would also expect premature responses on the UVD task and chain 
length on a FCN schedule, for example, to correlate as these tasks are both hypothesized 
to measure impulsive action. Finally, one would expect that a manipulation that alters 
performance on one task, such as administration of a psychoactive drug, to affect 
performance similarly on models within a subtype. Relationships such as these have 
received little attention in the animal literature. There are numerous examples of the same 
drug or environmental or neural manipulation assessed on separate tasks, but to the 
author’s knowledge, no reports exist relating these effects in individual subjects trained to 
respond on multiple tasks. A single report compared within-subject baseline performance 
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of rats trained to respond on multiple models of impulsive behavior (Delly-Hagedorn, 
2006). Comparing performance within-subject on the DD task, a FCN 8 schedule, and a 
multiple fixed-interval extinction (mult FI EXT) schedule (thought to be a model of 
hyperactivity, for review see Sagvolden, Russel, Aase, Johansen, & Fishbaf, 2005), 
general activity was found to correlate across tasks. Impulsive choice on the DD did not 
correlate with impulsive action on the FCN 8 schedule or hyperactivity on the mult FI 
EXT schedule, but impulsive action on the FCN 8 schedule did correlate with 
hyperactivity in the extinction component of the mult FI EXT schedule. No 
environmental or pharmacological manipulations were assessed on these tasks.  
The current experiments were designed to assess the underlying similarities and 
differences among the dependent measures of three purported models of impulsivity. Rats 
were trained on either the DD task, a paced FCN schedule, or the UVD task and drug 
effects were examined (for a complete account of drug effects, see Chapter 3, 
Chapter 4, and Chapter 5). Rats were then retrained on a different task, and 
selected drug effects were redetermined. Assuming that behavior maintained on tasks that 
measure the same underlying process will correlate and react similarly to 
pharmacological challenges, data were used to assess two questions: 1. Do individual 
differences in baseline performance correlate across the dependent measures of these 
tasks? 2. Do individual differences in changes in performance after drug administration 





Twenty-four male Sprague Dawley rats served as subjects (Harlan, Indianapolis, 
IN). Rats were approximately 10 weeks old at the start of the experiment. A food 
restriction protocol was in place to maintain the rats at approximately 325 g throughout 
the experiment. This weight was chosen as it is approximately 85% of the mean adult 
weight supplied by the manufacturer for this strain, and this weight was not changed once 
established. When not in session, rats were housed in accordance with institutional 
animal care and use guidelines in polycarbonate cages with fresh water continuously 
available. The lights in the housing colony were on from 7:00 AM to 7:00 PM, and 
sessions were conducted between 8:00 AM and 6:30 PM. These protocols were approved 
by the University of Michigan Committee on the Use and Care of Animals and 
conformed to the guidelines established by the NIH Guide for the Use of Laboratory 
Animals. 
Apparatus 
Sessions were conducted in two sets of similarly equipped rodent operant 
conditioning chambers with an area of 30.5 cm x 24.1 cm x 21.0 cm and stainless steel 
grid floors (ENV-008; Med-Associates Inc., St. Albans, VT). Both sides of the front 
panel of the chamber held a retractable lever (E23-17, Coulbourn Instruments, Whitehall, 
PA or ENV-112CM, Med-Associates, Inc.). Between the levers was a food tray 
connected to a 45 mg pellet dispenser (ENV-200R1AM and ENV-203M-45, Med-
Associates, Inc.). Above both of the levers and the food tray were triple stimulus lights 
containing a red, green, and yellow LED (ENV-222M, Med-Associates, Inc.). A 
houselight was located near the top of the opposite wall to provide illumination to the 
chamber (ENV-215M, Med-Associates, Inc.). The chambers used in the second phase of 
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the experiment also contained a nose-poke hole on the back wall which was not used 
(ENV-114BM, Med-Associates, Inc.). Chambers were connected to a computer running 
Med-PC IV software (Med-Associates, Inc.) to control experimental events and record 
data. 
Procedure 
A schematic of the procedure is displayed in Figure 6-1, and was split into five 
phases (A-E). After response training, each rat was trained to respond on two of the three 
tasks chosen in a counterbalanced order, with the same five drug tests performed on each 
task so baseline performance and drug effects could be compared across task within 
subject.   
Response training (Phase A). All rats were exposed to a common magazine- and 
lever-training procedure. Rats were trained to respond on a mixed fixed-time 60 s FR 1 
schedule of reinforcement, with the active lever alternating each session between the left 
and right levers. This schedule arranged one sucrose pellet to be delivered every 60 s 
independent of behavior, with every lever press also producing a pellet. This was 
continued for four sessions, at which point the schedule was switched to a FR 1 with no 
response-independent pellet deliveries. Rats were allowed to respond on this schedule 
until 80 responses or more were recorded on two consecutive 20-min sessions. 
Delay discounting (Phase B). The sessions were then extended to 75 min and split 
into five components of ten discrete-choice trials each. Total trial duration was 90 s and 
began with one or both levers extending into the chamber. If a single response was made 
within 20 s, the levers retracted and the consequence programmed for that lever was 
delivered. If no response was made within 20 s, that trial was recorded as an omission 
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and the levers retracted for the remaining 70 s of that trial. The first two trials of each 
component were always forced-choice trials where only one lever was extended into the 
chamber, forcing the subject to sample the contingencies for that component. The 
remaining eight trials were free-choice trials where both levers were extended into the 
chamber, allowing the rat to respond on either. The three stimulus lights above each lever 
were lit whenever that lever was inserted in the chamber, and the stimulus lights above 
the pellet tray were lit during sucrose pellet deliveries. Initially, the consequences for 
both levers were immediate deliveries of either one or three 45-mg sucrose pellets, with 
the side associated with each amount counterbalanced across subjects. This condition was 
continued until rats chose the three-pellet option on at least 85% of free-choice trials. The 
three-pellet and one-pellet levers were then switched two times, with each new lever 
assignments in place until rats responded on the three-pellet option on at least 85% of 
trials. When this training regimen was completed, delays were introduced between 
responses made on the three-pellet lever and the delivery of the three pellets. The delays 
to the three-pellet option were 0, 10, 20, 40, or 60 s and were always presented in 
ascending order with one delay in effect in each of the five 10-trial components. 
Uncertain visual discrimination (Phase B). Rats were trained to discriminate 
visual stimuli presented above the levers. In a series of discrete trials, the three stimulus 
lights above one of the levers were lit and both levers were extended into the chamber. 
The location of the lights was determined randomly at the start of each trial. A response 
to the lever below the illuminated stimulus lights was recorded as a correct response and 
led to both levers retracting, a 45-mg sucrose pellet delivery, and a 5-s timeout period. 
Responses to the lever with no stimulus lights was recorded as an incorrect response and 
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resulted in lever retraction and the timeout only. If no response occurred within a limited 
hold of 30 s, an omission was recorded, the levers were retracted, and a 5-s timeout 
occurred. After four sessions, a pre-stimulus lever insertion duration was added such that 
the levers were inserted into the chamber 1 s before the randomly-determined stimulus 
light was illuminated. Responses made before the stimulus presentation, regardless of 
lever, led to the levers retracting and a 5-s timeout. Over a number of sessions, the 
duration that the levers were inserted into the chamber before a stimulus was lit was 
extended to 8 s. Rats were allowed to respond with these contingencies until at least 85% 
of responses made after stimulus illumination were on the lever under the stimulus light. 
The test procedure was similar to the final training procedure, with the exception 
that the stimuli did not predict the correct lever with a probability of 1.0. Once each trial 
began, 8 s after the levers were inserted into the chamber, a series of 0.2-s cycles began 
with the stimulus location during each cycle determined on a probabilistic basis. During 
the first cycle, any of the three stimulus lights (“correct,” the light above the lever with 
the active FR 1 schedule; “incorrect,” the light above the other lever; or “irrelevant,” the 
light above the food cup that did not differentially signal food availability) had an equal 
probability of being illuminated. With each subsequent cycle (n), the probability that the 




  (6-1) 




 . (6-2) 
When 𝑛𝑛 = 1, both Equation 6-1 and Equation 6-2 equal .3� and the probability that 
each of the three stimuli being lit was the same. The probability that the lit stimulus was 
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above the correct lever increased to approximately .8 after 4 s elapsed (𝑛𝑛 = 21). A 
response on the correct lever at any point after stimuli were lit was reinforced with a food 
pellet, while a response on the other lever led to the 5-s timeout period. Sessions ended 
after 60 min or 144 trials, whichever occurred first. 
Paced fixed consecutive number schedule (Phase B). Paced FCN schedule 
training began with the subjects placed in the operant chambers and both levers extended. 
Left and right levers were randomly assigned to each subject as either the “chain lever” 
or the “sucrose lever”, and these assignments did not change over the course of the 
experiment. The FCN contingency reinforced responding on the chain lever a number of 
times equal to or greater than the FCN schedule value followed by a single response on 
the sucrose lever. Training started with an FCN 1 schedule, where one or more responses 
on the chain lever followed by one response on the sucrose lever resulted in a 45-mg 
sucrose pellet delivery and both levers being retracted for 5 s. After each response, both 
levers were retracted and reinserted such that the maximum response rate was controlled, 
but with no minimum response rate, as described in detail by Evenden (1998b). Sessions 
were also split into five components, separated by 1-min blocks with the houselight off 
and the levers retracted. Components 1, 3, and 5 were 10 min in duration with a pacing 
interval of 2.5 s, and components 2 and 4 were 20 min in duration with a pacing interval 
of 5.0 s. The FCN schedule value was then gradually increased over a number of sessions 
to FCN 8, where eight or more responses on the chain lever were required before one 
response on the sucrose lever was reinforced with a food pellet. At each FCN schedule 
value, more responses than required on the chain lever before switching to the sucrose 
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were reinforced with a sucrose pellet, but fewer responses than required led to both levers 
being retracted for 5 s and no sucrose pellet delivery. 
Drug Testing (Phase C). Drug testing began in each group after no increasing or 
decreasing trend in performance was apparent over a period of five sessions. Sessions 
were generally conducted five days per week with vehicle injections administered on the 
first and fourth days of the week, drugs administered on the second and fifth days, and no 
injections given on the third day. Vehicle injections always matched the schedules drug 
injections for the following day in number, substance, and time relative to the 
experimental session. Each session contained a vehicle or drug injection five minutes 
before the start of the session with the rat then immediately placed in the darkened 
experimental chamber. Pramipexole, d-amphetamine, SKF 81297, and SCH 23390 were 
administered at this 5-min pretreatment point, while PG01037 or its vehicle was 
administered 30 min before session start. When an injection was administered 30 min 
before session start, the rat was placed back in his home cage for the intervening 25 min 
before the second vehicle injection was given. SCH 23390 injections were immediately 
followed by a second saline injection before the rat was placed in the chamber. These rats 
were the same included in reports detailing the effects of various dopamine agonists and 
antagonists on these behavioral tasks. Those results are reported elsewhere (Chapter 
3, Chapter 4, and Chapter 5). 
Task reassignment (Phase D). After drug effects were determined as described 
above, all subjects were reassigned to another task. Four rats from each task were 
reassigned to each of the other two tasks (see Figure 6-1). This reassignment was not 
random; instead attempts were made to equalize the distribution of rats in each task based 
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on baseline performance. For example, of the eight DD rats, four were assigned to the 
UVD task and four were assigned to the paced FCN task. Rats were reassigned such that 
the effect of delay on choices of the delayed, three-pellet lever were roughly equal in the 
two sets of four rats, both in range and mean effect size of delay. Similar considerations 
were made when reassigning the UVD rats and paced FCN rats. Attempts were made to 
equalize range and mean response latency and premature responses in the UVD rats and 
mean chain lengths in the paced FCN rats. Once rats were reassigned, they went through 
an abbreviated training regimen as described above. They were first placed on the 
original response training schedule for five days, with responses reinforced on an FR 1 
schedule on either the left or right lever on alternating days. This was followed by 
training on the second task, as described above.  
Drug Testing (Phase E). After final schedule criteria were met and no increasing 
or decreasing trend in performance was noted on each of the tasks, the five drug tests and 
associated vehicles were readministered as described above. One subject died prior to 
Phase E (Figure 6-1). 
Drugs 
Pramipexole was generously provided by Drs. Jianyong Chen and Shaomeng 
Wang (University of Michigan, Ann Arbor, MI) and PG01037 by Drs. Amy H. Newman 
(Medicinal Chemistry Section – National Institute on Drug Abuse, Baltimore, MD) and 
Peter Grundt (University of Minnesota – Duluth, Duluth, MN). SKF 81297 and SCH 
23390 were obtained from Sigma-Aldrich (St. Louis, MO) and d-amphetamine was 
obtained by the National Institute on Drug Abuse (Bethesda, MD). All drugs were 
dissolved in sterile saline except PG01037 which was dissolved in 20% β-cyclodextrin. 
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All drugs were administered subcutaneously in a volume of 1.0 ml/kg except 56 mg/kg 
PG01037 which was administered in of volume of 1.75 ml/kg due to solubility limits. 
Data Analysis 
On each task, two or three measures were selected to characterize performance on 
that task. Performance was measured in the absence of any drug administrations for five 
consecutive sessions. For the DD task, the percent choice of the three pellet option was 
plotted as a function of the delay to that option. A linear regression line was drawn 
through those data with GraphPad Prism 5 (La Jolla, CA), and the slope and y-intercept 
of that line was recorded. The latency to respond after levers were inserted into the 
chamber was selected as an additional measure of interest for this task. For the UVD task, 
the average latency to respond after illumination of the uncertain stimuli was selected as 
the first measure. Premature responses, those responses recorded before the illumination 
of any stimuli, was the second measure of interest. For the paced FCN schedule, three 
measures were selected. The first two were derived measures obtained by first plotting 
chain length data as survival plots, or the percent of chains of at least X responses. 
Summarized in this manner, data were well-approximated by the sigmoidal equation 
  𝑌𝑌 = 100
1+10(𝐶𝐶50−𝑎𝑎 )∗𝑆𝑆
 (6-3)  
where Y is the percent chains meeting X or more responses and C50 and S are derived 
parameters, C50 indicating the chain length that 50% of chains met or exceeded, and S 
indicating the slope of the curve at point C50. The value of C50 was computed for the short 
and long pacing-interval components separately, and these values were two of the 
measures used to characterize this task. The third measure was perseverative sucrose-
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lever responses, defined as the percent of sucrose-lever responses occurring with no 
chain-lever responses preceding them.  
Each of these measures of interest was then compared within tasks (e.g., UVD 
latency and UVD premature responses) and between tasks (e.g., UVD latency and paced 
FCN perseverative responses). Baseline measures obtained in the absence of any drug 
over a period of five sessions were compared with a Pearson product-moment correlation 
in Systat SigmaStat 3.5 (San Jose, CA). Changes in performance after drug 
administrations (change in performance = performance on test session – performance on 
corresponding vehicle session) were also compared across tasks with Pearson 
correlations. 
Results 
The results of all correlations are shown in Table 6-1. Baseline performance was 
significantly correlated within a task in only one instance. Perseverative responses on the 
paced FCN schedule was negatively correlated with the derived C50 parameter from 
Equation 6-3 in the long components (r = -.845, n = 16, p < .001). However, examination 
of the associated scatter plot of this correlation (not shown) revealed a single outlier that 
was responsible for this apparent correlation. The C50 in the long component for one 
subject was 4.03 (range for the rest of the group was 8.86 to 13.03) and the percent 
perseverative responses for this same subject was 24.0 (range for the rest of the group 
was 1.0 to 7.5). With this outlier removed, no relationship existed between these 
variables (r = -.039, n = 15, p = .892). The C50 parameter did not correlate between the 
long and short component, nor baseline levels of C50 during the short components 
correlate amount of perseverative responses. On the DD task, the slope of a best-fit curve 
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fit to the individual rats’ choice data, the y-intercept of this line, and the average latency 
to respond did not correlate. On the UVD task, no significant correlation was found 
between premature response and response latency.  
When the selected dependent measures were compared across tasks, a significant 
positive correlation was found between latency to respond on the UVD task and latency 
to respond on the DD task (r = .823, n = 8, p = .012). All other pairs of variables across 
tasks were not significantly correlated (see Table 6-1). 
Changes in performance after administration of five drugs known to affect 
performance on these tasks in varied ways (1.0 mg/kg d-amphetamine, 0.1 mg/kg 
pramipexole, 56 mg/kg PG01037, 1.0 mg/kg SKF 81297, and 0.01 mg/kg SCH 23390) 
were compared within and across tasks (Table 6-1, shaded portion). Within the DD task, 
a negative correlation was found between the slope and y-intercept of the regression lines 
fit through the choice data (r = -.665, n = 72, p < .001), meaning when a drug increased 
the slope of the discounting line it also tended to decrease the y-intercept of that line in 
the same subject, and vice-versa. Within the paced FCN task, changes in each of the three 
measures after drug administrations were associated with a change in the other two. A 
positive correlation was found between drug effects on the derived C50 parameter from 
Equation 6-3 in the long and short components (r = .660, n = 56, p < .001), indicating that 
these drugs typically affected performance in each component similarly. In addition, 
perseverative responses was negatively correlated with the derived C50 parameter in both 
the short (r = -.300, n = 71, p = .011) and long (r = -.438, n = 56, p < .001) components. 
Drug administrations that increased perseverative responses also tended to decrease chain 
lengths in both components. 
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Comparing the effects of the chosen drugs between tasks, only one set of 
variables was significantly correlated. Just as with baseline performance correlations, 
changes in latency to respond on the UVD task after drug administrations were positively 
correlated with changes in latency to respond on the DD task (r = .458, n = 37, p < .001). 
Drug administrations tended to increase or decrease latency to respond on both tasks 
similarly within a given subject.  
Discussion 
Subjects learned the contingencies of each of the three tasks both in the original 
training, and retraining to a second task. This experiment represents the first assessment 
of psychoactive drugs on multiple rodent impulsivity tasks on a within-subject basis. 
Latency to respond on the UVD task and DD task were correlated at baseline, and 
drug effects on these measures were also correlated. This suggests the same underlying 
processes control these behaviors. Latency on both tasks represents time since the 
presentation of response levers and visual stimuli together (DD) or visual stimuli alone 
with levers already extended for 8 s (UVD). That this measure is correlated within 
subjects at baseline and after drug administration is not surprising, but raises 
interpretation questions about the UVD task. Latency on the UVD task has been 
hypothesized to measure impulsive preparation, or acting with incomplete information 
(Evenden, 1999a). In this regard, the UVD task has face validity. Since the visual stimuli 
are presented probabilistically, with the probability of correctly predicting reinforcer 
location increasing as trial duration increases, waiting on this task could be construed as 
processing or gathering information conveyed by the discriminative stimuli. The DD 
task, however, has no such features. Stimuli and levers are presented simultaneously and 
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signal the consequences of each choice option with the same probability (1.0) on each 
trial. Since latency to respond was highly correlated on both tasks, it is likely that latency 
on the UVD task is measuring a similar behavioral trait as latency on the DD task. The 
selected drugs also affected latency similarly on both tasks, indicating that these drug 
effects on the UVD task had little to do with enhancing propensity to gather information 
and prepare for a response. Instead, it seems likely that the drugs were affecting reaction 
time to discriminative stimuli in both tasks, and likely governed by similar processes as 
those in simple reaction time experiments.  
On the DD task, the slope and y-intercept of the best-fit regression lines fit 
through the choice data were not correlated significantly at baseline, but drug effects on 
these two measures were negatively correlated. A decrease in slope of the discounting 
curve is typically interpreted as a decrease in impulsive choice, but if this is also 
accompanied by a decrease in y-intercept, it is typically interpreted as a failure to 
discriminate amount through loss of stimulus control or similar mechanism (Acheson et 
al., 2006; Pitts & Febbo, 2004; note that since slopes were negative as plotted, a 
“reduction” in slope is an increase in absolute value, leading to a negative correlation for 
the described scenario). For the doses of drugs tested, this was the normal occurrence, as 
there was a robust negative correlation between these measures.  
On the paced FCN schedule, drug-induced changes in chain lengths were 
positively correlated in the short and long components, and drug-induced changes in 
perseverative responses were also correlated with chain lengths in both components. It is 
not surprising that changes in chain lengths were correlated between components, as the 
only difference between short and long components was the pacing interval that 
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controlled maximum response rate. That perseverative responses, or proportion of 
sucrose-lever responses not preceded by a chain lever response, were negatively 
correlated with chain lengths may be a function of how these responses were 
operationally defined. Perseverative responses could be conceptualized as chains of zero 
responses in length, or chains not preceded by a chain-lever response. Thought of in this 
way, it is not surprising that drugs that tended to reduced chain lengths overall also 
increased the proportion of the shortest chain length possible, zero responses. 
One set of correlations that is absent from these results is notable. There were no 
significant correlations between chain lengths in either component on the paced FCN 
schedule and premature responses on the UVD task, nor did the selected drugs affect 
these measures similarly. Premature responses and chain length are both purported 
measures of “impulsive action” (Dalley et al., 2008; Evenden, 1999a). That individual 
rats do not respond similarly on these two measures, nor react similarly with respect to 
these measures after drug challenges, raises doubt that these are simply two 
manifestations of the same behavioral construct. Group-level data also show differences 
between these tasks. The spontaneously hypertensive rat (SHR), selective bred from 
Wistar Kyoto (WKY) rats, is a much-studied rodent model of attention-
deficit/hyperactivity disorder (for review see Sagvolden et al., 2005). On the 5-CSRT 
task, SHR emit the same number of premature responses as WKY rats (De Bruin, 
Kiliaan, De Wilde, & Broersen, 2003; van den Bergh, Bloemarts, Chan, Groenink, 
Olivier, & Oosting, 2006), but have shorter chain lengths on a paced FCN schedule 
(Evenden & Myerson, 1999). Drug effects on a group level also occasionally correlated 
between premature responses on the UVD task and chain length on the paced FCN 
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schedule (e.g., d-amphetamine, see Cole & Robbins, 1987, Evenden, 1998; Chapter 4, 
Chapter 5), but other times a discordance is found (e.g., pramipexole, see Chapter 
4 and Chapter 5). 
Impulsivity is often described as a multidimensional trait, and dependent 
measures on behavioral models of impulsivity are often assigned to one of these trait 
subtypes. The present experiment represents one attempt at determining whether these 
model assignments are valid. Many of the dependent measures on the DD, UVD, and 
paced FCN models of impulsivity did not correlate, as theory predicts. However, the 
correlation between response latency on the UVD and DD tasks brings into question the 
validity of the UVD task as a model of impulsive preparation. In addition, the lack of 
correlation between baseline measures and drug effects on premature responses on the 
UVD task and chain length on the paced FCN brings into question the grouping of both 





Table 6-1. Pearson r correlations between measures of interest and the number of data 
points included in each correlation. Numbers in the unshaded, upper-right portion of the 
table represent correlations between baseline performance for each measure of interest, 
computed over five days of responding in the absence of any injections. Numbers in the 
shaded, lower-left portion of the table represent correlations between drug effects on 
performance for each measure.  
 
 DD  UVD  Paced FCN 
 









DD           
Lat.  -.394 (n = 16) 
.077 
(n = 16) 
 
.823* 
(n = 8) 
-.571 
(n = 8) 
 
.188 
(n = 8) 
.122 
(n = 8) 
-.156 
(n = 8) 
Slope .106 (n = 72)  
-.330 
(n = 16) 
 
-.506 
(n = 8) 
.282 
(n = 8) 
 
-.197 
(n = 8) 
-.132 
(n = 8) 
.212 
(n = 8) 
Y-int. -.145 (n = 72) 
-.665** 
(n = 72)  
 
.280 
(n = 8) 
.362 
(n = 8) 
 
.337 
(n = 8) 
-.132 
(n = 8) 
.177 
(n = 8) 
UVD           
Lat. .458** (n = 37) 
.093 
(n = 37) 
-.208 
(n = 37) 
 
 -.380 (n = 16) 
 
-.045 
(n = 8) 
-.255 
(n = 8) 
.138 




(n = 37) 
.137 
(n = 37) 
-.071 
(n = 37) 
 
.125 
(n = 79)  
 
-.066 
(n = 8) 
.451 
(n = 8) 
.222 
(n = 8) 




(n = 34) 
-.083 
(n = 34) 
-.081 
(n = 34) 
 
.098 
(n = 31) 
-.064 
(n = 31) 
 
 .405 (n = 16) 
.021 




(n = 25) 
-.044 
(n = 25) 
.076 
(n = 25) 
 
.092 
(n = 26) 
.066 
(n = 26) 
 
.660** 
(n = 56)  
-.845**a 




(n = 34) 
.093 
(n = 34) 
-.079 
(n = 34) 
 
.213 
(n = 31) 
.208 
(n = 31) 
 
-.300* 
(n = 71) 
-.438** 
(n = 56)  
* p < .05; ** p < .001 
a This correlation was driven by a single outlier that when removed, reduces the 








































Figure 6-1. Schematic of the experimental procedure and number of rats (n) in each subgroup of each 
Phase. The 24 subjects were split into subgroups at each phase of the experiment as indicated. A: Response 
and magazine training. B: Training on one of the three impulsivity tasks. C: The drugs listed described in 
Chapters 3, 4, and 5 were administered. D: The three groups were each split into two groups, each of which 
was assigned to a new task. This resulted in three counterbalanced groups of rats, each of which 
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The experiments in the preceding chapters represent steps toward validating three 
behavioral models of impulsive behavior. In Chapter 2, impulsive choice was found to be 
associated with demand for self-administered cocaine without being associated with 
demand for sucrose, a relationship relevant to the increased impulsive choice noted in 
human substance abusers. In the next three chapters, the effects of agonists and 
antagonists selective for specific dopaminergic receptor subtypes were assessed on three 
purported models of impulsivity. Dopamine D1-like antagonism and D4 agonism were 
found to have similar effects on impulsive choice in Chapter 3. In Chapter 4, D2 and D3 
receptors appeared to be important, with selective decreases in impulsive action with 
administration of either a D2 agonist or D3 antagonist. Agonists or antagonists at D1-like, 
D2, or D3 receptors reduced the purported measure of impulsive preparation in Chapter 5, 
raising questions about the validity of this result. These concerns were addressed more 
directly in Chapter 6, which challenged parts of the classification system used to assign 




Assessing the validity of the delay discounting (DD) task, paced fixed consecutive 
number (FCN) schedules, and the uncertain visual discrimination (UVD) task was a goal 
of the current set of experiments. Three evaluative criteria proposed for the assessment of 
animal models include face validity, construct validity, and predictive validity 
(Sagvolden, Russell, Aase, Johansen, & Fashbaf, 2005; Sarter, Hagan, & Dudchenko, 
1992). Face validity, or the degree to which a model resembles the associated clinical 
condition, was not directly assessed in the current experiments. Behavior maintained by 
the contingencies in each of these models had at least some face validity. On the delay 
discounting task, choices are made between large, delayed reinforcers and small, 
immediate reinforcers. Similar choices are made by people every day. We are 
continuously confronted with choices between an immediate piece of chocolate 
cheesecake versus delayed, improved health; or between an immediate bout of television-
watching versus delayed, better grades that could result from additional studying. The 
DD task resembles such choices to a large degree. The paced FCN schedule is less-
obviously related to impulsive action in people, although similarities exist. Impulsive 
action, or failure to inhibit a prepotent response, is present in both the clinic and the 
paced FCN schedule. Rats must respond repeatedly on the chain lever, a response that has 
never been directly reinforced (except during training), while continuously inhibiting 
responses on the sucrose lever, a response that is available and has been reinforced 
repeatedly in the past. Similarly, premature responses on the UVD task require the 
subject to initially inhibit a response on the levers when they are presented, despite such 
lever presses being reinforced many times previously. Response latency on the UVD task 
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also has face validity with respect to impulsive preparation in people. To respond 
optimally on this task, subjects must withhold a response for a period of time to observe 
the sequence of stimulus presentations above the two levers. When a sufficient number of 
stimulus presentations have been observed to discriminate the correct response location, 
an accurate response can be emitted. Responses made before a sufficient number of 
stimulus presentations are observed are faster and less accurate, a pattern that typifies 
impulsive preparation in people.  
A model with predictive validity should be affected by pharmacological and 
behavioral manipulations in an analogous way as in the clinic, including for previously-
unknown manipulations (Sarter et al., 1992). Assessing predictive validity is therefore a 
two-step process. Potential treatments should be assessed in the behavioral model, and 
those that show promise need to then be evaluated in the target human population. A 
number of previously-untested dopaminergic agonists and antagonists were assessed in 
the current experiments, with some results that warrant future study in either animal- or 
human-subjects research. Table 7-1 and Table 7-2 detail the effects of these compounds 
on the purported measures of impulsive behavior in each of the three tasks. In these 
tables, only those effects of drugs that were considered selective are highlighted. 
Relatively high doses of drugs often had significant effects on the measure of impulsive 
behavior on these tasks, but the relevance of these effects are questionable if 
corresponding behavioral disturbance was noted on a secondary measure. If response 
latency was significantly increased or if sensitivity to amount was significantly decreased 
on the DD task, behavior was considered disrupted. Behavior was similarly considered 
disrupted if total trials completed were significantly reduced on the paced FCN schedule 
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or if trials omitted were significantly increased on the UVD task. Organizing results in 
this way allows for an easier assessment of selective effects on the purported measures of 
impulsivity. The only drug assessed with known efficacy in the clinic was d-
amphetamine, which is a popular ADHD treatment (Table 7-1). The only model that 
demonstrated decreased impulsive behavior after administration of d-amphetamine was 
on the impulsive preparation measure of the UVD task. While this lends support to the 
predictive validity of this measure, the pattern of other results and the correlations with 
response latency on the DD task (Chapter 6) limit the generalizability of this result. In the 
DD task, d-amphetamine had no selective effect, and it selectively increased impulsive 
action on the paced FCN schedule and on the UVD task. These results, which do not 
correspond with the effectiveness of d-amphetamine as a treatment for ADHD, raise 
doubts regarding the predictive validity of these tasks. While others have found 
reductions in impulsive choice with d-amphetamine (Floresco, Tse, & Chods-Sharifi, 
2008; van den Bergh, Bloemarts, Groenink, Olivier, & Oosting, 2006; van Gaalen, van 
Koten, Schoffelmeer, & Vanderschuren, 2006; Wade, de Wit, & Richards, 2000; 
Winstanley, Theobald, Dalley, & Robbins, 2005; but see Evenden & Ryan, 1996; Helms, 
Reeves, & Mitchell, 2006; Stanis, Avila, White, & Gulley, 2008; Uslaner & Robinson, 
2006), d-amphetamine only been shown to increases impulsive action on paced FCN 
schedules (Evenden, 1998; Evenden & Myerson, 1999) and on the UVD task (Evenden, 
1999b).  
With these effects with d-amphetamine noted, a set of findings with the paced 
FCN still warrants further attention. The D2-preferring agonist sumanirole and the D3-preferring 
antagonist PG01037 selectively decreased impulsive action at low doses. Conversely, 
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The D3-preferring agonist pramipexole and the D2-preferring antagonist L-741,626 increased 
impulsive action, also at low doses. These results suggest a D2/D3 modulation of 
impulsive action, with either a D2 agonist or D3 antagonist being potential therapeutics. 
These or related compounds would require assessment in humans with impulse-control 
disorders to comment further about the relevance of these findings to the predictive 
validity of the paced FCN schedule. 
A model has construct validity if it shares underlying theoretical and neural 
mechanisms with the clinical condition being modeled. Construct validity was assessed 
with distinct approaches in each of the three specific aims of the preceding chapters. 
Substance abuse is defined by the Diagnostic and statistical manual of mental disorders-
IV-TR (American Psychiatric Association, 2000) as an impulse-control disorder. The 
demonstration that choices on the DD task are associated with demand for self-
administered cocaine injections improves the construct validity of the DD task and drug 
demand as models of impulsive choice and drug abuse, respectively. Importantly, this 
relationship was restricted to cocaine demand, with no relationship between choices on 
the DD task and demand for sucrose. The specificity of the relationship to impulsive 
choice and cocaine demand, demonstrated by excluding a relationship between impulsive 
choice and sucrose demand, indicates greater construct validity of these models (Sarter et 
al., 1992). Aspects of construct validity of the DD task and paced FCN schedule were 
also demonstrated in Chapter 3 and Chapter 4 with the administration of selective 
dopamine agonists and antagonists to rats performing on these tasks. Based on 
neurological experiments in humans and animals, it was predicted that compounds 
binding to D1-like and D4 receptors would be more involved in impulsive choice on the 
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DD task, and that D2 and D3 receptors would be more involved in impulsive action on the 
paced FCN schedule and UVD task (see Chapter 1). The results with the DD task and the 
paced FCN schedule match these predictions. The D1-like antagonist and D4 partial agonist 
increased impulsive choices on the DD task, and D2 and D3 compounds showed 
opposing, selective effects on impulsive action on the paced FCN schedule (see Table 7-1 
and Table 7-2). Since these findings agree with neurological correlates of impulsive 
choice and impulsive action, the construct validity of these tasks is improved.  
Construct validity of these tasks was also assessed in Chapter 6. The DD task, the 
paced FCN schedule, and the UVD task have been hypothesized to model the human 
behavior patterns of impulsive choice, impulsive action, and both impulsive action and 
preparation, respectively (Evenden, 1999a). This classification system was assessed in 
Chapter 6 by comparing individual differences in behavior on these tasks, both at 
baseline and after pharmacological challenges. Discrepancies were found between the 
theoretical classification system proposed and the results of this experiment, challenging 
the construct validity of these tasks in some cases and supporting it in others. Most 
notably, response latency on the UVD task, a purported measure of impulsive 
preparation, correlated with response latency on the DD task both at baseline and after 
pharmacological challenges. This suggests the UVD task may not be a measure of 
impulsive preparation. Also notable was the finding that premature responses on the 
UVD task were not correlated with chain length on the paced FCN schedule, both 
purported measures of impulsive action. This finding suggests that either at least one of 
these measures is not a valid model of impulsivity, or the theoretical construct of 
impulsive action is not as unified as hypothesized. Finally, choices on the DD task were 
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not correlated with the other impulsivity measures, supporting the assertion that this 
represents a distinct subtype of impulsivity. 
Subtypes of Impulsivity Revisited  
The theoretical classification system proposed by Evenden (1999a) is appealing in 
that it provides a framework in which the vast majority of tasks used to model 
impulsivity in both humans and animals can be classified with respect to Skinner’s 
(1953) three-term contingency. Skinner’s three-term contingency has been widely 
successful in describing the interrelationship between behavior and the consequences of 
behavior, and the stimuli that signal this relationship. Evenden (1999a) envisioned 
behavior that is abnormal with respect to discriminative stimuli as impulsive preparation, 
behavior that is abnormal in its execution as impulsive action, and behavior that is 
abnormal with respect to valuation of consequences as impulsive choice.  
The validity of this classification system was directly assessed in Chapter 6. 
Impulsive choice, as measured by the DD task, was distinct from the measures of 
impulsive action and impulsive preparation, supporting Evenden’s framework. Two 
purported models of impulsive action were assessed: premature responses on the UVD 
task and chain length on the paced FCN schedule. These were found to be uncorrelated, 
both at baseline and after drug administration. This result leads to one of three 
conclusions regarding Evenden’s hypothesis: impulsive action is not a unitary construct 
and is also composed of multiple subtypes, at least one of these tasks is not a model of 
impulsive action, or the procedure of Chapter 6 does not provide a valid test of Evenden’t 
hypothesis. While both of these tasks involve a component of behavioral inhibition, they 
differ in many respects. On the paced FCN schedule, the animal is actively emitting a 
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behavior almost continuously, and must inhibit a shift in behavior to a second response 
manipulandum. On the UVD schedule, behavior must be suppressed at the presentation 
of response manipulana, and withheld until the illumination of visual stimuli. Perhaps the 
inhibition of behavior in these contexts is sufficiently distinct that subtypes of impulsive 
action should be proposed. Further experimentation would be required to determine if 
this is the case. It may also be the case that either the paced FCN schedule or the UVD 
task is not a valid measure of impulsive action. Direct analogues of these two tasks have 
not been studied in humans with impulse control disorders known to involve deficits of 
behavior inhibition. Such an experiment would help determine which of these models is 
better suited for the study of impulsive action in animals. Finally, it may be that the 
experiment described in Chapter 6 is not a valid test of these models. While the evidence 
for dopaminergic pathways in the expression of impulsive behavior is quite extenstive 
(Chapter 1), the effects of systemically administered dopaminergic ligands may not be 
adequately or selectively affecting these pathways. Dopamine receptors are distributed 
throughout the brain, and it is possible that any effects of these compounds on impulsive 
behavior were overshadowed by behavioral effects mediated through other brain systems. 
Furthermore, it is possible that both tasks were measuring impulsive action but with 
differences in sensitivity. Since a small subset of drug doses was assessed in Chapter 6, it 
might not be expected that similar effects should be observed on both tasks. Significant 
effects on chain length in the paced FCN schedule were observed at much lower doses of 
each drug tested than were seen on premature reponses on the UVD task. Perhaps these 
two tasks are both models of impulsive action, but the paced FCN schedule and UVD 
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task show changes in impulsive action across different dose ranges, and the limited doses 
used in Chapter 6 did not find a correlatiosn between these tasks for that reason.  
The results of Chapters 5 and 6 suggest the UVD task is not a measure of 
impulsive preparation. While this suggests that the UVD task requires rethinking, it does 
not necessarily mean Evenden’s (1999a) hypothesis regarding the classification system of 
impulsive behavior was incorrect with respect to impulsive preparation being a subtype 
of impulsivity. Impulsive preparation has been studied extensively in people, with 
convincing evidence supporting this construct as a component of impulsivity (Chapter 1). 
Attempting to model impulsive preparation in animals was a worthwhile endeavor, and it 
is the view of this author that it should not be abandoned despite the apparent lack of 
validity of the UVD task. The UVD task appears to have face validity, so perhaps 
modifications of this task could improve its predictive and construct validity. As 
originally designed (Evenden, 1999b; Chapter 5), the UVD task provides response 
opportunities that, depending on response latency, are reinforced between roughly 50% 
and 85% of the time. It may be that the difference between these probabilities is not 
sufficient to influence waiting behavior that is central to the contruct of impulsive 
preparation. Without such influence, response latencies appear to be similar to other tasks 
that signal response availability (e.g., the DD task). If the UVD task was modified to 
increase the advantage of waiting, its validity may be improved. This could be done by 
ranging the reinforcement percentage from 0% to 85%, for example, to increase the 
benefit of waiting. In addition, the consequence of incorrect responses could be made 
more salient by adding a punisher such as mild shock to the timeout that is currently the 




The prevalence of impulsive behavior both in a normal behavioral repertoire and 
in many psychological disorders assures that further research on impulsive behavior will 
be required for quite some time. The results of the experiments described in the preceding 
chapters suggest some specific follow-up experiments that may prove fruitful.  
The experiments described in Chapter 5 and Chapter 6 suggest that the UVD task 
is not a valid model of impulsive preparation, despite the phenomenon of impulsive 
preparation being well documented in people (Evenden, 1999a). Developing a model of 
impulsive preparation that has face, construct, and predictive validity with respect to the 
human condition would be very useful to the further understanding of this subtype of 
impulsivity in humans. The UVD task has face validity, but does not seem to measure the 
behavior pattern intended. Impulsive preparation is studied in people using tasks 
originally developed to model aspects of executive function. Perhaps impulsive 
preparation is unique to situations involving complex stimuli and cognitive processes, 
and would be better-modeled using animals with more complex behavioral repertoires 
such as non-human primates.  
The results of Chapter 2 demonstrate that impulsive choice on the DD task is 
associated with demand for cocaine, resembling the relationship in people between 
substance abuse and impulsive choice (see Chapter 1; for review, see Reynolds, 2006). 
Although less extensively documented, impulsive action and impulsive preparation in 
people have also been shown to correlate with substance abuse (e.g., Clark, Robbins, 
Ersche, & Sahakian, 2006; Ersche, Clark, London, Robbins, & Sahakian, 2006; Lane, 
Moeller, Steinberg, Buzby, & Kosten, 2007; Yakir et al., 2007; but see Li, Milivojevic, 
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Hong, & Sinha, 2006). Determining whether individual differences in impulsive action or 
impulsive preparation (should a suitable model be developed) are associated with demand 
for drugs of abuse would be informative. 
A fourth subtype of impulsivity, lapses in attention, has been proposed (de Wit, 
2009). Lapses in attention are assessed by measuring the skew of a distribution of 
reaction times on an attention task. Sustained attention tasks are commonly used in 
animals (e.g., Robbins, 2002), and adapting one to measure lapses in attention as a model 
of impulsivity may be quite straightforward, and could be the impetus for important 
findings. 
Occasionally engaging in behavior patterns that appear impulsive is normal, but 
when these patterns become excessive the results can be devastating. Through rigorously 
conducted behavioral experiments in animal subjects, it may be possible to discover new 
treatment mechanisms to assist those with impulse-control disorders interact more 





Table 7-1. Summary of effects of environmental manipulations, d-amphetamine, GBR 
12909, apomorphine, SKF 81297, and SCH 23390 on selected measures from Specific 
Aim 2. Symbols indicate the effects of that dose (s.c.) on the dependent measure 
indicated. Changes in impulsivity as defined for each task without a corresponding 
disruption of behavior are indicated with arrows representing an increase () or decrease 
(). Behavior was considered disrupted () if there was a reduced choice of the large 
reinforcer when not delayed (DD Choice), if response latency was increased (DD 
Choice), if total trials were decreased (PFCN C50 Short and Long), or if trials omitted 
were increased (UVD premature responses and latency). Conditions or doses that had no 
significant effect (–) or were not tested (·) are also indicated. 
 DD  Choice 
PFCN  
C50 Short 
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 10 s 












 Stimuli Certain · · · – – 
d-Amphetamine 
 0.032 mg/kg 
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 0.32 mg/kg 






















 1.0 mg/kg 
 3.2 mg/kg 

















 0.032 mg/kg 
 0.1 mg/kg 

















 0.1 mg/kg 
 0.32 mg/kg 

















 0.001 mg/kg 
 0.0032 mg/kg 
 0.01 mg/kg 





















DD = Delay discounting task; PFCN = paced fixed consecutive number schedule; UVD = 
uncertain visual discrimination task; C50 = C50 from Equation 4-1.  
252 
 
Table 7-2. Summary of effects drugs acting as agonists (sumanirole, pramipexole, and 
ABT-724) and antagonists (haloperidol, L-741,626, PG01037, and L-745,870) at D2-like 
receptors on selected measures from Specific Aim 2. All details as in Table 7-1. 
 DD  Choice 
PFCN  
C50 Short 







 0.032 mg/kg 
 0.56 mg/kg 
 1.0 mg/kg 






















 0.01 mg/kg 
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 0.1 mg/kg 






















 0.1 mg/kg 
 0.32 mg/kg 
 1.0 mg/kg 






















 0.01 mg/kg 
 0.032 mg/kg 

















 0.32 mg/kg 
 1.0 mg/kg 

















 10 mg/kg 
 32 mg/kg 

















 0.32 mg/kg 
 1.0 mg/kg 
















DD = Delay discounting task; PFCN = paced fixed consecutive number schedule; UVD = 
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